KR20180100303A - Composition and method for chimeric embryo-assist organ generation - Google Patents

Abstract

Human or humanized tissues and organs suitable for transplantation are disclosed herein. Genetic editing of host animals provides a niche for supplementing missing genetic information by donor stem cells. To knock out or destroy the gene responsible for the growth and / or differentiation of the target organ, the host genome is edited and injected with the donor stem cells into the animal at the embryonic stage to remove the missing genetic information for organ growth and development Supplement. The result is a chimeric animal in which the complemented tissue (human / humanized organ) matches the donor's genotype and phenotype. Such organs can be made into a single generation and the stem cells can be harvested or produced from the patient ' s body. As described herein, multiple genes can be simultaneously edited in a cell or embryo to produce a " locus " for the complemented tissue. A number of genes can be targeted for editing using nuclease targeted and homologous target recovery (HDR) templates in vertebrate cells or embryos.

Description

Composition and method for chimeric embryo-assist organ generation

Cross reference of related application

This application claims the benefit of U.S. Provisional Application Nos. 62 / 246,926, 62 / 246,927, 62 / 246,929, 62 / 246,947, 62 / 247,092, 62 / 947,096 62 / 247,115, 62 / 247,117, 62 / 247,118 and 62 / 247,122, all of which are incorporated herein by reference. The entire contents of each of the aforementioned provisional sources are incorporated herein by reference.

The subject matter of this application is International Patent Application Publication No. WO2015 / 168125A1 published Nov. 5, 2015, WO 2016/141234 published Sep. 9, 2016, International PCT / US2016 / 040378, filed June 30, 2016, and PCT / US2016 / 040431, filed June 30, The entire contents of each of the above-cited international applications are incorporated herein by reference.

STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH

The present invention was made with government support under grant number W81XWH-15-1-0393 granted by the US Department of Defense and award numbers 1R43HL124781-01A1 and 1R43GM113525-01 granted by the US National Institutes of Health. The Government has specific rights to the invention.

Over the past 100 years, scientists and doctors have shown that people have had an excellent effect on survival and well-being, at least until the last decade of life with old age disease and disability. It has been used in the United States for more than $ 1 trillion annually for the treatment of these diseases. Organ transplants may be effective, but the available organs are too small and in many cases problems arise due to immunological inconsistencies. For example, since 2003, over 7,000 Americans have died while waiting for organ transplants.

Genetic complementation of animal somatic cells by various stem cells enables the manipulation and production of humanized tissues and organs used in therapy, transplantation and regenerative medicine. The organ sources for the present transplant are mechanical or biological and originate from xenotransplantation of human donors, dead bodies, and, in limited cases, other mammalian species such as pigs in particular. Unfortunately, all of these can be rejected by the host and / or cause other side effects.

SUMMARY OF THE INVENTION

The following paragraphs, successively listed from 1 to 92, describe various aspects and related implementations of the present invention.

1. A chimeric embryo comprising a non-human embryo having at least one human cell, wherein the one or more endogenous genes of a non-human embryo responsible for the development of one or more endogenous organs or tissues have been destroyed and one or more corresponding human organs Or wherein at least one gene of a human cell responsible for the development of the tissue complements the function of one or more destroyed endogenous genes such that the animal resulting from said chimeric embryo comprises at least one human organ or tissue.

2. A chimeric embryo comprising a non-human embryo having at least one human cell, wherein one or more endogenous genes of a non-human embryo responsible for the development of one or more endogenous organs or tissues have been destroyed and one or more corresponding human organs Or one or more genes of a human cell responsible for the occurrence of a tissue complement the function of one or more destroyed endogenous genes such that the animal originating from the chimeric embryo comprises at least one human organ or tissue, As such,

Wherein said endogenous gene comprises MYF5, MYOD, and / or MRF4 and said human organ or tissue comprises skeletal muscle cells;

Wherein said endogenous gene comprises ETV2 and said human organ or tissue comprises human vascular cells;

Wherein the endogenous gene comprises NKX2-5, HANDII, and / or TBX5, and wherein the human organs or tissues comprise myocardial cells.

3. A chimeric embryo comprising a non-human embryo having at least one human cell, wherein both alleles of one or more endogenous genes of a non-human embryo responsible for the development of one or more endogenous organs or tissues have been destroyed and one The at least one gene of a human cell responsible for the development of the corresponding human organ or tissue supplements the function of one or more destroyed endogenous genes such that the animal resulting from the chimeric embryo comprises at least one human organ or tissue ,

Wherein said endogenous gene comprises NURR1, LMX1A and / or PITX3 and said human organ or tissue comprises dopamine neurons;

Wherein the endogenous gene comprises OLIG and / or OLIG2 and the human organs or tissues comprise a rare dendritic glial cell;

Wherein said endogenous gene comprises RAG2, IL2rg, C-KIT and / or ETV2, said human organ or tissue comprising young blood;

Wherein said endogenous gene comprises RUNX1, C-KIT and / or FLK1 and said human organ or tissue comprises hematopoietic cells;

Wherein said endogenous gene comprises ETV2 and said human organ or tissue comprises human vascular cells;

Wherein said endogenous gene comprises MYF5, MYOD, MRF4 and / or PAX3 and said human organ or tissue comprises skeletal muscle cells;

Wherein said endogenous gene comprises NKX2-5, HANDII and / or TBX5 and said human organ or tissue comprises myocardial cells;

Wherein said endogenous gene comprises Pdx and / or ETV2 and said human organ or tissue comprises pancreatic cells;

Wherein said endogenous gene comprises HHEX and / or Ubc and said human organ or tissue comprises human liver cells; or

Wherein the endogenous gene comprises Nkx2.1, Sox2, Id2 and / or Tbx4, and wherein the human organ or tissue comprises lung cells.

4. A chimeric embryo comprising a non-human embryo having at least one human cell, wherein both alleles of one or more endogenous genes of a non-human embryo responsible for the development of one or more endogenous organs or tissues have been destroyed and one The at least one gene of a human cell responsible for the development of the corresponding human organ or tissue supplements the function of one or more destroyed endogenous genes such that the animal resulting from the chimeric embryo comprises at least one human organ or tissue ,

Wherein said endogenous gene comprises NURR1, LMX1A and / or PITX3 and said human organ or tissue comprises dopamine neurons;

Wherein the endogenous gene comprises OLIG and / or OLIG2 and the human organs or tissues comprise a rare dendritic glial cell;

Wherein said endogenous gene comprises RAG2, IL2rg, C-KIT and / or ETV2, said human organ or tissue comprising young blood;

Wherein said endogenous gene comprises RUNX1, C-KIT and / or FLK1 and said human organ or tissue comprises hematopoietic cells;

Wherein said endogenous gene comprises PAX3 and said human organ or tissue comprises skeletal muscle cells;

Wherein said endogenous gene comprises Pdx and / or ETV2 and said human organ or tissue comprises pancreatic cells;

Wherein said endogenous gene comprises HHEX and / or Ubc and said human organ or tissue comprises human liver cells; or

Wherein said endogenous gene comprises Nkx2.1, Sox2, Id2 and / or Tbx4 and said human organ or tissue comprises lung cells.

5. A chimeric embryo comprising a non-human embryo having at least one human cell, wherein both alleles of one or more endogenous genes of a non-human embryo responsible for the development of one or more endogenous organs or tissues have been destroyed and one The at least one gene of a human cell responsible for the development of the corresponding human organ or tissue supplements the function of one or more destroyed endogenous genes such that the animal resulting from the chimeric embryo comprises at least one human organ or tissue ,

Wherein said endogenous gene is RAG2 and IL2rg and / or ETV2 and said human organ or tissue comprises young blood;

Wherein said endogenous gene is MYF5, MYOD and MRF4 and / or PAX3 and said human organ or tissue comprises skeletal muscle cells; or

Wherein said endogenous gene is NKX2-5, HANDII and / or TBX5 and said human organ or tissue comprises myocardial cells.

6. A chimeric embryo comprising a non-human embryo having at least one human cell, wherein both alleles of one or more endogenous genes of a non-human embryo responsible for the development of one or more endogenous organs or tissues have been destroyed and one The at least one gene of a human cell responsible for the development of the corresponding human organ or tissue supplements the function of one or more destroyed endogenous genes such that the animal resulting from the chimeric embryo comprises at least one human organ or tissue ,

Wherein said endogenous gene is RAG2 and IL2rg and / or ETV2 and said human organ or tissue comprises young blood;

Wherein said endogenous gene is PAX3 and said human organ and / or tissue comprises skeletal muscle cells; or

Wherein said endogenous gene is NKX2-5, HANDII and / or TBX5 and said human organ or tissue comprises myocardial cells.

7. The chimeric embryo according to any one of paragraphs 1 to 3, wherein said endogenous gene comprises NURR1, LMX1A, and / or PITX3 and said human organ or tissue comprises dopamine neurons.

8. The chimeric embryo according to any one of paragraphs 1 to 3, wherein said endogenous gene comprises OLIG and / or OLIG2 and said human organs or tissues comprise rare dendritic glue cells.

9. The chimeric embryo according to any one of paragraphs 1 to 3, wherein said endogenous gene comprises RAG2, IL2rg, C-KIT and / or ETV2 and said human organ or tissue comprises young blood.

10. The chimeric embryo according to any one of paragraphs 1 to 3, wherein said endogenous gene comprises RUNX1, C-KIT and / or FLK1, said human organs or tissues comprising hematopoietic cells.

11. The chimeric embryo according to any one of paragraphs 1 to 3, wherein the endogenous gene comprises ETV2 and the human organs or tissues comprise human blood vessel cells.

12. The chimeric embryo according to any one of paragraphs 1 to 3, wherein said endogenous gene comprises MYF5, MYOD, MRF4 and / or PAX3 and said human organ or tissue comprises skeletal muscle cells.

13. The chimeric embryo according to any one of paragraphs 1 to 3, wherein said endogenous gene comprises NKX2-5, HANDII and / or TBX5 and said human organs or tissues comprise myocardial cells.

14. The chimeric embryo according to any one of paragraphs 1 to 3, wherein said endogenous gene comprises Pdx and / or ETV2 and said human organ or tissue comprises pancreatic cells.

15. The chimeric embryo according to any one of paragraphs 1 to 3, wherein said endogenous gene comprises HHEX or Ubc and said human organ or tissue comprises human liver cells.

16. The chimeric embryo according to any one of paragraphs 1 to 3, wherein said endogenous gene comprises Nkx2.1, Sox2, Id2 and / or Tbx4 and said human organ or tissue comprises lung cells.

17. The chimeric embryo according to paragraph 1 or 2, wherein both alleles of said endogenous gene have been destroyed.

18. The chimeric embryo according to any one of paragraphs 1 to 17, wherein the non-human embryo is a non-human vertebrate embryo.

19. The chimeric embryo according to paragraph 18, wherein the vertebrate non-human embryo is an artiodactyl embryo or a non-human primate embryo.

20. The method of paragraph 18 wherein the non-human vertebrate embryo is selected from the group consisting of cows, horses, pigs, sheep, chickens, birds, rabbits, goats, dogs, cats, laboratory animals, crustaceans, Embryo.

21. The chimeric embryo of paragraph 20 wherein the vertebrate non-human embryo is a cow, a pig, a sheep, a goat, a chicken, or a rabbit embryo.

22. In any one of paragraphs 1-21, one or more endogenous genes of a non-human embryo responsible for the development of one or more endogenous organs or tissues are selected from the group consisting of Transcription Activator-Like Effector Nucleases (CRISPR), 9 (Cas9), Zinc Finger Nucleases (ZFNs), site-specific (CRISPR) A chimeric embryo that has been destroyed by a molecule encoding an endo-nuclease, a synthetic artificial chromosome, a RecA-gal4 fusion, an RNAi, a CRISPRi, or a combination thereof.

23. The chimeric embryo according to paragraph 22, wherein said at least one endogenous gene is disrupted by Cas9.

24. The method of any one of paragraphs 1 to 23, wherein said human cells are derived from at least one donor cell, said at least one donor cell is embryonic stem cells, tissue-specific stem cells, mesenchymal stem cells A chimeric embryo that is a stem cell or an induced pluripotent stem cell.

25. In any one of paragraphs 1-24, said destruction comprises both genetic editing, knockout, insertion of one or more DNA residues, deletion of one or more bases, or insertion and deletion of one or more DNA residues In chimeric embryos.

26. The chimeric embryo of any one of paragraphs 1 to 24, wherein said destruction comprises a substitution of one or more DNA residues.

27. The chimeric embryo of paragraph 26, wherein said destruction comprises replacement of one or more DNA residues.

28. An animal derived from a chimeric embryo according to any one of paragraphs 1 to 27.

29. A human tissue or organ harvested from an animal resulting from a chimeric embryo according to any one of paragraphs 1 to 27.

30. A method of producing a chimeric embryo comprising the steps of:

(a) destroying one or more endogenous genes responsible for the occurrence of one or more endogenous organs or tissues in at least one non-human cell or non-human embryo;

(b) when step (a) is performed in a non-human cell, cloning the cell to produce an embryo; And

(c) introducing at least one human cell into the embryo of step (a) or step (b), wherein the human cell carries one or more genes responsible for the development of one or more organs or tissues to produce a chimeric embryo How to do it.

31. A method of producing a chimeric embryo comprising the steps of:

(a) destroying one or more endogenous genes responsible for the occurrence of one or more endogenous organs or tissues in at least one non-human cell or non-human embryo;

(b) when step (a) is performed in a non-human cell, cloning the cell to produce an embryo; And

(c) introducing at least one human cell into the embryo of step (a) or step (b), said human cell carrying one or more genes responsible for the development of one or more organs or tissues,

Chimeric embryos are produced and chimeric embryos are excluded,

Wherein said endogenous gene comprises MYF5, MYOD, and / or MRF4 and said human organ or tissue comprises skeletal muscle cells;

Wherein said endogenous gene comprises ETV2 and said human organ or tissue comprises human vascular cells;

Wherein said endogenous gene comprises NKX2-5, HANDII and / or TBX5 and said human organ or tissue comprises myocardial cells.

32. A method of producing a chimeric embryo comprising the steps of:

(a) destroying both alleles of one or more endogenous genes responsible for the occurrence of one or more organs or tissues in at least one non-human cell or non-human embryo;

(b) when step (a) is performed in a non-human cell, cloning the cell to produce an embryo; And

(c) introducing at least one human cell into the embryo of step (a) or step (b), wherein the human cell carries one or more genes responsible for the development of one or more organs or tissues to produce a chimeric embryo As a result,

Wherein said endogenous gene comprises NURR1, LMX1A and / or PITX3 and said human organ or tissue comprises dopamine neurons;

Wherein the endogenous gene comprises OLIG and / or OLIG2 and the human organs or tissues comprise a rare dendritic glial cell;

Wherein said endogenous gene comprises RAG2, IL2rg, C-KIT and / or ETV2, said human organ or tissue comprising young blood;

Wherein said endogenous gene comprises RUNX1, C-KIT and / or FLK1 and said human organ or tissue comprises hematopoietic cells;

Wherein said endogenous gene comprises ETV2 and said human organ or tissue comprises human vascular cells;

Wherein said endogenous gene comprises MYF5, MYOD, MRF4 and / or PAX3 and said human organ or tissue comprises skeletal muscle cells;

Wherein said endogenous gene comprises NKX2-5, HANDII and / or TBX5 and said human organ or tissue comprises myocardial cells;

Wherein said endogenous gene comprises Pdx and / or ETV2 and said human organ or tissue comprises pancreatic cells;

Wherein said endogenous gene comprises HHEX and / or Ubc and said human organ or tissue comprises human liver cells; or

Wherein said endogenous gene comprises Nkx2.1, Sox2, Id2 and / or Tbx4 and said human organ or tissue comprises lung cells.

33. A method of producing a chimeric embryo comprising the steps of:

(a) destroying both alleles of one or more endogenous genes responsible for the occurrence of one or more organs or tissues in at least one non-human cell or non-human embryo;

(b) when step (a) is performed in a non-human cell, cloning the cell to produce an embryo; And

(c) introducing at least one human cell into the embryo of step (a) or step (b), wherein the human cell carries one or more genes responsible for the development of one or more organs or tissues to produce a chimeric embryo ;

Wherein said endogenous gene comprises NURR1, LMX1A and / or PITX3 and said human organ or tissue comprises dopamine neurons;

Wherein the endogenous gene comprises OLIG and / or OLIG2 and the human organs or tissues comprise a rare dendritic glial cell;

Wherein said endogenous gene comprises RAG2, IL2rg, C-KIT and / or ETV2, said human organ or tissue comprising young blood;

Wherein said endogenous gene comprises RUNX1, C-KIT and / or FLK1 and said human organ or tissue comprises hematopoietic cells;

Wherein said endogenous gene comprises PAX3 and said human organ or tissue comprises skeletal muscle cells;

Wherein said endogenous gene comprises Pdx and / or ETV2 and said human organ or tissue comprises pancreatic cells;

Wherein said endogenous gene comprises HHEX and / or Ubc and said human organ or tissue comprises human liver cells; or

Wherein said endogenous gene comprises Nkx2.1, Sox2, Id2 and / or Tbx4 and said human organ or tissue comprises lung cells.

34. A method of producing a chimeric embryo comprising the steps of:

(a) destroying both alleles of one or more endogenous genes responsible for the occurrence of one or more organs or tissues in at least one non-human cell or non-human embryo;

(b) when step (a) is performed in a non-human cell, cloning the cell to produce an embryo; And

(c) introducing at least one human cell into the embryo of step (a) or step (b), wherein the human cell carries one or more genes responsible for the development of one or more organs or tissues to produce a chimeric embryo ;

Wherein said endogenous gene is RAG2 and IL2rg and / or ETV2 and said human organ or tissue comprises young blood;

Wherein said endogenous gene is MYF5, MYOD and MRF4 and / or PAX3 and said human organ or tissue comprises skeletal muscle cells; or

Wherein said endogenous gene is NKX2-5, HANDII and TBX5 and said human organ or tissue comprises myocardial cells.

35. A method of producing a chimeric embryo comprising the steps of:

(a) destroying both alleles of one or more endogenous genes responsible for the occurrence of one or more organs or tissues in at least one non-human cell or non-human embryo;

(b) when step (a) is performed in a non-human cell, cloning the cell to produce an embryo; And

(c) introducing at least one human cell into the embryo of step (a) or step (b), wherein the human cell carries one or more genes responsible for the development of one or more organs or tissues to produce a chimeric embryo ;

Wherein said endogenous gene is RAG2 and IL2rg and / or ETV2 and said human organ or tissue comprises young blood;

Wherein said endogenous gene is PAX3 and said human organ or tissue comprises skeletal muscle cells; or

Wherein said endogenous gene is NKX2-5, HANDII and TBX5 and said human organ or tissue comprises myocardial cells.

36. The method according to any one of paragraphs 30 to 32, wherein said endogenous gene comprises NURR1, LMX1A, and / or PITX3 and said human organ or tissue comprises dopamine neurons.

37. The method according to any one of paragraphs 30 to 32, wherein the endogenous gene comprises OLIG and / or OLIG2 and wherein the human organs or tissues comprise rare dendritic glial cells.

38. The method according to any one of paragraphs 30 to 32, wherein said endogenous gene comprises RAG2, IL2rg, C-KIT and / or ETV2 and said human organ or tissue comprises young blood.

39. The method according to any one of paragraphs 30 to 32, wherein said endogenous gene comprises RUNX1, C-KIT and / or FLK1 and said human organ or tissue comprises hematopoietic cells.

40. The method of paragraph 30 or 32 wherein said endogenous gene comprises ETV2 and said human organ or tissue comprises human vascular cells.

41. The method of paragraph 30 or 32 wherein said endogenous gene comprises MYF5, MYOD, MRF4 and / or PAX3 and said human organ or tissue comprises skeletal muscle cells.

42. The method of paragraph 30 or 32 wherein said endogenous gene comprises NKX2-5, HANDII and / or TBX5 and said human organ or tissue comprises myocardial cells.

43. The method according to any one of paragraphs 30 to 32, wherein said endogenous gene comprises Pdx and / or ETV2 and said human organ or tissue comprises pancreatic cells.

44. The method according to any one of paragraphs 30 to 32, wherein said endogenous gene comprises HHEX and / or Ubc and said human organ or tissue comprises human liver cells.

45. The method according to any one of paragraphs 30 to 32, wherein said endogenous gene comprises Nkx2.1, Sox2, Id2 and / or Tbx4 and said human organ or tissue comprises lung cells.

46. The method of paragraph 30 or 31 wherein both alleles of one or more endogenous genes are destroyed.

47. The method of any one of paragraphs 30 to 46, wherein said non-human embryo is a non-human vertebrate embryo.

48. The method of paragraph 47, wherein the vertebrate non-human embryo is a right embryo or a non-human primate embryo.

49. The method of paragraph 47, wherein said non-human vertebrate embryo is selected from the group consisting of cows, horses, pigs, sheep, chickens, birds, rabbits, goats, dogs, cats, laboratory animals, and fish.

50. The method of any one of paragraphs 30 to 49, wherein said at least one human donor cell is an embryonic stem cell, tissue-specific stem cell, mesenchymal stem cell, pluripotent stem cell, or induced pluripotent stem cell .

51. The method of any one of paragraphs 30 to 50, further comprising the step of transplanting said chimeric embryo into the uterus of an animal, wherein said chimeric embryo occurs with a chimeric animal comprising human cells.

52. The method of paragraph 51, further comprising harvesting the human cells from the chimeric animal.

53. The method of paragraph 52, further comprising the step of transplanting said human cells into a human patient in need thereof.

54. The method of paragraph 53 wherein said at least one human cell is donated by a human patient.

55. The method of any one of paragraphs 30 to 54, wherein one or more endogenous genes of said non-human embryo responsible for the occurrence of one or more endogenous organs or tissues are selected from the group consisting of transcriptional activator-like effector nuclease (TALENS) (CRISPR), a CRISPR-related protein 9 (Cas9), a zinc finger nuclease (ZFNS), a molecule encoding a site-specific endonuclease, a synthetic artificial chromosome, RecA-gal4 Fused, < / RTI > RNAi, CRISPRi or a combination thereof.

56. The method of paragraph 55 wherein the method is Cas9.

57. A method according to any one of paragraphs 55 to 56, further comprising the step of introducing a homology directed repair (HDR) template having a template sequence homologous to one of said endogenous genes, Wherein the template sequence replaces at least a portion of the endogenous gene sequence to destroy the endogenous gene.

58. The method of paragraph 57 further comprising introducing a plurality of homologous target recovery (HDR) templates, each having a template sequence that is homologous to one of said endogenous genes, Wherein the sequence replaces at least a portion of one of the endogenous gene sequences to destroy the endogenous gene.

59. The method of paragraph 57 or 58, wherein said disruption comprises the substitution of one or more DNA residues of said endogenous gene.

60. The method of paragraph 57 or 58, wherein said destruction comprises replacement of one or more DNA residues of said endogenous gene.

61. A chimeric embryo or chimeric animal produced using the method of any one of paragraphs 30 to 60.

62. A method of producing a human or humanized organ or tissue in a non-human host animal, comprising the steps of:

(a) destroying one or more endogenous genes responsible for the development of organs or tissues in at least one cell of a non-human embryo;

(b) when step (a) is performed in a cell of an animal host, cloning the cell to produce an embryo; And

(c) introducing at least one human cell into the embryo of step (a) or step (b) to produce a chimeric host embryo, said human cell comprising one or more genes responsible for the generation of the corresponding human organ or tissue Lt; / RTI >

Wherein the animal resulting from the chimeric host embryo is human or humanized organ or tissue in a non-human host animal, including human or humanized organs or tissues.

63. A method of producing a human or humanized organ or tissue in a non-human host animal, comprising the steps of:

(a) destroying one or more endogenous genes responsible for the occurrence of one or more endogenous organs or tissues in at least one non-human cell or non-human embryo;

(b) when step (a) is performed in a non-human cell, cloning the cell to produce an embryo; And

(c) introducing at least one human cell into the embryo of step (a) or step (b)

Wherein the human cell carries one or more genes responsible for the generation of one or more organs or tissues to produce chimeric embryos and exclude chimeric embryos,

Wherein said endogenous gene comprises MYF5, MYOD, and / or MRF4 and said human organ or tissue comprises skeletal muscle cells;

Wherein said endogenous gene comprises ETV2 and said human organ or tissue comprises human vascular cells;

Wherein said endogenous gene comprises NKX2-5, HANDII and / or TBX5 and said human organ or tissue comprises myocardial cells.

64. A method of producing a human or humanized organ or tissue in a non-human host animal, comprising the steps of:

(a) destroying both alleles of one or more endogenous genes responsible for the development of organs or tissues in at least one cell of a non-human embryo;

(b) when step (a) is performed in a cell of an animal host, cloning the cell to produce an embryo; And

(c) introducing at least one human cell into the embryo of step (a) or step (b) to produce a chimeric host embryo, said human cell comprising one or more genes responsible for the generation of the corresponding human organ or tissue Lt; / RTI >

An animal resulting from the chimeric host embryo is a human or humanized organ or organism in a non-human host animal, including a human or humanized organ or tissue,

Wherein said endogenous gene comprises NURR1, LMX1A and / or PITX3 and said human organ or tissue comprises dopamine neurons;

Wherein the endogenous gene comprises OLIG and / or OLIG2 and the human organs or tissues comprise a rare dendritic glial cell;

Wherein said endogenous gene comprises RAG2, IL2rg, C-KIT and / or ETV2, said human organ or tissue comprising young blood;

Wherein said endogenous gene comprises RUNX1, C-KIT and / or FLK1 and said human organ or tissue comprises hematopoietic cells;

Wherein said endogenous gene comprises ETV2 and said human organ or tissue comprises human vascular cells;

Wherein said endogenous gene comprises MYF5, MYOD, MRF4 and / or PAX3 and said human organ or tissue comprises skeletal muscle cells;

Wherein said endogenous gene comprises NKX2-5, HANDII and / or TBX5 and said human organ or tissue comprises myocardial cells;

Wherein said endogenous gene comprises Pdx and / or ETV2 and said human organ or tissue comprises pancreatic cells;

Wherein said endogenous gene comprises HHEX and / or Ubc and said human organ or tissue comprises human liver cells; or

Wherein said endogenous gene comprises Nkx2.1, Sox2, Id2 and / or Tbx4 and said human organ or tissue comprises lung cells.

65. A method of producing a human or humanized organ or tissue in a non-human host animal, comprising the steps of:

(a) destroying both alleles of one or more endogenous genes responsible for the development of organs or tissues in at least one cell of a non-human embryo;

(b) when step (a) is performed in a cell of an animal host, cloning the cell to produce an embryo; And

(c) introducing at least one human cell into the embryo of step (a) or step (b) to produce a chimeric host embryo, said human cell comprising one or more genes responsible for the generation of the corresponding human organ or tissue Lt; / RTI >

An animal resulting from the chimeric host embryo is a human or humanized organ or organism in a non-human host animal, including a human or humanized organ or tissue,

Wherein said endogenous gene comprises NURR1, LMX1A and / or PITX3 and said human organ or tissue comprises dopamine neurons;

Wherein the endogenous gene comprises OLIG and / or OLIG2 and the human organs or tissues comprise a rare dendritic glial cell;

Wherein said endogenous gene comprises RAG2, IL2rg, C-KIT and / or ETV2, said human organ or tissue comprising young blood;

Wherein said endogenous gene comprises RUNX1, C-KIT and / or FLK1 and said human organ or tissue comprises hematopoietic cells;

Wherein said endogenous gene comprises PAX3 and said human organ or tissue comprises skeletal muscle cells;

Wherein said endogenous gene comprises Pdx and / or ETV2 and said human organ or tissue comprises pancreatic cells;

Wherein said endogenous gene comprises HHEX and / or Ubc and said human organ or tissue comprises human liver cells; or

Wherein said endogenous gene comprises Nkx2.1, Sox2, Id2 and / or Tbx4 and said human organ or tissue comprises lung cells.

66. A method of producing a human or humanized organ or tissue in a non-human host animal, comprising the steps of:

(a) destroying both alleles of one or more endogenous genes responsible for the development of organs or tissues in at least one cell of a non-human embryo;

(b) when step (a) is performed in a cell of an animal host, cloning the cell to produce an embryo; And

(c) introducing at least one human cell into the embryo of step (a) or step (b) to produce a chimeric host embryo, said human cell comprising one or more genes responsible for the generation of the corresponding human organ or tissue As shown in FIG.

Wherein said endogenous gene is RAG2 and IL2rg or ETV2 and said human organ or tissue comprises young blood;

Wherein said endogenous gene is MYF5, MYOD and MRF4 or PAX3 and said human organ or tissue comprises skeletal muscle cells; or

Wherein said endogenous gene comprises NKX2-5, HANDII and / or TBX5 and said human organ or tissue comprises myocardial cells.

67. A method of producing a human or humanized organ or tissue in a non-human host animal, comprising the steps of:

(a) destroying both alleles of one or more endogenous genes responsible for the occurrence of one or more organs or tissues in at least one non-human cell or non-human embryo;

(b) when step (a) is performed in a non-human cell, cloning the cell to produce an embryo; And

(c) introducing at least one human cell into the embryo of step (a) or step (b), wherein the human cell carries one or more genes responsible for the development of one or more organs or tissues to produce a chimeric embryo ;

Wherein said endogenous gene is RAG2 and IL2rg and / or ETV2 and said human organ or tissue comprises young blood;

Wherein said endogenous gene is PAX3 and said human organ or tissue comprises skeletal muscle cells; or

Wherein said endogenous gene is NKX2-5, HANDII and TBX5 and said human organ or tissue comprises myocardial cells.

68. The method according to any one of paragraphs 62 to 64, wherein said endogenous gene comprises NURR1, LMX1A, and / or PITX3 and said human organ or tissue comprises dopamine neurons.

69. The method according to any one of paragraphs 62 to 64, wherein said endogenous gene comprises OLIG and / or OLIG2 and said human organs or tissues comprise rare lobular glue cells.

70. The method according to any one of paragraphs 62 to 64, wherein said endogenous gene comprises RAG2, IL2rg, C-KIT and / or ETV2 and said human organ or tissue comprises young blood.

71. The method according to any one of paragraphs 62 to 64, wherein said endogenous gene comprises RUNX1, C-KIT and / or FLK1 and said human organ or tissue comprises hematopoietic cells.

72. The method of paragraph 62 or 64, wherein said endogenous gene comprises ETV2 and said human organ or tissue comprises human vascular cells.

73. The method according to paragraph 62 or 64, wherein said endogenous gene comprises MYF5, MYOD, MRF4 and / or PAX3 and said human organ or tissue comprises skeletal muscle cells.

74. The method of paragraph 62 or 64 wherein said endogenous gene comprises NKX2-5, HANDII and / or TBX5 and said human organ or tissue comprises myocardial cells.

75. The method according to any one of paragraphs 62 to 64, wherein said endogenous gene comprises Pdx and / or ETV2 and said human organ or tissue comprises pancreatic cells.

76. The method according to any one of paragraphs 62 to 64, wherein said endogenous gene comprises HHEX and / or Ubc and said human organ or tissue comprises human liver cells.

77. The method according to any one of paragraphs 62 to 64, wherein said endogenous gene comprises Nkx2.1, Sox2, Id2 and / or Tbx4 and said human organ or tissue comprises lung cells.

78. The method of paragraph 62 or 63 wherein both alleles of one or more endogenous genes are destroyed.

79. The method according to any one of paragraphs 62 to 78, wherein the non-human embryo is a non-human vertebrate embryo.

80. The method of paragraph 79 wherein said vertebrate non-human embryo is a right embryo or a non-human primate embryo.

81. The method of paragraph 79 wherein said non-human vertebrate embryo is selected from the group consisting of cows, horses, pigs, sheep, chickens, birds, rabbits, goats, dogs, cats, laboratory animals, and fish.

82. The method according to any of paragraphs 62 to 81, wherein said at least one human cell is an embryonic stem cell, tissue-specific stem cell, mesenchymal stem cell, pluripotent stem cell or induced pluripotent stem cell.

83. The method according to any one of paragraphs 62 to 82, further comprising harvesting human cells from the chimeric animal.

84. The method of paragraph 83 further comprising transplanting said human cells into a human patient in need thereof.

85. The method of paragraph 84 wherein said at least one human cell is donated by a human patient.

86. A method according to any one of paragraphs 62 to 85, further comprising the step of introducing a homologous target recovery (HDR) template having a template sequence that is homologous to one of said endogenous genes, Is to replace at least a portion of said endogenous gene sequence to destroy said endogenous gene.

87. The method of paragraph 86, further comprising introducing a plurality of homologous target recovery (HDR) templates, each having a template sequence that is homologous to one of said endogenous genes, Wherein the sequence replaces at least a portion of one of the endogenous gene sequences to destroy the endogenous gene.

88. The method of paragraph 86 or 87 wherein said disruption comprises the substitution of one or more DNA residues of said endogenous gene.

89. The method of paragraph 86 or 87 wherein said destruction comprises replacement of one or more DNA residues of said endogenous gene.

90. A method according to any one of paragraphs 62 to 89, wherein at least one endogenous gene of a non-human embryo that is responsible for the development of one or more endogenous organs or tissues is transactivated-pseudo-effector nuclease (TALENS) (CRISPR), a CRISPR-related protein 9 (Cas9), a zinc finger nuclease (ZFNS), a molecule encoding a site-specific endonuclease, a synthetic artificial chromosome, a RecA-gal4 fusion , ≪ / RTI > RNAi, CRISPRi, or a combination thereof.

91. The method of paragraph 90 wherein at least one endogenous gene of said non-human embryo responsible for the occurrence of one or more endogenous organs or tissues is destroyed by Cas9.

92. A chimeric animal produced using the method of any one of paragraphs 62 to 91.

Certain elements of any of the foregoing aspects and embodiments of the invention may be combined or substituted with elements of other aspects and embodiments of the invention. Also, while the benefits associated with certain aspects and implementations of the present disclosure have been described in the context of such aspects and implementations, it is to be understood that other aspects and embodiments may also exhibit these benefits, and that all such aspects and embodiments, .

BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a schematic diagram illustrating the problems of tissue / organ transplantation and the solutions provided by genomic manipulation of human cells and animals for organ transplantation.
Figure 2a shows the process of making a homozygous animal for two knockouts using a single compilation.
Figure 2b shows a hypothetical process of making animals with multiple edits by producing a single compilation at a time.
Figure 3 shows the multiplex gene editing used to establish founders in the F0 generation.
Figures 4a-4d show the pigRAG2AndIL2R?(orIL2Rg). ≪ / RTI > Figure 4a shows the results of a Surveyor and a restriction fragment to determine the efficiency of non-homologous end joining (NHEJ) and homology depended repair HDR in cell populations 3 days after transfection Lt; / RTI > is a graph showing restriction fragment length polymorphism (RFLP) analysis. Figure 4b is a graph showing RFLP analysis of homologous-dependent restoration of cell populations 11 days after transfection. Figure 4cIL2R?,RAG2≪ / RTI > or both, showing a positive colony percentage for HDR. Cells were plated from the group labeled " C " in FIG. 4A. Figure 4d shows the amount of 30 transcriptional activator-like effector nuclease (TALENS) mRNAs andIL2R?1 μg andRAG2And colony assays from cells transfected in the amount of 1 [mu] M each for HDR templates. The distribution of the colony genotype is shown at the bottom. In the present application,IL2R? AndIL2RgAre used interchangeably.
Figures 5a-5d show the pigAPCAndThis shows the multiplex gene editing of p53.FIG. 5A is a graph showing a Surveyor and RFLP assay for determining the efficiency of non-homologous terminal junction (NHEJ) and homology-dependent repair (HDR) in a population of cells after 3 days of transfection. Figure 5b is a graph showing RFLP analysis for homologous dependent recovery of cell populations 11 days after transfection. Figures 5c and 5d showAPC,p53≪ / RTI > or " D " in FIG. Colonies with three or more HDR alleles were listed at the bottom.
Figures 6a and 6b show the effect of oligonucleotide HDR template concentration on the 5 gene multiplex HDR efficiency. pigRAG2, IL2R?, P53, APCAndLDLRWas co-transfected with porcine fibroblasts in the indicated amounts of TALEN mRNA with either homologous HDR template of 2 [mu] M (Fig. 6A) or 1 [mu] M (Fig. 6B), respectively. NHEJ and HDR percent were measured by the Surveyor and RFLP assays.
Figures 7a and 7b are five gene multiplex data sets showing a plot of experimental data on the effect of oligonucleotide HDR template concentrations on five gene multiplex HDR efficiencies. pigRAG2, IL2R?, P53, APCAndLDLRWere co-transfected with porcine fibroblasts in the presence of either 2 [mu] M or 1 [mu] M homologous HDR template, respectively. NHEJ and HDR percent were measured by the Surveyor and RFLP assays. Colony Genotype from Five Gene Multiplex HDRs: The colony genotype was evaluated by RFLP analysis. In Figure 7a, each line represents a genotype of a single colony in each particular locus. Three genotypes were identified; A second allele having a predicted RFLP genotype of heterozygous HDR or homozygous HDR and those with RFLP positive fragments and a visible size shift indicating an insert or indel allele. The percentage of colonies with compartments at a particular locus was shown under each column. Figure 7b provides a record of colony numbers edited from 0 to 5 loci.
Figures 8a and 8b are another five gene multiplex data set showing a plot of experimental data for a second experiment involving the effect of oligonucleotide HDR template concentration on five gene multiplex HDR efficiency. Colony genotype of the second 5 gene multiplex test. In Figure 8A, each line represents a genotype of a single colony in each particular locus. Three genotypes were identified; A second allele having a predicted RFLP genotype of heterozygous or homozygous HDR, and those with RFLP positive fragments, and a visible size shift indicating an inserted or deleted allele. The percentage of colonies with compartments at a particular locus was shown under each column. Figure 8b provides a record of the number of colonies edited from 0 to 5 loci.
Figures 9a and 9b are another five gene multiplex test data set showing the colony genotype. In Figure 9a, each line represents a genotype of a single colony in each particular locus. Three genotypes were identified; A second allele having a predicted RFLP genotype of heterozygous HDR or homozygous HDR, and those with RFLP positive fragments and a visible size shift indicating an inserted or deleted allele. The percentage of colonies with compartments at a particular locus was shown under each column. Figure 9b provides a record of the number of colonies edited from 0 to 5 loci.
FIG. 10 shows the process of preparing the F0 generation chimera using the targeted gene knockout or the targeted nuclease producing the selective allele.
Figure 11 shows the establishment of F0 generation animals with normal phenotype and progeny with a failure to thrive (FTT) phenotype and genotype.
Figure 12 shows the process of manufacturing a chimeric animal using a spouse with genetic characteristics of the donor embryo.
Figures 13a-13c show multiplex editing at three targeted loci of NKX2-5, GATA4, and MESP1. FIG. 13A is a schematic diagram of the experiment, and FIG. 13B shows the targeting of the genes using NKX2-5, GATA4, and MESP1 listed in SEQ ID NOS: 1-3, respectively. 13C shows an analysis result of the experiment. Oligonucleotides for each target gene. The new nucleotides are shown in upper case. PTC was lightly colored in the box and the new HindIII RFLP site was underlined.
Figure 14 shows a multiplex gene editing using a combination of TALEN and RGEN; Analysis of transfected cells evaluated by RFLP revealed HDR at both sites.
15A to 15E are images showing the incorporation of human umbilical cord blood stem cells (hUCBSC) into a female reproductive blastocyst. 15A is a phase contrast image of a blastocyst. 15B is a DAPI image of cells in blastocysts. Figure 15c is human nuclear antigen (HNA) staining. 15D is a merged DAPI and HuNu image. 15E is a merged image of Figs. 15A to 15C. 15F is a graph showing the quantification of HuNu cells in the inner cell mass (ICM), the trophectoderm (TE), or the blastocoel cavity (CA). FIG. 15G is a graph showing the proliferation of HNA cells at 6 days, 7 days, and 8 days after activation of oocytes. hUCBSC was injected on day 6.
16A to 16C are images showing chimeric human-porcine fetuses. 16A is an image showing chimeric fetus 28 days after hUCBSC injection into a virgin female reproductive blastocyst. 16B is an immunohistochemical image showing the staining of red human nuclear antigen (HNA) and blue DAPI. Figure 16c is a control for immunohistochemical staining of Figure 16b, in which no primary antibody was added to the stain.
Figures 17a and 17b show TALEN mediated knockout of porcine genes. Figure 17aLMXA1,NURR1, AndPITX3As shown in Fig. Figure 17B provides an electrophoresis image showing the TALEN cleavage product as indicated by the double arrows.
Figs. 18A to 18F show the results of the experiments in which pig embryos with human umbilical cord blood stem cellsPITX3This is an image showing the visual effect of supplementing the knockout. The images in Figs. 18a to 18f show the total shape of the fetal pig eye on the 62nd day of pregnancy. Figures 18a and 18b show the eyes of a wild-type pig. Figures 18c and 18d showPITX3 Knockout Represents a small eye from a pig. Figures 18e and 18f illustrate the use of human umbilical cord blood stem cell (hUCBSC) supplementPITX3 Represents a big eye from knockout. The arrows in Figs. 18A, 18C and 18E show the positions of the eyes of the respective fetuses.
Figures 19a and 19b showETV2RTI ID = 0.0 > TALEN-mediated < / RTI > 19A is a schematic diagram showing a three-step PCR analysis used to detect gene editing. Amplification from primers a to d indicates the presence of the deletion allele. To distinguish between homozygous and homozygous clones, primers a to b and c to d were used to amplify the wild type allele. The clone is considered a homozygous for the deletion allele only if a to d products are present and both a to b, c to d products are absent. Figure 19b provides an electrophoresis image showing confirmation of homozygous deletion. Put a clone in the green box that meets the criteria described above.
Figs. 20Etv2Pigs representing mutant phenotypesETV2Lt; / RTI > Figure 20a shows the wild-type E18.0 porcine embryo and Figure 20b shows theETV2Knockout embryo. The illustration shows an enlarged view of the allantois. In the mutation, attention is drawn to the abnormal whole form together with the deficiency of vascular plexus formation (illustration). Figures 20c-20h are cross-sectional views at embryonic membranes (Figures 20c and 20d), cardiac levels (Figures 20e and 20f) and trunk levels (Figures 20g and 20h), shown in A and B, respectively, Tie2, ; Gata4, cardiovascular markers; And 4 ', 6-diamidino-2-phenylindole (DAPI) which is a nuclear stain. The wild type platelets form a high blood vessel with the Tie2 positive endothelial lining and contain blood (Figure 20c, arrow), but the mutation lacks this group (Figure 20d). The endocardium, cardinal veins (CV), and dorsal aortae (DA) were clearly visible in wild-type embryos (E, G). In contrast,ETV2The null embryo was completely deficient in these constructs, but there were cardiac precursors and intestines labeled by Gata4 (green) (F and H, respectively). Scale bars: 1000 m (Figs. 20a and 20b), 200 m (illustrations of Figs. 20a and 20b), 100 m (Figs. 20c-20h).
Figures 21a-21c illustrate the use of human induced pluripotent stem cells (hiPSC)ETV2It is an immunohistochemical image showing complementing a mutant porcine embryo.ETV2Mutant blastocysts were generated as SCNTs and 10 hiPSCs were injected at the morula stage and then transferred to hormonally synchronized young sows. FIG.AluSequence hybridization. Figures 21b and 21c are immunohistochemical images for human CD31 (Figure 21b), HNA (Figure 21c, red), and human vWF (Figure 21c, green). The box area was expanded in the lower panel. Arrowheads indicate positive cells. Note the formation of structures such as vessels. All scale bars represent 50 microns. nt: neural tube, noto: notochord, som: somite.
Figures 22a-22d are images showing Nkx2-5 and HandII (also known as dHand) dual knockout lacking both ventricles (rv and lv) and having a single small primitive atrium (dc) . Figure 22A shows a wild-type animal. 22B is a cross-Nkx 2.5 ^{- / -}  Animals. Figure 22cdHand ^{- / -}  Animals. Fig.NKx2.5 ^{- / -} dHand ^{- / -}  Represents a double knockout animal.
Figures 23A and 23B show that in pig fibroblastsNKX2-5AndHANDIILt; / RTI > 23A is a schematic diagram of the coding sequence for each gene shown; The alternate hue represents the exon boundary, the blue region (bottom) represents the DNA binding domain of each transcription factor, and the triangle represents the position TALEN binding site. Fig.HANDIIAndNKX2-5Lt; RTI ID = 0.0 > of < / RTI > the fibroblast colony of the double allele KO of E. coli.
Figures 24A-24C show that the Nkx2-5 / HANDII / TBX5 triple knockout pig embryo has acardia. Figure 24a provides an image of immunohistochemical staining of Gata4 protein. The wild-type embryo (upper) was stained positively whereas the triple knockout pig embryo (lower) had essentially Gata4 immunohistochemically positive cells (representing the heart) at E18.0 (h, heart and fg, There was no heart. Figure 24b provides DAPI staining images for wild type embryos (upper) and triple knockout embryos (lower). Figure 24c provides the merged image of Figures 24a and 24b.
25A and 25B are images showing Myod expression. Myf5, Myod, and Mrf4 are master modulators of skeletal muscle and are restricted to development and skeletal muscle in adults. What is shown here is Myod-GFP gene transplantation expression restricted to somatic cells, diaphragms, and established skeletal muscle at E11.5 (Fig. 25a). Figure 25b is an in situ hybridization of a parasagittal section of E13.5 (mid-pregnancy) mouse embryo using a 35S-labeled MyoD riboprobe. , And the expression of the intercostal and limb muscle groups.
Figures 26a-26c show knockout of porcine MYOD, MYF5, and MYF6 genes. FIG. 26A is a schematic view showing this. The TALEN pair was designed for the pigs MYOD, MYF5, and MYF6 (also known as MRF4) genes. The TALEN binding site (represented by the red arrowhead) was located upstream of the critical (+) helical-loop-helix (HLH) domain for each gene. The TALEN binding site is shown below (indicated by the red arrow) and the amino acid targeting the early termination codon by homology-dependent repair (HDR) is indicated by the yellow arrow. Figure 26b provides an electrophoresis image showing the HDR event identified by RFLP analysis. The HDR template is designed to introduce a novel restriction enzyme recognition site (HindIII) that facilitates the analysis of early termination codons and HDR events. The region of interest for each gene was amplified by PCR and RFLP was evaluated for a population of transfected cells. Closed arrowheads represent uncut or wild-type alleles, while open arrowheads represent the HDR allele. The percent of alleles positive for HDR for MYOD, MYF5, and MYF6 were 14%, 31%, and 36%, respectively. Figure 26C provides an electrophoresis image and sequencing graph for identifying triple knockout. These groups were plated for individual colony isolation. 38 out of 768 (4.9%) colonies represented more than four RFLP events and were further analyzed by sequencing. Five clones were confirmed to be homozygous knockout for all three genes by HDR or frame shift that incorporates early termination codons and by insertion / deletion (in / del) leading to subsequent early termination codon. An example of RFLP analysis and sequencing of triple knockout clones for MYOD / MYF5 / MYF6 is shown.
Figures 27a and 27bMYF5 / MYOD / MRF4The phenotype of triple knockout (KO) is shown. In E18.0, wild-type (Wt) embryos well defined degeneration (s), desmin positive (red) myotome (m), and ongoing muscle tissue (Fig. 27a). Also, the developing cardiac tube showed a strong desmin signal (h). In contrast,MYF5 / MYOD / MRF4The KO embryo showed deficiency of epidermal growth while the heart remained desmin positive (Figure 27b).
Figures 28A-28C show the results of a < RTI ID = 0.0 >MYF5 / MYOD / MRF4Showing the complement of the null embryo. Figure 28a shows the E20 pig supplemented with GFP-MYF5 / MYOD / MRF4It is an image representing a null embryo. Negative GFP was observed in the liver and yolk sac of the embryo. FIG. 28B shows the GFP-MYF5 / MYOD / MRF4Is an image representing the section between pigs from the null embryo E20. Negative GFP was seen in the liver (sinusoids). Figure 28c shows the E20 pig supplemented with GFP-MYF5 / MYOD / MRF4A bar graph showing the PCR of the yolk sac from a null embryo (embryo 1 [shown in FIGS. 28a and 28b], 3, 5). GFP-labeled porcine fibroblasts are positive control whereas wild-type pig liver is negative control.
29A through 29EPDX1 - / -The production of pigs is shown. 29A is a cross-PDX1It is a schematic diagram showing the editing of the TALEN gene of the locus. Figure 29b provides an electrophoresis image showing that the RFLP assay identifies an unmodified heterozygous knockout (open arrowhead) or homozygous knockout (closed arrowhead). 41% of the clonesPDX1Was homozygous knockout. Figures 29c and 29d show E32 (Figure 29c) cloned compared to the pancreas of a wild-type E30 embryoPdx1 - / -Is an image showing pancreatic elimination (?) In a porcine embryo (Fig. 29d). Fig. 29PDX ^{- / -} This is an image showing a comparison of early beta cells between mutant fetuses. Wild type E30 fetal P pancreas, S-stomach, D duodenum.
Figs. 30A to 30C are diagramsHHEX Showing the generation of the knockout (KO). 30A is a cross-HHEX It is a schematic diagram showing the knockout of the gene.HHEXThe gene contains four exons.HindIII KO allele by genetic editingHHEXAnd inserted into exon 2 of the gene. 30B shows the efficiency of gene editingHindLt; RTI ID = 0.0 > III < / RTI > RFLP assay. NewHindThe proportion of chromosomes with the III KO allele (represented by the cleavage product, open triangle) is shown on the gel. Figure 30c shows a fibroblast cloneHindIII < / RTI > RFLP assay. A homozygous KO clone was shown as an asterisk.
Figures 31a and 31b show liver development in the wild type (Figure 31a) and HHEX KO pig embryo (Figure 31b) at 30 days of gestation. Note the absence of liver development in the HHEX KO sample of Figure 31B. The wild type control group in the same gestational period is shown in Fig.
Figures 32A-32F illustrate that knockout of NKX2.1 causes loss of the fetal lung. 32A-32C are images showing lung development in wild-type animals. Figures 32d to 32f are images showing that no lungs occurred in the NKX2.1 knockout animal.
Figure 33 shows an MR image of a fetus pig at 16.4 T representing an internal organ. The gestational age of pigs is 30 days when the crown-rump length is about 20 mm.
34 is a schematic diagram showing the function of dopamine neuron / eye lens PITX3. The illustration is the same gel electrophoresis image showing the generation of TALEN cleavage of the PITX3 gene in FIG.
Figure 35PITX3 KO pigs are images showing the introduction of donor hiPSC or hUCBSC into the blastocyst.
FIG.PITX3 Knockout (KO) provides a schematic diagram showing the transfer of the embryo to the surrogate sow.
FIG. 37 is a graph showing the effect ofPITX3 It is a viscosity chart showing the structure of ocular defect in knockout.PITX3 The knockout essentially eliminated the open eyelid. Supplementation with wild-type stem cells (hiPSC or hUCBSC)PITX2The removal of the open eyelids caused by the knockout of the eyelids was rescued. The graph of Fig. 37 shows the quantitative analysis of the " eyelids " shown in Figs. 18A, 18C and 18E. In FIG. 18A, the eyes of the wild-type pig embryo can be observed. In contrast, the eyes of PITX3 knockout (FIG. 18c) are not visible because the covering skin or eyelids are not translucent. In some PITX3 knockout embryos supplemented with stem cells, they can now be seen through translucent or "open" eyelids (FIG. 18e). These qualitative findings were quantified by evaluating whether each of the nine eyes was "open" or "closed" with blind analysis. Each data point represents an individual percentage that evaluates each eye as " open " to produce an " open eyelid ".
Figs. 38A and 38B show the pigPITX3 Provides immunohistochemical images showing loss of dopaminergic neurons in fetal black cells (SNc) due to knockout. Figure 38A shows tyrosine hydroxylase (TH) -positive neurons in the SNc of the 62nd day of wild-type fetal pigs in the pregnancy. Fig.PITX3 Knockout represents TH positive neurons in the SNc of fetal pigs. Note the loss of dopamine neurons in knockout pigs. VTA = double skin
Figures 39a-39d provide images showing the incorporation of human neurons into chimeric embryos. Figure 39a shows HNA staining of 5 fetal pigs showing that human neuronal cells are present in at least some chimeric embryos. Figure 39b shows tyrosine hydroxylase staining and Figure 39c shows the same 5 NeuN staining of fetal pigs as shown in Figure 39a. Figure 39d provides the merged images of Figures 39a-39c. HNA: human nuclear antigen; TH: tyrosine hydroxylase
Figure 40 provides an immunohistochemical image showing the staining of black stain stained with TH (tyrosine hydroxylase), DAPI and NeuN against black pigment dopamine neurons.
Figure 41 provides a bar graph showing that hiPSC supplementation induces survival of black dopamine neurons. FIG. 41 is a graph showing the results of a comparison between wild type pig (WT)PITX3 Knockout pigs (KO) supplemented with hUCBSCPITX3 KO, and hiPSCPITX3 It shows approximate values of TH-immunoreactivity (TH-IR) counted in both whole black dopamine neurons and inner black matter of KO.
Figure 42LMX1A / PITX3 And dopamine neuron outgrowth. Illustrations using TALENLMXA1AndPITX3 17, which shows gene knockout.
Figure 43 provides a schematic diagram illustrating the generation of chimeric pigs with complementing GFP-expressing porcine nodules and dopaminergic neuron knockout. As disclosed hereinLMX1A / PITX3Knockout fibroblasts were generated. Wild-type pig parasite is derived from knockout fibroblastLMX1A / PITX3Were introduced into blastocysts to produce chimeric blastocysts. Chimeric blastocysts occur as chimeric pigs with immune system organ / cells originating from the donor.
Figures 44a through 44f showPITX3 / LMX1AOf pig-pig supplementation rescues embryonic development. Figures 44A-44C show that the gestational age of the fetus was normal,PITX3 / LMX1A Knockout Illustrates the fetus. Figures 44d-44f show poor embryo development indicating poor complementation.
FIG. 45A shows hemotoxylin and Eosin (H & E) staining of wild-type fetal pig's lens (L). Figure 45B illustrates the lack of lens (L) generation in PITX3 knockout fetuses. R = retina, C = cornea.
Figures 46a-46cPITX3 / LMX1A Provides hemotoxylin and eosin (H & E) staining, which indicates that knockout (KO) pig-pig supplementation restores lens development after stem cell supplementation with porcine precursor cells.
Figures 47a-47d show donor GFP donated to fetal pig brain⁺ It is an immunohistochemical image showing cells. 47B-47D are enlarged detail views of the corresponding portions of FIG. 47A.
Figures 48a-48c show pig-PITX3 / LMX1A It provides an immunohistochemical image of tyrosine hydroxylase, which results in the generation of DA neurons in the primordial midbrain (VM) in the knockout pig embryo. The VMs shown in Figs. 48a to 48c originated from a fetus that showed normal development based on the length of the head buttocks.
Figure 49RAG2 AndIL2RgLt; RTI ID = 0.0 > T cells, < / RTI > B cells, and NK cells.
Figure 50RAG2 AndIL2RgLt; / RTI > is important for thymic development.
Figure 51 provides a schematic diagram illustrating the process of complementing with hematopoietic knockout and GFP-expressing piglets. As disclosed hereinIL2Rg / RAG2 Knockout fibroblasts were generated. Wild-type pig parasite is derived from knockout fibroblastIL2Rg / RAG2 Knockout blastocysts to produce chimeric blastocysts. Chimeric blastocysts occur as chimeric pigs with immune system organ / cells originating from the donor.
Figures 52A-IL2Rg / RAG2 / C-KIT Providing an image indicating that complementation of the knockout results in the production of the thymus. Thymus occurred in the wild-type pig embryo (Fig. 52A)IL2Rg / RAG2 No thymus developed in the knockout pig embryo (Figure 52b). Complementation using wild-type animals from wild-type animals is chimeraIL2Rg / RAG2 / C-KIT Resulting in the development of thymus in the knockout pig (Figure 52c).
Figure 53 shows that GFP < RTI ID = 0.0 >⁺ Providing a graph showing the production of immune cells. Cells were collected from umbilical cord blood, thymus, spleen, peripheral blood mononuclear cells (PBMC) and mesenteric lymph nodes (MLN). Live cells were subjected to FACS without staining. GFP of living cells⁺ Percentages of cells are shown in each graph.
Figures 54a through 54f provide graphs showing immune cell production of the thymus. Cells were collected from the thymus of wild type pig embryos (Figures 54a to 54c) and chimeric pigs (Figures 54d to 54f) and stained for T cells, B cells, and NK cells. Cells were subjected to FACS. The chimeric pigs showed similar immune cell composition in the thymus of the wild-type pig.
Figure 55IL2Rg / RAG2 / C-KIT The supplementation of knockout is associated with T cells in the blood (CD172a^- CD2⁺ CD3⁺) ≪ / RTI > Cells were collected and stained from the blood of wild-type pig embryos, chimeric pig embryos and knockout pig embryos. Collected cells were identified by FACS and counted T cells.
Figure 56IL2Rg / RAG2 / C-KIT The complementation of knockout was found in T cells in the spleen (CD172a^- CD2⁺ CD3⁺) ≪ / RTI > Cells were collected and stained from wild-type pig embryos, chimeric pig embryos and knockout pig embryos. Collected cells were identified by FACS and counted T cells.
Figure 57IL2Rg / RAG2 / C-KIT The supplementation of knockout was found in B cells (CD3^- CD79a⁺ CD21⁺ Or CD21^-) ≪ / RTI > Cells were collected and stained from the blood of wild-type pig embryos, chimeric pig embryos and knockout pig embryos. Collected cells were identified by FACS and B cells were counted.
58IL2Rg / RAG2 / C-KIT Knockout complementation was observed in B cells (CD3^- CD79a⁺ CD21⁺ or CD21^-) ≪ / RTI > Cells were collected and stained from wild-type pig embryos, chimeric pig embryos and knockout pig embryos. Collected cells were identified by FACS and B cells were counted.
59IL2Rg / RAG2 / C-KIT The supplementation of the knockout inhibits NK cells (CD172a^- CD16⁺ CD2⁺) ≪ / RTI > Cells were collected and stained from the blood of wild-type pig embryos, chimeric pig embryos and knockout pig embryos. Collected cells were identified by FACS and NK cells were counted.
Figure 60IL2Rg / RAG2 / C-KIT Knockout complementation was observed in NK cells (CD172a^- CD16⁺ CD2⁺) ≪ / RTI > Cells were collected and stained from the spleen of wild-type pig embryos, chimeric pig embryos and knockout pig embryos. The collected cells were identified by performing FACS and NK cells were counted.
Figure 61PAX3Lt; RTI ID = 0.0 > muscle differentiation. ≪ / RTI >
Figures 62A and 62B show a cross-PAX3 Provide images that represent mutations. FIG. 62PAX3 Lt; / RTI > mice.Splash delayed The mousePAX3 It has an allelic gene mutation. After birth at P0Stain delay The animals showed vertebral fractures (red arrow). Muscle differentiation did not occur at the limb muscle level (white arrow). 62B is a cross-PAX3 The effect of supplementation of blastocysts with mutant mice is shown. Compared with wild-type chimeras, Act-GFP iPSCPAX3 And selectively contributed to the limb skeletal muscle of mutant mice.
Figure 63PDX10.0 > pancreas < / RTI >
Fig. 64NKX2.1Is a schematic diagram showing the regulation of lung development.
Figure 65OLIG1 / OLIG2This is a schematic diagram showing that it is important for generation of the rare prominent glue cells.
Figures 66a through 66c showOLIG1 / OLIG2 Electrophoresis images, and graphs illustrating the production of knockout fibroblasts. The TALEN technique is used to generate the knockout as disclosed herein. Figure 66OLIG1 / OLIG2 Illustrate strategies to generate knockout animals. ssOLIG1 CDS and OLIG2 CDSOLIG1 AndOLIG2 Each open reading frame was used to introduce a stop codon. The two polynucleotides also introduce a Hind III restriction site for RFLP analysis. FIG. 66B shows the effect ofOLIG1 AndOLIG2 It is an electrophoresis image confirming that the termination codon is introduced into the gene. Figure 66c shows theOLIG1 AndOLIG2 To confirm that the termination codon was introduced into the open reading frame of the geneOLIG1 / OLIG2 Provides sequencing results of three colony and wild-type (WT) cells of knockout cells.
FIGS. 67A and 67B are graphs showing changes in GFP-OLIG1 / OLIG2 Knockout pigs provide an image of fetus. The expression of wild typeOLIG1 / OLIG2 Knockout blastocysts. FIG. 69A shows a porcine fetus of the 30th day of pregnancy. FIG. Figure 69b shows systemic fluorescence images of GFP supplemented porcine fetuses.
FIGS. 68A and 68B show that GFP-OLIG1 / OLIG2 Knockout Provides an image that shows the contribution to fetal pig brain. 68A is an image of a fetal pig brain. 68B is an image showing the expression of GFP in the fetal chimeric pig brain showing the incorporation of wild type donor cells into the knockout fetal pig brain.
Figures 69a and 69b illustrate the use of GFP-OLIG1 / OLIG2 And provides an image representing GFP-labeled 3D reconstruction in the spinal cord of knockout (KO). 71A is an image showing tubular restoration. 71B is an image showing lateral restoration.
Figure 70HHEXLt; RTI ID = 0.0 > liver < / RTI >
Figure 71 shows that T cells (CD172a^- CD2⁺ CD3⁺(RG-KO) pigs representing the (pregnant) 100-day-old Il2rg / Rag2 (RG-KO)
72 shows B cells (CD3^- CD79a⁺ CD21⁺(RG-KO) pigs representing the (pregnant) 100-day-old Il2rg / Rag2 (RG-KO)
73 shows the expression of NK cells (CD172a-CD16⁺CD2⁺(RG-KO) pigs representing the (pregnant) 100-day-old Il2rg / Rag2 (RG-KO)
74A to 74C show the results of the post-Pax3 < / RTI > mutant chimeric mice. Figure 74PAX3 Lt; RTI ID = 0.0 > IPSCs < / RTI > (induced pluripotent stem cells) into mutant mouse blastocysts. 74 (b)PAX3 An image showing the presence of a hind leg in a homozygous chimeric mouse. The dashed line shows the position of the cross-section made for histological study of the hind limb (Fig. 74). Figure 74c provides an image showing the histology of the transverse plane of the hindlimb foot. 74c: TP: posterior tibialis muscle; TA: total tibia; EDL; FHL: Zhang Moji; FB / FL: endosseous / endosseous; Sol: Gaza; M-Ga: medial gastrocnemius muscle; L-GA: lateral gut ganglion.
Figures 75a-75fPAX3 A mutant pigPAX3 Indicating the repetition of the phenotype of mutant mice. Figure 75A illustrates the use of the TALENS method as disclosed hereinPAX3 It is a schematic diagram showing the knockout of the gene. 75B provides an electrophoresis image identifying the mutant cells using RFLP analysis as disclosed herein. Figures 75c-75f provide images comparing wild-type and mutant animals. Figures 75c and 75d are images of wild type and mutant pigs at E30, respectively. Figures 75e and 75f are images of wild-type and mutant mice at E12.5, respectively. The hind legs were present in wild-type animals (pig and mouse, Figures 75c and 75e), while the hind paw occurrence was significantly affected in mutant animals (pig and mouse, Figures 75d and 75f).
Figures 76 (a) -PAX Mutant pigs show loss of limb skeletal muscle. 76A is an image of a wild-type pig embryo at E30. 76B is an image of a mutant porcine embryo at E30. The dashed lines in both FIGS. 76A and 76B show the positions of the cross-sections made for immunohistochemistry studies of FIGS. 76C and 76D. Figure 76c provides images showing desmin, MHC and Pax7 staining in wild-type animal hind legs. Figure 76d provides images showing desmin, MHC and Pax7 staining in the mutant animal hind limb.
FIG. 77 shows the distribution ofIL2Rg / RAG2Lt; RTI ID = 0.0 > (RG-KO). ≪ / RTI > The piglets were harvested 2 weeks before birth and genotyped.IL2Rg / RAG2 The expected RFLP banding pattern of double allele knockout was observed. Cells from piglets 2 were used to add another mutation to the C-Kit gene.
Figures 78IL2Rg / RAG2 / C-KIT(RGK) cellsIL2Rg / RAG2 It shows that V831M was incorporated into RG-KO cells. 78A,C-KIT Provides a schematic representation of the location of the mutations introduced into the gene and the polynucleotide design of the C-Kit V831M HDR. 78B provides an array of mice representing the amino acid replaced with the sequence of a portion of the porcine C-KIT protein. 78A and 78B demonstrate that the correct residues have been identified. Figure 78c provides an electrophoresis image confirming that the mutation has been introduced into the genome. Colonies 285 and 286 are examples of homozygous positive for V-M RFLP.
Figure 79 provides a sequencing graph that confirms the incorporation of the C-Kit gene mutation into the cell genome. Clones 162, 285, and 286 contain the V831M mutation. These clones were used in the production of chimeras.
Figure 80IL2Rg / RAG2 / C-KITOf the chimeric fetus. The unbroken band in the red box indicates that the fetus can be a chimera.

The present invention encompasses real human organs such as the heart, liver, kidney, lung, pancreas and skeletal muscle, And methods of manipulating and producing cells such as neurons and spindle glue cells, immune cells, and endothelial cells for angiogenesis. The strategy to achieve this goal is to destroy key genes that are important for the development of certain organs. These genes are evaluated using knockout techniques to knock out specific genes to see if any genes can cause specific organ or cell types, alone or in combination, when knocked out in mouse and pig blastocysts. Gene knockout in blastocysts can create a niche in which normal allogeneic or xenogeneic stem cells can contribute to the desired organ or cell development (Fig. 1). New gene editing and gene regulation techniques using TALENS, CRISPR, and synthetic pig artificial chromosomes are used to improve the function of other genes that can knock out the desired target gene and minimize the off-target effect. Human stem cells are tested to determine what kind of stem cells produce strong replication of specific human organs and cells. This problem is solved by evaluating whether various human stem cells contribute to the inner cell mass of the pig blastocyst and the developing chimeric fetus. The interaction between these three technical domains is important to successfully achieve genuine human organ and cell production.

Justice

Prior to further description of the invention, certain terms used in the specification, examples, and appended claims are collected herein.

As used herein, " humanized " refers to an organ or tissue harvested from a non-human animal whose protein sequence and genetic complement is more similar to that of a human than a non-human host.

&Quot; Organ, " as used herein, refers to a collection of tissues that are joined together in structural units to perform a common function. As used herein, " tissue " refers to a collection of similar cells that together perform a particular function.

As used herein, " meganuclease " is another useful technique for gene editing and is an endo-deoxyribonuclease which is characterized by a large recognition site (a double-stranded DNA sequence of 12 to 40 base pairs) The site usually occurs only once in any given genome. For example, the 18 base pair sequence recognized by the I-SceI meganuclease will require an average of 20 genomes of the human genome size found by chance (but the sequence with only one mismatch is the human size genome Occurs about 3 times). Thus, meganuclease is regarded as the most specific naturally occurring restriction enzyme.

The term " targeted gene " refers to the site of chromosomal DNA selected for endonuclease attack by the design of endonuclease systems, such as TALEN or CRISPR.

As used herein, the term gene editing refers to selecting and modifying genes. Random insertion and gene trapping are not genetic editing. Examples of gene editing include, but are not limited to, gene knockout, nucleic acid addition, nucleic acid removal, removal of all functions, gene transfer of alleles, hypermorphic alteration, hypomorphic alteration, And substitution of one or more alleles.

The term " knockout, inactivated, and destroyed ", as well as variations thereof, means that the gene expression product is removed or greatly reduced by any means so that the expression of the gene does not significantly affect the animal as a whole Are used interchangeably herein. This term is sometimes used to refer to diminishing its role in observing, without fundamentally eliminating the role of the gene. This term generally refers to preventing the formation of functional gene products. The gene product is functional only if it performs normal (wild type) function. Gene disruption includes the insertion, deletion, or substitution of one or more bases in a sequence that prevents the expression of a functional agent encoded by the gene and is encoded by genes and / or promoters essential for the expression of the gene in the animal and / or by the operator do. The destroyed gene may be destroyed, for example, by removal of at least some genes from the genome of the animal, alteration of the gene to prevent expression of the functional factor encoded by the gene, RNA interference, or expression of the dominant negative factor by an exogenous gene .

The term " substitution " of the term allele means, in some cases, a change from the original allele to an exogenous allele without an insert-deletion or other change, except a degenerate substitution.

The term " retrogressive substitution " means that the base of the codon is changed to another base without changing the encoded amino acid. Degenerative substitutions may be selected as exons or introns. One use of degenerative substitutions is to create restriction sites to readily test for the presence of an interfering sequence. Endogenous alleles are also referred to herein as native alleles.

The term " gene " refers to chromosomal DNA that is expressed to produce a broad and functional product.

The term " selection " is used to refer to the ability to identify and isolate cells for later use; Because there was no reporter gene that could be expressed anywhere in the process, it was a very important advantage to distinguish this process from many other approaches.

The term " blastocyst " is used extensively herein to refer to an embryo from two cells to about three weeks.

The term " embryo " is used extensively to refer to animals from the zygote to live births.

The term " gametogenesis " refers to the production of haploid somatic cells (ovaries and sperm) that each transfer half of the parent's genetic complement from the respective parental germ cells. Sperm production is spermatogenesis. The fusion of sperm and egg during fertilization produces zygote cells with the diploid genome.

The term " spouse cell " refers to a precursor of an oocyte or sperm, typically a germ cell or sperm cell.

The term " large vertebrate " refers to apes, livestock, dogs, and cats.

The term " livestock " refers to animals that are conventionally raised for food, such as cattle, sheep, goats, birds (chickens, turkeys), pigs, buffalo and fish.

The term " homologue " typically refers to two interacting biomolecules, such as a receptor and its ligand. With respect to the HDR process, one of the biomolecules can be designed using sequences intended for association with a homologous, DNA region or protein region.

The term " insertion " is used extensively to mean the use of an exogenous sequence as a template for insertion into, or repair of, a chromosome.

The term " exogenous nucleic acid " refers to a nucleic acid added to a cell or embryo regardless of whether the nucleic acid is identical or distinct to the natural nucleic acid sequence in the cell. The term " nucleic acid fragment " is broad and includes chromosomes, expression cassettes, genes, DNA, RNA, mRNA, or portions thereof. For example, the cells or embryos may be selected from the group consisting of non-human vertebrates, non-human primates, cows, horses, pigs, sheep, chickens, birds, rabbits, goats, dogs, cats, laboratory animals, .

As used herein, " operably linked " refers to the location of the regulatory region relative to the nucleic acid sequence in a manner to allow or facilitate the transcription of the target nucleic acid.

As used herein, " replacement of an allele " refers to a non-meiotic process that copies an exogenous allele on an endogenous allele. The gene has an allele. Genotypes are homozygous if two identical alleles are at a specific locus and homozygous if the two alleles are different. An allele is an alternative form of a gene (a pair of members) located at a specific location on a particular chromosome. Alleles determine distinct traits. Alleles have base pair (bp) differences at specific positions in their DNA sequences (distinct positions or bp) that cause unique traits and distinguish them from each other, and this distinct location serves as an allele marker. Alleles are commonly described and are described herein as having the same bases at the locations where they are distinguished; An animal naturally has certain mutations in another bp within another locus. Those skilled in the art will normally accept natural variations when comparing alleles. The term exactly the same is used herein to mean that there is absolutely no bp difference or insertion-deletion in the DNA sequence.

Genetic complement

Classically, genetic complementation refers to the production of wild-type phenotypes when two different mutations are combined in a diploid or heterokaryon. However, the modern technology of chimeric production can now rely on stem cell supplementation, whereby more than one embryo-derived cell is combined into a single genetically mixed animal. In this case, the complement does not involve any change in the genotype of the individual chromosomes; Rather, it represents a mixture of gene products . Complementation occurs during the time when the two cell types are in the same embryo and each can provide function. Thereafter, each chromosome remains unchanged. In the case of chimeras, complementation occurs when two different sets of chromosomes are active in the same embryo. However, the offspring resulting from this supplement can have cells of each genotype. In complementing the embryo, the gene of the host embryo is edited to produce knockout or otherwise non-functional genes. When human stem cells are injected into genetically-edited blastocysts, they can rescue or " complement " the binding of the host (edited) genome. If the knockout genes or genes support the growth of a particular organ or tissue, then the complementarily produced tissue may be the result of unedited growth and differentiation, such as stem cell induced genotypes. When human stem cells are used to complement the host-edited genome, the resulting tissue or organ can be composed of human cells. In this way, using other animals as a host for complementary organs, a complete human organ can be produced in vivo.

Multiplex gene editing procedures are also described because multiple genes can be responsible for the growth and differentiation of any particular organ or tissue. Multiple genes can be transformed or knocked out for use in research or in cells or embryos that can be used to make whole chimeric animals. This embodiment involves complementing cell or organ loss by selective depopulation of the host niche. This invention provides rapid production of animals that serve as a source of cells and cell products for models, foods, and industries and medicines.

BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 provides a schematic description of the problem and proposed approach for providing customized human organs and tissues to those in need using pigs as host animals. One of skill in the art will recognize that techniques that allow the production of induced pluripotent stem cells (IPCS) will allow the patient to supplement the edited gene and provide the patient's own stem cells for the production of human or humanized " It is possible to understand that it is possible.

The use of multiplex gene editing is important for producing host animals with multiple edited genes that need to be supplemented. In Figure 2a, there is a timeline that explains why it takes years to create a livestock with only two edited alleles using a single edit, which is about six years for cattle. Editing in this context refers to selecting and modifying genes. First, the gene of interest must be edited, e.g., knocked out (KO), in cultured somatic cells cloned to produce a heterozygous calf with targeted knockout (KO). The heterozygotes were raised to maturity for breeding until they reached the age of 2 years in the cattle, so that first-generation (F1) male and female heterozygous calves were born and breed to form homozygous knockout calves (F2) Will occur. It would be impractical to generate a homozygous for a multitargeted mutation using conventional approaches in cattle. The number of years required and the number of animals required to manufacture additional compartments increases in an approximately exponential manner according to the particular schedule used as illustrated in Figure 2b. Among vertebrates, even animals with more offspring per generation and shorter gestation periods than cattle would require an excessively long time to achieve multiple compilations. For example, pigs have more offspring per breed and pregnancy is about half the size of cattle, but the time to make multiple edits can take years. In addition, plans to minimize time by active inbreeding can be quite impossible for multiple compilations. Sequential cloning is also undesirable in terms of process and results, especially when the animal must be useful as a livestock or laboratory model.

The opportunity provided by the present invention shown in Figure 3 shows multiple compilations made in the first generation animal (F0). The embryo may be prepared by direct cloning into two or more complements that are independently selected to be heterozygous or homozygous, and placed in a surrogate mother to become pregnant. The animal that is created is the F0 generation founder. A plurality of embryos may be prepared and placed in one or more surrogate mothers to produce offspring of both sexes, or a well known embryo-segmentation technique may be used to produce a plurality of cloned embryos. Typically, livestock such as pigs producing one litter of both genders can be crossed and breed.

Multiple alleles may be destroyed or otherwise edited in a cell or embryo using a targeted endonuclease and homologous target recovery (HDR) as described herein. One embodiment is a method for producing a genetic compartment in a vertebrate animal cell or embryo in a vertebrate animal cell or a plurality of target chromosomal DNA regions of an embryo, the method comprising: obtaining a first targeted endogenous A first homologous target recovery (HDR) template homologous to the cleavage and first target site sequence; And introducing a second targeted endonuclease directed at a second target chromosomal DNA region and a second HDR template homologous to a second target site sequence into a vertebrate animal cell or embryo, wherein the first HDR template sequence Replaces the original chromosomal DNA sequence at the first target site and the second HDR template sequence replaces the original chromosomal DNA sequence at the second target site sequence.

It was surprising and unpredictable to know that multiple edits such as knockouts or substitutions could be obtained. One theorized mechanism is that there are a few cells that are receptive to multiple complements because they are at a particular stage of the cell cycle. When exposed to endonuclease and HDR templates, they react easily. The related theory of operation is that the HDR templating process itself is suitable for multiple substitutions because the activation of the cell repair machinery for one targeted site is equally likely to result in recovery or HDR molding . Since HDR was historically inefficient, multiple HDR compilations were obviously not attempted, observed, or perceived.

Previously, previous experiments using xenogeneic complementation were performed only in a single editing genome. However, the platform disclosed for multiplex gene editing now provides host blastocysts with multiple edited genes that enable complementation of such edits by human stem cells and resulting organ and tissue production.

The present results show that too much or too little endogenous nucleases and / or HDR templates can have a negative effect, which can prove that previous studies in this area are wrong. In fact, it has been observed that the targeted endonuclease may fail because it is designed and manufactured correctly but nevertheless is too efficient. Furthermore, successfully transformed cell populations often do not improve over time. Those skilled in the art of transforming cells will routinely seek the lifespan and variability of the cell as an indicator of stability and health for successful cloning or other uses. However, this prediction was often not useful in our multiplexing process. Furthermore, homologous recombination (HR) gene transfer efficiency was observed to be variable in the multiplex approach compared to single-locus gene transfer. Some loci were very sensitive, but other loci declined significantly. There is obvious interference between endonucleases, but the net effect can not be briefly described, for example, by assuming that endonuclease is competing for universal resources.

There are a variety of well-known techniques for making random or inaccurate insertion of many genes into multiple locations of chromosomal DNA, or for producing many random compartments that destroy multiple genes. As demonstrated, random or imprecise processes will not be of assistance to scientists who need to edit a plurality of specifically targeted genes to achieve an effect. Thus, the HDR process taught herein can be easily distinguished by the fact that the complements and the resulting organisms are made only at the intended target site. One difference is that the HDR editing embodiments of the present invention can be performed without additional gene copies and / or without destroying genes other than those targeted by endonuclease. And, a specific compilation is made at one location because the HDR template sequence is not copied into the site without proper homology. Embodiments include organisms and processes in which an exogenous allele is copied into chromosomal DNA only at its cognate allele site.

The advantage of HDR-based editing is that edits can be selected. In contrast, other attempts by the non-homologous end joining (NHEJ) procedure can create insertion-deletion at multiple locations to cancel each other if the insertion-deletion does not create a frame shift. This problem becomes significant when multiplexing is involved. However, the successful use of HDR provides that a compilation can be made to ensure that the target gene has the intended frame shift, if desired. In addition, allele replacement requires HDR and can not be achieved by NHEJ, vector-driven insertion of nucleic acids, transposon insertion, and the like. Moreover, selecting an organism that does not contain undesired compilations increases the degree of difficulty.

However, it is generally believed that multiplex complements as described herein have not already been achieved in targeted areas of cells or animals associated with livestock or large vertebrates. It is well known that when an animal is cloned from cells with high subculture numbers, genetic damage is too much to make animals that are not useful as experimental models or livestock F0 pounders.

Genetic editing is a stochastic process; As a result, the arts have traditionally highlighted various screening techniques to identify a small percentage of successfully edited cells. Since this is a stochastic process, the difficulty in manufacturing a plurality of compilations can be expected to increase exponentially by the skilled artisan as the number of intended compilations increases.

One embodiment of the invention provides a method of producing a multi-targeted gene knockout or other compartment in a single cell or embryo, a process referred to herein as multiplex gene knockout or editing.

A similarity test for allele identification is to align the chromosomal DNA in the altered organism with the chromosomal DNA of the exogenous allele as it is recognized in nature. An exogenous allele may have one or more allelic markers. The DNA sequence upstream and downstream of the marker may be the same for a certain distance. Depending on the desired test, this distance may be, for example, 10 to 4000 bp. Of course, the base on either side of the templateed region will have some degree of natural variation, although the HDR template may be expected to produce an exact matching sequence. Those skilled in the art routinely distinguish alleles despite the presence of natural variations. Those skilled in the art will readily appreciate that all ranges of values between the exemplary boundaries are taken into account and any of the following distances is available as an upper or lower limit: 15, 25, 50, 100, 200, 300, 400 , 500, 600, 800, 1000, 1200, 1400, 1600, 1800, 2000, 4000.

One skilled in the art can also distinguish gene complements from alleles that are the result of gene editing in contrast to sex reproduction. It is obvious that an allele is derived from another species that can not reproduce sexually to mix an allele. And many compilations are simply not found in nature. Also, compilations can be easily distinguished when they are transferred from one variety to the next, even when substitutions are made to accurately reproduce alleles found naturally in another. Alleles are located stably on DNA for most of the time. However, while forming a spouse, meiosis causes the male and female DNA to occasionally exchange alleles, and this event is called a crossover. Cross-frequency and genetic maps have been extensively studied and developed. In the case of livestock, the lineage of the animal can be traced in more detail during many generations. In genetics, centimorphan (cM, also referred to as map unit (m.u.)) is a unit for measuring genetic linkage. This is defined as the distance between chromosomal locations (locus or locus markers) with an expected average number of intervening chromosome crosses in a single generation. Genes close to each other have a lower crossover rate compared to genes that are remotely located on chromosomes. Crossing is a very rare event when two genes are directly next to each other on a chromosome. This crossing of a single allele associated with two neighboring alleles of a single allele is not feasible and should be the product of genetic manipulation. Even when animals of the same breed are involved, natural alleles versus engineered alleles can be easily identified if parents are known. And bloodlines can be identified with high accuracy by genetic analysis of potential parents. Parental identification is routine in animal groups and humans.

Embodiments include simultaneous multiplex gene editing methods. The term coincidence is in contrast to the hypothetical process of processing cells multiple times to achieve multiple complements, such as sequential knockout or sequential cloning or cycle of animal breeding. Simultaneous means that they are present simultaneously in a useful concentration, for example, that there is a multi-targeted endonuclease. The procedures are applied to the zygote and the embryo so that all or essentially all cells can produce an edited allele or knockout organism. For example, essentially all cells in the context of a knockout refer to knocking out genes in many cells, so that the gene product of the gene is ineffective in terms of the function of the organism, so that the gene is virtually absent. These processes transform cells, and cells within the embryo, during a minimum number of cell divisions, preferably between about 0 and about 2 divisions. Embodiments include processes that occur over a rapid course or multiple times, or are considered to be, for example, 0-20 replications (cell division) where cell division numbers are considered. Those skilled in the art will appreciate that all values and ranges within expressly stated limit values, such as from about 0 to about 2 replications, from about 0 to about 3 replications, about 4 replications, from about 0 to about 10 replications, 17 times; Less than about 7 days, less than about 1 day, less than about 2 days, less than about 3 days, less than about 4 days, less than about 5 days, or less than about 6 days; About 0.5 to about 18 days, etc. will be considered. The term low number of subculture refers to primary cells in which up to about 20 replications have been performed.

Wherever, the allele of a single embryo, maternal allele, paternal allele, or both can be edited in bovine and porcine embryos, thus template editing of both alleles can be performed using HDR in the embryo Respectively. These compilations were formed at the same locus. Specifically, gene transfer from sister chromatids was observed. Carlson et al., PNAS 43 (109): 17382-17387, 2012.

Referring to Figures 4A-4D, Example 1 illustrates using HDR editing to knock out two genes at once, and further using homozygous for both knockout or heterozygous cells for each knockout Of the experiments that have successfully attempted to be screened. Introducing first and second targeted endonuclease (each of TALENS pairs) to a first gene target (recombinant activation gene 2, RAG2) and a second gene target (interleukin receptor 2, gamma, IL2Rg or ILR2γ) Lt; / RTI > cells. TALENS was designed to target the intended site and had to be manufactured in the proper amount. Treatment of the cells took less than 5 minutes. Electroporation has been used, but there are a number of other suitable proteins or DNA introduction processes described herein. The cells were then cultured to allow the formation of individual colonies of cells derived from untreated cells. Cells from various colonies were tested after 3 or 11 days. The knockout rate of RAG2 was about six times faster than the knockout rate of IL2Rg; Obviously, some genes are more difficult to knock out than others. Both knockout genes were highly efficient and successfully identified heterozygous or homozygous cells for both knockout. Significantly, the doses of TALEN mRNA and HDR templates had specific and non-specific effects. The increase in TALEN mRNA for IL2Rg increased both NHEJ and HDR against IL2Rg, but the level of NHEJ for RAG2 remained unchanged. The increase in the IL2Rg HDR template decreased HDR in the RAG2 locus, suggesting a nonspecific inhibition of homologous target recovery by elevated concentrations of oligonucleotides. This dose sensitivity, especially at such low doses, has allowed others to deviate from the objectives of the multiplex process. The cells of Example 1 were cloned and two animals were pregnant with these derived embryos at the time of application.

Referring to Figures 5a to 5d, Example 2 describes an experiment with the same objective of multiplex HDR editing except for the different genes. The first gene target was Adenomatous polyposis coli (APC). The second gene target was p53 (TP53 gene). Both homozygous for the knockout and heterozygous for the knockout of both were identified and identified.

Referring to Figures 6 to 9, Example 3 describes multiplex HDR editing for knocking out 2 to 5 genes. There were three experiments and the number of cell colonies tested for genotypes ranged from 72 to 192 for each experiment. Were treated for multiplex knockout of various combinations of the genes APC, p53, RAG2, LDLR, IL2Rg, Kisspeptin receptor (KISSR or GPR54), and eukaryotic translation initiation factor 4GI (EIF4GI) . The gene LDLR was consistently less receptive to deformation than other genes. As evidenced by the results, multiple alleles can be disrupted simultaneously using TALEN-specific, homologous target recovery (HDR). The five TALEN pairs, each resulting in an excess of 20% HDR / region and resulting in their homologous HDR template, co-transfected simultaneously in three combinations (Table A). The proportion of colonies in each replicate was positive for HDR events in at least four genes, and two colonies from duplicate-A had HDR events in all five genes. Although the simultaneous formation of insertion-deletion in five genes has been demonstrated by Cas9 / CRISPR-stimulated NHEJ in mouse embryonic stem cells (ES or ESC, used interchangeably), the targeted nuclease-stimulated HDR The precise transformation of the five genes (less than 7 alleles) by the gene is unexpected and surprising and unparalleled. When the replicate TALEN was replaced with Cas9 / CRISPR (vector introduced into the cell for expression), the level of deformation was below detection (data not shown); Other data, however, refer to RGEN multiplexes, for example, as in Example 9 below. Four genes were confirmed to have been edited in all experiments, and five genes were identified in one experiment.

The speed and efficiency of this process increases the scale of itself so that multiplex knockout of more than five genes can be achieved without changing the nature of the process. With reference to Table A, about 72 to 192 cells were tested; Since this process has been established, it is not unreasonable to increase the number of tests to a much larger number of cells so that more multiplexes of genes / alleles can be predicted. The number of multiplex genes or alleles may be from 2 to 25; Those skilled in the art will readily appreciate that all ranges and values between the explicitly stated boundaries are taken into account and any of the following numbers available as upper or lower bounds are combined with each other: 2, 4, 5, 6, 7, 8, 9 , 10, 11, 12, 14, 16, 18, 20, 25.

[Table A]

As evidenced, cells and embryos comprising multiplex knockout as well as the animals produced thereby are embodiments of the present invention.

Example 4 describes a somewhat detailed process for producing various animals, and reference is made to a specific gene as an example. Example 5 describes an embodiment of the design and manufacture of CRISPR / Cas9.

Example 6 provides additional examples of multiplex gene editing using targeted nuclease driven HDR procedures. GATA binding protein 4 (GATA4); Homoe box proteins NKX2-5 (NKX2-5) and mesodermal lobe protein 1 (MESP1) were simultaneously targeted using TALEN and HDR templates to induce frame-shift mutations and premature termination codons for each gene. The objective was to generate a biallelic knockout for each gene for use in complementary studies. Since the two clones had the intended allele HDR in each gene, the process was about 0.5% efficient. Knocking out a given gene, either alone or in combination, can lead to uncomplicated growth disorder genotypes and early embryo lethality. Those skilled in the art will understand that knockout of such genes and breeding of heterozygotes separately from each other to achieve triple knockout for FTT and complementary studies (about 1/66 chance) are not feasible in livestock.

Example 7 provides data that TALEN and Cas9 / CRISPR can be mixed to perform multiplex editing of genes. Some genes / alleles are more easily targeted by TALEN, or Cas9 / CRISPR, and situations may arise in which multiplexing must be performed using a combination of these tools. In this example, the eukaryotic translation initiation factor 4GI (EIF4GI) was targeted by TALEN and the p65 (RELA) gene was targeted by Cas9 / CRISPR. Cells were analyzed by RFLP assay for HDR events, and HDR was demonstrated in both sites. Thus, TALEN and RGEN can be combined with one or more RGEN reagents such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 TALEN and 1, 2, 3, 4, 5, 6, 7, May be used together or separately for multiplexing combinations comprising any combination.

chimera

Chimera can be prepared by preparing a host blastocyst and adding donor cells derived from a donor animal. The resulting animal may be a chimera with cells originating from both the host and the donor. Some genes are important in embryos to produce certain types of cells and cell lines. If such genes are knocked out in host cells, the introduction of donor cells with the missing gene may allow such cells and cell lines to restore to the host embryo; The recovered cells have donor genotypes. This process is called a complementary process.

Matsunari et al., PNAS 110: 4557-4562, 2013 describe a supplemental procedure for producing donor-derived porcine pancreas. They produced modified host pig blastocysts to prevent the formation of functional pancreas. They produced host blastocysts by somatic cell cloning. Somatic cells were modified to overexpress Hes1 under the promoter of Pdx1 (pancreatic and duodenal humeno box 1) known to inhibit pancreatic development. Donor cells added to host blastocysts did not have this modification; Donor cells supplied to the cell line needed to form the pancreas. These have already proven elsewhere that functional organs can be generated from pluripotent stem cells (PSC) in vivo by blastocyst supplementation in mouse embryos that are not capable of organogenesis. They proposed a future study using xenogenic pluripotent stem cells (PSCs), including human induced PSCs. In fact, xenotransplantation has been considered as a potential solution to organ / tissue deficiency for over 40 years. It is important that no genes are knocked out to disable pancreatic formation.

Knocking out even a single gene in large vertebrates is a significant resource investment using conventional processes. In contrast, overexpression of a gene product in a cell is readily accomplished using a plasmid or vector that now positions the multiple gene cassette copy in the art, such as the genome. Adding gene expression is easier than targeting genes and knocking them out. The ability to prevent organogenesis by differentiation of gene products is now considered to be unusual. In fact, the limitations of the ability to manipulate large animal genomes can be substantial. Nonetheless, pigs are desirable donor animals for xenotransplantation because their size and physiological characteristics are similar to humans, as well as their fertility and growth rate.

Figure 10 shows the multiplex process used herein to produce a gene knockout or other gene complements as applied in the context of chimeras. Low-staged primary somatic cells are produced by gene knockout. Cells with precisely targeted heterozygosity and homozygosity distribution for knockout are isolated. These cells are used in cloning to produce embryos that are allowed to develop as host blastocysts. Donor embryos are constructed and used as a source of donor cells providing genes for filling the site formed by knockout. Donor cells are introduced into host blastocysts and replicated with host cells to form chimeras with both host cells and donor cells. The embryo is transferred to the surrogate mother and becomes pregnant. Chimeric offspring have a host genotype when the host cell forms a spouse. Chimeras have a sex determined by their host blastocysts.

Figure 11 shows a growth inhibition phenotype (FTT) supplementation process. FTT refers to animals that are not expected to survive to sexually mature age. Host embryos with FTT genotypes and phenotypes are provided. The multiplex procedure is ideal because the available FTT by knockout of only one gene is limited and not known to some organs and tissues. Donor cells provide missing genes in FTT and provide missing cell types. The embryo can be a large vertebrate and the knockout can be a multiplex, such as 2 to 25 genes. In addition, targeted endonuclease may be used to achieve knockout. In an immunodeficient embodiment, IL2Rg- / y RAG2 - / - knockout is an FTT, since the host is essentially immunocompromised. However, donor cells do not have such gene deletion and the resulting chimera has an inherently normal phenotype for the purpose of raising and maintaining the animal. However, the offspring have the FTT phenotype. Thus, animals can be maintained and FTT animals are conveniently created. A chimera may be any combination of heterozygotes and homozygotes for knockout. Thus, a chimera manufacturing process is described that is an F0 generation animal that produces a growth inhibition (FTT) phenotype when the other process requires an additional generation or more.

Chimeras typically carry the genetic characteristics of host cells. However, alternative chimeras have been disclosed herein that deliver the genetic characteristics of the donor cells to their offspring and not the genetic trait of the host cell. Changing genetic succession has been shown to create some useful opportunities. Referring to Figure 12, a G-host labeled embryo is shown. Embryos were produced using nonfunctional spouses. Donor blastocysts are prepared and used as a source of donor cells. Donor cells provide the genes and cell lines necessary to produce donor spouses. The generated chimera has a spouse of donor cells and produces offspring with genetic characteristics of donor cells. In the example, the host embryo is a male Brahman bull. Donor cells are derived from double-muscled bulls. Chimera has a Brahman bull phenotype, but its offspring are double muscles. The host and the donor may be from the same or different varieties or from the same or different species. The host is made to be infertile, which means that the host can not reproduce sexually. Some infertile animals can be used to produce non-functional germ cells, such as immature sperm, or for example, to prevent premature spousal formation from creating destroyed germ cells at all. The donor cell can be, for example, a wild-type cell, a cell of an animal breed with the desired trait, or a genetically modified cell.

Embodiments of the invention include chimeric infertility animals, such as chimeric livestock, with genetic modifications to chromosomes that prevent spousal formation or spermatogenesis. The chromosome may be an X chromosome, a Y chromosome, or an autosomal chromosome. Deformation may involve the destruction of existing genes. Destruction can be generated by altering existing chromosomal genes so that they can not be expressed, or by genetically expressing factors that can inhibit transcription or translation of the gene. One embodiment is the knockout of spermatogonial stem cells (SSC) in the host. An animal may be produced using donor cells that have desirable genetic characteristics and provide SSC cells that produce a spouse with a donor genotype. Some genes are combined and destroyed to exert one or more effects that cause infertility, for example the following combinations: Acr / H1.1 / Smcp, Acr / Tnp2 / Smcp, Tnp2 / H1.1 / Smcp, Acr / Smcp, Tnp2 / H1t / Smcp (Nayernia K; Drabent B; Meinhardt A; Adham IM; Schwandt I; Muller C; Sancken Kleene KC; Engel W Triple knockouts reveal gene interactions affecting fertility of male mice. Dev 70 (4): 406-5 16, 2005). Embodiments include that the male offspring of the lineage is infertile, including the first line of the animal with knockout of the first gene or genes and the second line of the animal with the second gene or genes.

The use of genetic engineering to generate genetically modified large vertebrates can accelerate the production of animals with desirable traits. Traditional cattle breeding is a costly and time-consuming process, with generous choice of genetic traits and long wait for generation to breed. Even with careful selection of the traits, variations in ovarian reproduction cause considerable problems in culturing and delivering the desired trait combination. However, the production of chimeras that carry donor traits constitutes an animal breeding method that allows rapid propagation of desirable genetic traits as well as protection of proprietary control of traits. Embodiments include the production of genetically and genetically infertile animals that can serve as hosts for the donated genetic material. Mating by the host can propagate the genetic material of the donor. Using the group of genetically infertile animals, the same gene from a single donor can be propagated by sexual reproduction, and thus a large number of donor offspring can be produced rapidly. The embodiment prevents a user receiving an animal from easily breeding an animal having this trait, including animals modified to produce only one sex.

Embodiments include applying a genetic modification to a cell or embryo to inactivate an optional gene or genes for spouse formation or sperm activity. One process of genetic modification involves the introduction of a targeted nuclease such as Cas9 / CRISPR or mRNA to a TALEN pair that specifically binds to the gene. The animal is cloned or transformed from the cell and the embryo is raised directly from the surrogate mother. The animal may be a livestock animal or other animal. Spousal formation can be blocked at an early stage. Or sperm activity that is important to fertility but is not important to animals can be destroyed. Thus, animals are infertile because they can not reproduce sexually; However, ART can be used to generate offspring from transformed sperm. A donor animal with the desired genetic trait (as a result of breeding and / or genetic manipulation) is selected.

F0 generation with two or more knockouts

Two, three or more genes (2 to 25) can be knocked out simultaneously using a multiplex to produce an F0 generation with the desired combination of alleles. If homozygosity for all knockouts produces FTTs, one option is to make the founders homozygous for all knockouts, except when there should be minimal heterozygosity for the situation. One heterozygous gene can enable non-FT expression. Alternatively, multiplex knockout may be used in combination with complementary to produce a proliferating chimera with FTT progeny. This process can eliminate the generation of multiple knockout animals.

In either case, the advantage is large and moves many processes to areas that can actually achieve them. Generation of animals with knockout of two loci by conventional breeding is costly because F2 generation can have the desired phenotype of only about 6% of its offspring (Table B). In contrast, the multiplex approach allows the generation of desirable genotypes in the F0 generation, a significant advantage over conventional knockout and breeding. It should be emphasized that time and animal conservation is not theoretical: it is progress that enables some kind of transformation because success is expected instead of failure. Also, in order to continue the example, breeding between one or two chimeric RG-KO parents will significantly increase the production rate of RG-KO progeny by 25% and 100%, respectively (Table B).

[Table B]

An immunodeficient animal

One class of embodiments relates to immunodeficient pigs or other animals, and methods of making them. This embodiment is an example of a knockout that takes advantage of the opportunity to manage selection of multiplex edits, e.g., homozygous and heterozygous knockout genotypes. They demonstrate the power of the multiplex to build the foundation system quickly. It also encompasses additional aspects of the invention, including making chimeras.

Pigs are non-primate animal models that are most relevant to humans mimicking human size and physiology. Unfortunately, fully immunodeficient pigs are not widely available because (1) single gene knockout (KO) is usually not sufficient and (2) multiple-locus null Are extremely costly and may be possible depending on the number of KOs, and (3) only a small scale of sterile facilities are available to pigs. Herein, embodiments include large vertebrates with both RAG2 and IL2Rg ( i.e., RG-KO) knocked out. These genes can be knocked out in somatic cells and used for cloning to produce whole animals. Alternatively, the embryo can be processed to knock out the gene, and the animal is directly derived from the embryo. Multiplex gene-targeting platforms can simultaneously destroy T, B, and NK cell development in pigs. Thus, animals produced without these cells can be produced directly by the methods herein as F0 pounders, but the phenotype is FTT.

Agricultural Targets for Multiplex Editing

Editing of the edible animal genome can be greatly accelerated by editing numerous loci simultaneously, omitting many generations of animal breeding instead of collecting alleles generated one at a time. In addition, some agricultural traits are complex, meaning that these traits appear as a result of the influence of alleles in more than one (2 to several hundred) genes. For example, polymorphisms in DGAT, ABCG2, and chromosome 18 together account for most of the variation in Net Dairy Merit in dairy cows. Animal cells or embryos can undergo multiplex editing of a number of genes, including a variety of agricultural targets: one or more ACAN, AMELY, BLG, BMP 1B (FecB), DAZL, DGAT, Eif4GI, GDF8, Horn-poll locus, IGF2, CWC15, KissR / GRP54, OFD1Y, p65, PRLR, Prmd14, PRNP, Rosa, Socs2, SRY, ZFY,? -Lactoglobulin, CLPG.

Disease Modeling Targets for Multiplexing

Some traits such as cancer are induced based on mutations in multiple genes (see APC / p53). In addition, many disease traits are so-called complex traits that appear as a result of the effect of alleles in more than one gene. For example, diabetes, metabolic diseases, heart diseases, and neurological diseases are considered to be complex traits. Examples include animal models that are heterozygous and homozygous for the individual alleles, or animal models that are combined with alleles from other genes in different combinations. MODY 1 (HNF4α), MODY 2 (GCK), MODY 3 (HNF1α (HNF1α), and MODY 3 (HNF1α) have been associated with diabetes mellitus, MODY 4 (Pdx1), MODY 5 (HNF-1β), MODY 6 (Eurogenic Differentiation 1), MODY 7 (KLF11), MODY 8 (CEL) 11 (BLK). The animal cell or embryo can undergo multiplex editing of various genes for animal modeling, including various disease modeling targets: APC, ApoE, DMD, GHRHR, HR, HSD11B2, LDLR, NF1, NPPA, NR3C2, p53, PKD1, Rbm20, SCNN1G, tP53, DAZL, FAH, HBB, IL2RG, PDX1, PITX3, Runx1, RAG2, GGTA. Embodiments include cells, embryos and animals, e.g., of KO, wherein one or more of the above targets are edited.

The genes in one species always have orthologs in other species. The genes of humans and mice consistently in the livestock, especially in cattle, pigs, sheep, goats, chickens, and rabbits. The genetic mutation between these species and fish is often consistent with the function of the gene. Biologists are familiar with the process of looking for gene orthologs, so genes can be described in terms of one of the species without listing the species orthologs here. Thus, an embodiment describing the destruction of a gene involves the destruction of an ortholog having the same or different names in different species. There is a database specialized for the identification of genetic nursery as well as general genetic databases. Those skilled in the art are also well aware of the abbreviations commonly used for genes and use the context to identify which genes are referenced when there is more than one abbreviation for the gene or when two genes are referred to by the same abbreviation .

Stem cell provides a second genetic modification method of livestock. Genetic modification or gene editing can be performed in vitro in stromal stem cells isolated from donor testes. The transformed cells are transplanted into the testes that lack the germ cells of the recipient. Transplanted stem cells produce sperm with genetic modification (s), which can be used in breed improvement through artificial sperm injection or in vitro fertilization (IVF) to induce founder animals.

Supplementation of nullomorphic cells or organ loss by selective de-aggregation of host spots

Multiplex editing may be used to deliberately remove cells or organs from a particular embryo or animal site to create an environment that helps in better donor cell integration, proliferation, and differentiation to produce organs, cells or tissues in the embryo, fetus, They can supplement their organs and enhance their contribution. Animals with empty spots are deficient carriers because they are engineered to have deficiencies that can be filled by donor cells and genes. Specific examples include donor-depletion and donor-structures of the spousal cell lineage (DAZL, VASA, MIWI, PIWI, etc.).

In another embodiment, multiplex gene editing can be used to induce congenital alopecia and can provide donor-derived cells with an opportunity to participate in folliculogenesis. Genes considered to be multiplexed gene edits to cause alopecia include those identified in OMIM and human phenotypic ontology databases: DCAF17, VDR, PNPLA1, HRAS, telomerase -vert, DSP, SNRPE, RPL21, LAMA3, UROD, EDAR, OFD1, PEX7, COL3A1, ALOX12B, HLCS, NIPAL4, CERS3, ANTXR1, B3GALT6, DSG4, UBR1, CTC1, MBTPS2, UROS, ABHD5, NOP10, ALMS1, LAMB3, EOGT, SAT1, RBPJ, ARHGAP31, ACVR1, RAG2, RAG2, RAG2, RAG2, RAK2, RAK2, RAK2, RAK2, RAK2, IKKG, LPAR6, HR, ATR, HTRA1, AIRE, BCS1L, MCCC2, DKC1, PORCN, EBP, SLITRK1, BTK, DOCK6, APCDD1, ZIP4, CASR, TERT, EDARADD, ATP6V0A2, PVRL1, 1, ROR2, CLAUDIN1, ABCA12, SLA-DRA1, B4GALT7, COL7A1, NHP2, GNA11, WNT5A, USB1, LMNA, EPS8L3, NSDHL, TRPV3, KRAS, TINF2, TGM1, DCLRE1C, PKP1, WRAP53, KDM5C, ECM1, TP63, KRT14, RIPK4. The chimeric phenomenon of donor cells with potential hair growth can be used to grow human hair follicles. Removal of organs or tissues from pigs or other vertebrates, and growth of organs or tissues of human origin are particularly useful as sources of medical organs or tissues.

Additional complementary targets for multiplexing are: PRKDC, BCL11a, BMI1, CCR5, CXCR4, DKK1, ETV2, FLI1, FLK1, GATA2, GATA4, HHEX, C-KIT, LMX1A, MYF5, MYOD1, MYOG, NKX2-5 , NR4A2, PAX3, PDX1, PITX3, Runx1, RAG2, GGTA, HR, HANDII, TBX5.

Implementations include targeting one, two, or more (two to twenty-five) of the targets by a multiplex approach or other approach.

Edited gene

The methods and inventions described herein with respect to particular targets and targeted endonuclease are broadly applicable. All of the following genes were used to produce primary livestock cells suitable for cloning using compilations.

[Table C]

Genetically modified animal

Genomic or double-allelic genotype for chromosomal anomalies, by using a method that allows genetically expressible markers to be placed in place so that they can be propagated from the animal, or by not placing such markers in the animal Can be prepared. For example, homology-dependent recombination (HDR) methods have been used to alter chromosomes in animals or to insert foreign genes. Tools such as, for example, TALEN and recombinant enzyme fusion proteins, and conventional methods are discussed elsewhere herein. Some of the experimental data supporting genetic modification disclosed herein are summarized as follows. Exceptional cloning efficiency has been demonstrated when cloning from a polygenic population of transformed cells and this approach has been claimed to avoid variation in cloning efficiency due to somatic cell nuclear transfer (SCNT) to isolated colonies [Carlson et al., 2011]). However, additionally, TALEN-mediated genomic modification and modification by recombinant enzyme fusion molecules provide a double-allelic alteration that should be achieved in a single generation. For example, animal homozygotes for knockout genes can be produced by SCNT and can produce homozygotes without inbreeding. Maturation to gestation and breeding age for livestock such as pigs and cattle is a significant barrier to research and production. For example, the production of homozygous knockout from heterozygous mutant cells (both positive) by cloning and breeding requires 16 and 30 months for pigs and cattle, respectively. Assumptively, some have reduced this burden by using sequential cycles of genetic modification and SCNT (Kuroiwa et al., 2004), both of which are technically difficult and costly, There are many reasons for avoiding sequential cloning to produce F0 animals that are actually useful in experimental models or livestock. Prior to SCNT, the ability to routinely produce double-allele KO cells is a significant advance in large animal genetic manipulation. Double-allele knockout was achieved in immortal cell lines using other procedures such as ZFN and dilution cloning (Liu et al., 2010). Another group recently showed dual-allelic KO of porcine GGTAl using commercial ZFN reagent (Hauschild et al., 2011), wherein the double-allelic null cells are the absence of GGTAl-dependent surface antigenic determinants Can be enriched by FACS. Although these studies show certain useful concepts, they do not show that animals or livestock can not be modified because simple cloning dilutions are generally not suitable for primary fibroblast isolates (fibroblasts are poor at low density Because the biological thickening of the null cells can not be used for most genes.

Targeted nuclease-derived homologous recombination can be used to eliminate the need for linked selectable markers. TALEN can be used to accurately deliver certain alleles into the livestock genome by homologous dependent repair (HDR). In a preliminary study, a specific 11 bp deletion (Belian Blue allele) (Grobet et al., 1997; Kambadur et al., 1997) was introduced into the bovine GDF8 locus (see U.S. When transfected alone, the btGDF8.1 TALEN pair cleaved less than 16% of the chromosomes at the target locus. Co-transfection with a supercoiled homologous DNA repair template with an 11 bp deletion resulted in a gene shift frequency (HDR) of less than 5% on day 3 without selection for the event of interest. Gene conversions were identified in 1.4% of screened isolated colonies. These results show that TALEN can be used to efficiently derive HDR without the help of a connected selectable marker.

Homologous target recovery (HDR)

Homologous target recovery (HDR) is a mechanism in cells to restore ssDNA and double stranded DNA (dsDNA) lesions in cells. Such a repair mechanism may be used by cells in the presence of HDR templates with sequences that have significant homology to the lesion site. Specific binding, which is a commonly used term in the biological field, refers to a molecule that binds to a target with a relatively high affinity as compared to non-specific tissue, and generally has a number of non-covalent interactions, Action, van der Waals interactions, hydrogen bonding, and the like. Specific hybridization is a form of specific binding between nucleic acids having complementary sequences. In addition, the protein may specifically bind to DNA, for example, in a TALEN or CRISPR / Cas9 system or by a Gal4 motif. The gene insertion of an allele refers to the process of replicating an exogenous allele on the endogenous allele using a template-guided process. Although the endogenous allele is actually cleaved and can be replaced by an exogenous nucleic acid allele in some circumstances, our theory is that this process is a cloning mechanism. Because the allele is a gene pair, there is considerable homology between them. An allele may be a gene encoding a protein, or it may have other functions such as coding of a biologically active RNA chain or provision of a site that accommodates a regulatory protein or RNA.

The HDR template is a nucleic acid containing an allelic gene. The template may be dsDNA or single-stranded DNA (ssDNA). The ssDNA template may have other lengths, but preferably has about 20 to about 5000 residues. Those skilled in the art will readily appreciate that all ranges and values within the stated ranges, for example, 500 to 1500 residues, 20 to 100 residues, etc., are contemplated. The template may further comprise DNA adjacent to the endogenous allele or a side sequence that provides homology to the DNA to be replaced. The template may also comprise a sequence that is bound to a targeted nuclease system and thus is a homologous binding site for a DNA-binding member of the system.

The targeted endonuclease system

Genome editing tools such as transcription activation-like effector nuclease (TALEN) and zinc finger nuclease (ZFN) have been implicated in the field of biotechnology, gene therapy and functional genomics in many organisms. More recently, RNA-guided endonuclease (RGEN) has been directed to its target site by complementary RNA molecules. The Cas9 / CRISPR system is REGEN. The tracrRNA is another tool. These are examples of targeted nuclease systems; Such a system has a DNA-binding member that positions the nuclease at the target site. These sites are then cleaved by nuclease. TALEN and ZFN have a nuclease fused to a DNA-binding member. Cas9 / CRISPR is a family of mutually found mutations on the target DNA. DNA-binding members have homologous sequences in chromosomal DNA. DNA-binding members are typically designed in the light of the intended homologous sequence to obtain the nucleic acid degrading action at the intended site. Certain embodiments are applicable without limitation to all such systems; An embodiment that minimizes nuclease re-cleavage, an embodiment that produces a SNP with the precision in the intended residue, and the placement of the gene-transferred allele at the DNA-binding site.

TALENS

As used herein, the term TALEN is broad and includes monomeric TALEN that is capable of cleaving double-stranded DNA without the aid of another TALEN. The term TALEN is also used to refer to one or both members of a TALEN pair engineered to work together to cleave DNA at the same site. TALEN working together can be referred to as left -TALEN and right -TALEN, which represent the DNA or TALEN-pair symmetry (handedness).

A cipher for TAL has been reported (PCT Publication No. WO 2011/072246), wherein each DNA binding repeat serves to recognize a single base pair in the target DNA sequence. The residue can be assembled to target the DNA sequence. In short, the target site for binding of TALEN is determined and a fusion molecule containing a nuclease that recognizes the target site and a series of RVDs is generated. Once ligated, the nuclease cleaves the DNA, allowing the cell repair mechanism to form a genetic alteration at the cleavage end. The term TALEN refers to a protein comprising a transcriptional activation-like (TAL) effector binding domain and a nuclease domain, which is itself a functional monomeric TALEN as well as another ≪ / RTI > The dimerization can result in the homodimer TALEN when the monomer TALEN is the same, or it can lead to the heterodimer TALEN if the monomer TALEN is different. TALEN has been shown to induce genetic modification in immortalized human cells by means of two major eukaryotic DNA repair pathways, non-homologous end joining (NHEJ) and homologous target repair. TALEN is often used in pairs, but monomeric TALEN is known. Cells to be treated by TALEN (and other genetic tools) include cultured cells, immortalized cells, primary cells, primary somatic cells, zygotes, germ cells, primitive germ cells, blastocysts or stem cells. In some embodiments, a TAL effector may be used to target other protein domains (e.g., non-nuclease protein domains) for a specific nucleotide sequence. For example, the TAL effector can be, without limitation, interacting with DNA 20 interacting enzymes (e.g., methylase, topoisomerase, integrase, transporter, or ligase), transcriptional activator or inhibitor, It can be bound to a protein domain from a protein that modifies it. Such TAL effect fusion applications include, for example, forming or modifying a progeny genetic control element, creating site-specific insertion, deletion or repair in DNA, modulating gene expression, and modifying chromatin structure .

The term nuclease includes exonuclease and endonuclease. The term endonuclease refers to any wild-type or mutant enzyme capable of catalyzing the hydrolysis (cleavage) of a DNA or RNA molecule, preferably between a nucleic acid in a DNA molecule. Non-limiting examples of the endonuclease comprises a Type II restriction endonuclease for example, Fok I, Hha I, Hin dlII , Not I, Bbv Cl, Eco RI, Bgl II, and Alw I. Endonuclease also encompasses rare-cutting endonucleases, typically having polynucleotide recognition sites that are about 12 to 45 base pairs (bp) in length, and more preferably between 14 and 45 bp in length. Rare-cleavage endonucleases induce DNA double strand breaks (DSBs) at defined loci. The rare-chopping endonuclease may be a targeted endonuclease, which is a chimeric zinc-finger domain generated from the fusion of the engineered zinc-finger domain with the catalytic domain of a restriction enzyme, such as FokI or chemical endonuclease, Nuclease (ZFN). In chemical endonuclease, a chemical or peptide cleavage agent is conjugated to a polymer of nucleic acid or another DNA that recognizes a particular target sequence to target cleavage activity for a particular sequence. Chemical endonucleases also include synthetic nucleases, DNA cleavage molecules, and tri-forming oligonucleotides (TFO), such as those of orthophenanthroline, which are known to bind to specific DNA sequences. Such chemical endonuclease is included in the term " endonuclease " according to the present invention.

Examples of such endonuclease include I-See I, I-Chu I-Cre I, I-Csm I, PI-See L PI-Tti L PI-Mtu I, I- PI III, HO, PI-Civ I, PI-Ctr L PI-Aae I, PI-Bsu I, PI-Dha I, PI-Dra L PI- I, PI-Mga I, PI-Mgo I, PI-Mga I, PI-Mma I, PI-Mma I, PI- -Mxe I, PI-Npu I, PI-Pfu L PI-Rma I, PI-Spb I, PI-Ssp L PI- -Tko I, PI-Tsp I, and I-MsoI.

Genetic modifications made by TALENS or other tools can be selected from the list consisting, for example, of insertions, deletions, insertions and substitutions of exogenous nucleic acid fragments. Typically, the target DNA region is identified and a TALEN-pair is generated that can specifically bind to this site. TALEN is delivered to the cell or embryo, for example, as a protein, mRNA, or by a vector encoding TALEN. TALEN cleaves DNA to create double-stranded cuts, which are then recovered and often incorporate sequences or polymorphisms contained in exogenous nucleic acids that form insertions or deletions, and these exogenous nucleic acids are inserted into chromosomes or have altered sequences And acts as a mold for restoring the cut portion. This template-driven recovery is a useful process for transforming chromosomes and provides an effective change to the cell chromosome.

Some embodiments include introducing a TALEN-pair into a livestock and / or a thawed cell or embryo that causes genetic modification to the DNA of the cell or embryo at a site that is specifically bound by the TALEN-pair, Lt; RTI ID = 0.0 > animal / animal. ≪ / RTI > Direct injection can be used to introduce cells or embryos into, for example, zygotes, blastocysts or embryos. Alternatively, TALEN and / or other factors may be introduced into the cell using any of a number of known techniques for the introduction of a protein, mRNA, DNA, or vector. Genetically modified animals can be made from embryos or cells according to known methods, such as by implantation of embryos into a pregnancy host or by various cloning methods. The phrase " genetic modification to the DNA of a cell at a site specifically bound by TAELN " and the like indicates that when the TALEN is specifically bound to its target site, the genetic modification at the site cleaved by the nuclease on TALEN . The nuclease does not exactly cleave the binding site of the TALEN-pair, but rather cleaves at a defined site between the two binding sites.

Some embodiments involve compositions or treatments of cells used to clone animals. The cells can be livestock and / or uterine cells, cultured cells, primary cells, primary somatic cells, zygotes, germ cells, primitive germ cells or stem cells. For example, one embodiment is a composition or method that produces a genetic modification comprising exposing a plurality of primary cells to a nucleic acid or TALEN encoding a TALEN protein or TALEN in culture. TALEN can be introduced, for example, as a nucleic acid fragment or protein encoded by an mRNA or DNA sequence in a vector.

Zinc finger nuclease

Zinc-finger nuclease (ZFN) is an artificial restriction enzyme produced by fusing a zinc finger DNA-binding domain to a DNA-cleavage domain. The zinc finger domain can be engineered to target the desired DNA sequence, which allows the zinc-finger nuclease to target unique sequences within the complex genome. By using an endogenous DNA repair mechanism, such reagents can be used to alter the genome of higher organisms. ZFN can be used in methods to inactivate genes.

The zinc finger DNA-binding domain has about 30 amino acids and folds into a stable structure. Each finger primarily binds to a triplet in a DNA substrate. Amino acid residues at key positions contribute largely to sequence-specific interactions with DNA sites. These amino acids can be changed while maintaining the remaining amino acids to preserve the essential structure. Binding to longer DNA sequences is achieved by tandem-joining several domains. Other functional groups such as non-specific FokI cleavage domain (N), transcription activation domain (A), transcription repressor domain (R) and methylase (M) fused to ZFP to form ZFN, zinc finger transcription activator ), Zinc finger transfer inhibitor (ZFR), and zinc finger methylase (ZFM). Materials and methods for using zinc finger and zinc finger nuclease to produce genetically modified animals are described, for example, in U.S. Pat. 8,106,255; U.S.A. 2012/0192298; U.S.A. 2011/0023159; And U.S. Pat. 2011/0281306.

Vector and nucleic acid

A variety of nucleic acids can be introduced into the cell for knockout, for gene inactivation, to obtain gene expression, or for other purposes. The term nucleic acid as used herein includes DNA, RNA, and nucleic acid analogs, and nucleic acids that are double-stranded or single-stranded (i.e., sense and antisense single strands). Nucleic acid analogs can be modified in a base moiety, sugar moiety, or phosphate backbone to improve, for example, stability, hybridization or nucleic acid solubility. The deoxyribose phosphate backbone can be modified to produce a morpholino nucleic acid, wherein each base moiety is linked to a 6-membered morpholino ring, or peptide nucleic acid, wherein the dioxyphosphate backbone is a peptide monomer (pseudopeptide) backbone and retains four bases.

The target nucleic acid sequence may be operably linked to a regulatory region, e.g., a promoter. The control region may be a pig control region or may be derived from another species.

Generally, the type of promoter can be operably linked to a target nucleic acid sequence. Examples of promoters include, without limitation, tissue-specific promoters, constitutive promoters, inducible promoters, and promoters that are responsive or non-responsive to a particular stimulus. In some embodiments, a promoter that promotes the expression of a nucleic acid molecule without significant tissue-specificity or transient-specificity can be used (e.g., a constitutive promoter). For example, a promoter such as a beta-actin promoter such as a chicken beta-actin gene promoter, a ubiquitin promoter, a mini CAG promoter, a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter, or a 3-propoglycerate kinase A viral promoter such as a herpes simplex virus thymidine kinase (HSV-TK) promoter, SV40 promoter, or cytomegalovirus (CMV) promoter may be used. In some embodiments, the fusion of the chicken beta actin gene promoter and the CMV enhancer is used as a promoter. See, for example, Xu et al., Hum. Gene Ther. 12: 563,2001; and Kiwaki et al., Hum. Gene Ther. 7: 821, 1996).

Additional regulatory regions that may be useful in nucleic acid constructs include, but are not limited to, polyadenylation sequences, translation control sequences (e.g., internal ribosome entry fragments, IRES), enhancers, inducible elements, or introns. These regulatory regions may not be essential, but they can increase expression by affecting transcription, mRNA stability, translation efficiency, and the like. Such regulatory regions may be included within the nucleic acid construct as desired to obtain optimal expression of the nucleic acid in the cell (s). However, sufficient expression can often be obtained without these additional elements.

Nucleic acid constructs encoding signal peptides or selectable expressed markers may be used. The signal peptide can be used to direct the encoded polypeptide to a specific cell location (e.g., cell surface). Non-limiting examples of selectable markers include, but are not limited to, puromycin, ganciclovir, adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo, G418, APH), dihydrofolate reductase (DHFR) Hygromycin-B-phosphotransferase, thymidine kinase (TK), and xanthine-guanine phosphoribosyltransferase (XGPRT). Such markers are useful for selecting stable transformants in culture. Other selectable markers include fluorescent polypeptides such as green fluorescent protein or yellow fluorescent protein.

In some embodiments, the sequence encoding the selectable marker may be located on the side by recognizing the sequence for the recombinase, e.g., Cre or Flp. For example, selectable markers may be located side by side with loxP recognition sites (recognition sites of 34-bp recognized by Cre recombinase) or FRT recognition sites, so that selectable markers can be cleaved from the construct. For review of the Cre / lox technique, see Orban et al., Proc. Natl. Acad. Sci., 89: 6861, 1992 and Brand and Dymecki, Dev. Cell, 6: 7, 2004). A transposon containing a Cre- or Flp-activatable transgene that is blocked by a selectable marker gene may also be used to obtain a transgenic animal having a conditional expression of the transgene. For example, the promoter driving the expression of the marker / transgene may be ubiquitous or tissue-specific, leading to ubiquitous or tissue-specific expression of the marker in the F0 animal (e.g., pig). Tissue-specific activation of the transgene can be achieved, for example, by crossing pigs ubiquitously expressing the marker-blocked transgene with pigs expressing Cre or Flp in a tissue-specific manner, or in a tissue- The pig expressing the blocked transgene can be accomplished by crossing the pig with a ubiquitously expressing Cre or Flp recombinase. Controlled expression of the transgene or controlled cleavage of the marker enables the expression of the transgene.

In some embodiments, the exogenous nucleic acid encodes a polypeptide. The nucleic acid sequence encoding the polypeptide may comprise a tag sequence coding for " tag " designed to facilitate subsequent manipulation of the encoded polypeptide (e. G., To facilitate localization or detection). The tag sequence may be inserted into a nucleic acid sequence encoding the polypeptide such that the coded tag is located at the carboxyl or amino terminus of the polypeptide. Non-limiting examples of coded tags include glutathione S-transferase (GST) and FLAG? Tags (Kodak, New Haven, CT).

The nucleic acid construct can be used for the treatment and / or prophylaxis of, for example, reproductive cells such as oocytes or eggs, progenitor cells, adult or embryonic stem cells, primitive germ cells, kidney cells such as PK-15 cells, Including embryonic fibroblasts, using any of a variety of techniques, into any type of embryo, embryo, or adult uterus / livestock cell. Non-limiting examples of techniques include the use of transposon systems, recombinant viruses capable of infecting cells, or liposomes or other non-viral methods such as electroporation, microinjection, or calcium phosphate precipitation, The nucleic acid can be delivered to the cell.

In a transposon system, a transcription unit of a nucleic acid construct, i. E., A regulatory region operably linked to an exogenous nucleic acid sequence, is located at the side by inversion of the transposon. For example, Sleeping Beauty (see U.S. 6,613,752 and U.S. 2005/0003542); Frog Prince (Miskey et al., Nucleic Acids Res. 31: 6873, 2003); Tol2 (Kawakami, Genome Biology 8 (Suppl.1): S7, 2007); Minos (Pavlopoulos et al., Genome Biology, 8 (Suppl. 1): S2, 2007); Hsmar1 (Miskey et al., Mol Cell Biol., 27: 4589, 2007); And Passport have been developed to introduce nucleic acids into cells, including mouse, human, and porcine cells. Sleeping beauty transposons are particularly useful. The transposable agent may be delivered as a protein, or may be encoded on the same nucleic acid construct as an exogenous nucleic acid, introduced on a separate nucleic acid construct, or provided as an mRNA (e. G., In vitro-transcribed or capped mRNA) .

The nucleic acid can be incorporated into the vector. The vector is a broad term that encompasses any specific DNA fragment designed to migrate from the carrier into the target DNA. The vector may be referred to as an expression vector or vector system, which is a set of components necessary to bring DNA inserts into genomic or other targeted DNA sequences such as episomes, plasmids, or even virus / phage DNA fragments. Vector systems such as viral vectors (e.g. retroviruses, adeno-associated viruses and integrated phage viruses) and non-viral vectors (e.g., transposons) used in gene delivery in animals have two basic components: (1) DNA Or RNA reverse transcribed into cDNA), and (2) another integrase enzyme that recognizes both a transposase, a recombinant enzyme, or a vector and a DNA target sequence, and inserts the vector into the target DNA sequence. The vector contains most of the one or more expression cassettes containing one or more expression control sequences, wherein the expression control sequences are DNA sequences that control and regulate transcription and / or translation of another DNA sequence or mRNA sequence, respectively.

A number of different types of vectors are known. For example, plasmids and viral vectors, such as retroviral vectors, are known. Mammalian expression plasmids typically contain a source of replication, a suitable promoter and a selective enhancer, and also any necessary ribosome binding sites, polyadenylation sites, splice donor and acceptor sites, transcription termination sequences, and 5 ' . Examples of vectors include plasmids (which may be another type of carrier ), adenovirus, adeno-associated virus (AAV), lentivirus (e.g., modified HIV-1, SIV or FIV) (E.g., ASV, ALV or MoMLV), and transposons (e.g., sleeping beauty, P -element, Tol-2 , Prog Prince, piggyBac).

As used herein, the term nucleic acid is intended to encompass both naturally occurring nucleic acids and chemically modified nucleic acids, such as cDNA, genomic DNA, synthetic (e.g., chemically synthesized) DNA, as well as both RNA and DNA, ≪ / RTI > The nucleic acid molecule may be a double strand or a single strand (i.e., a sense and an antisense single strand). The term gene transplantation is used extensively herein and refers to genetically modified organisms or genetically engineered organisms whose genetic material has been modified using genetic engineering techniques. Thus, knockout yeast is a gene transplant, regardless of whether the exogenous gene or nucleic acid is expressed in the animal or its offspring.

Genetically modified animal

The animal may be modified using TAELN or other genetic engineering tools, including recombinant enzyme fusion proteins, or a variety of vectors known in the art. Genetic modifications made by these tools can involve the destruction of genes. Materials and methods for genetically altering animals are described in U.S. Pat. 8,518,701; U.S.A. 2010/0251395; And U.S. Pat. 2012/0222143, which are incorporated herein by reference for all purposes; In the event of conflict, the present specification shall control. The term trans-action refers to the process of acting on a target gene from different molecules (i. E. Intermolecular). Trans-acting elements are typically DNA sequences containing genes. These genes encode proteins (or microRNAs or other dispersible molecules) used to control the target gene. The trans-acting gene may be on the same chromosome as the target gene, but the activity is mediated by the intermediary protein or RNA it encodes. An embodiment of the trans-acting gene is, for example, a gene encoding a targeting endonuclease. Inactivation of genes using dominant negative usually involves trans-acting elements. The term cis-regulating or cis-acting refers to an action that does not encode a protein or RNA; In the context of gene inactivation, this generally refers to inactivation of the promoter and / or the coding portion of the operator, which is essential for the expression of the gene or functional gene.

A variety of techniques known in the art can be used to inactivate genes to produce knockout animals and / or to introduce nucleic acid constructs into animals to generate founder animals and animal lines, where knockout or nucleic acid constructs Integrated into the genome. These techniques, without limitation, pronuclear (pronuclear) microinjection (US 4,873,191 Lake), retrovirus mediated gene transfer into the germ line (as described in [Van der Putten et al, Proc Natl Acad Sci USA, 82.....: (Thompson et al., Cell, 56: 313-321, 1989), embryonic electroporation (Lo, Mol. Cell. Biol (Lavitrano et al., Proc. Natl. Acad. Sci. USA, 99: 14230-14235, 2002; Fert. Develop., 18: 19-23, 2006) and in vitro transformation of somatic cells such as cumulus or mammalian cells, or adult, fetal, or embryonic stem cells and subsequent nuclear transfer et al., Nature, 385: 810-813, 1997; and Wakayama et al., Nature, 394: 369-374, 1998). Precursor microinjection, sperm-mediated gene delivery, and somatic cell nuclear transfer are particularly useful techniques. Genetically modified animals are animals in which all of their cells have genetic modifications, including their germline cells. When a method of producing an animal that is mosaic in gene modification is used, the animal can be inbreeded and a genetically modified offspring can be selected. For example, cloning can be used to make a mosaic animal if the cell is transformed in the blastocyst, or genome modification can occur if the single-cell is transformed. Modified animals that are not sexually mature may be homozygous or heterozygous for the strain according to the particular approach used. When a particular gene is inactivated by knockout transformation, homozygosity is usually not sufficient. When specific genes are inactivated by RNA interference or dominant negative strategies, heterozygosity is often appropriate.

Typically, in prokaryotic microinjection, nucleic acid constructs are introduced into fertilized eggs and one or two embryonic cells are used as progenitors containing genetic material from sperm heads, and the oocytes are visible in the protoplasm. Embryos at the prokaryotic stage may be obtained in vitro or in vivo (i.e., surgically recovered from the fallopian tubes). In vitro fertilized eggs can be produced as follows. For example, pig ovaries can be collected at slaughterhouses and maintained at 22 to 28 ° C during transport. Ovary can be washed and isolated for follicular aspiration and follicles ranging from 4 to 8 mm can be aspirated into a 50 mL conical centrifuge tube under vacuum using an 18 gauge needle. Follicular fluid and aspirated oocytes can be rinsed through pre-filters using commercial TL-HEPES (Minitube, Verona, Wis.). Oocytes surrounded by compact cumulus mass were selected and cultured in the presence of 0.1 mg / mL cysteine, 10 ng / mL epidermal growth factor, 10% porcine follicular fluid, 50 μM 2-mercaptoethanol, 0.5 mg / ml cAMP (TCM-199 OOCYTE MATURATION MEDIUM (Minitube, Verona, WI) supplemented with 10 IU / mL of each gestational week serum gonadotropin (PMSG) and human chorionic gonadotropin (hCG) RTI ID = 0.0 > 0 C < / RTI > and 5% CO2. Subsequently, oocytes can be transferred to fresh TCM-199 maturation medium without cAMP, PMSG or hCG and incubated for an additional 22 hours. Matured oocytes can be detached from cumulus cells by vortexing for 1 minute in 0.1% hyaluronidase.

For pigs, mature oocytes can be modified in a 500 μl PORCPRO IVF MEDIUM SYSTEM (Minitube, Verona, WI) in a Minitube 5-well modified dish. In preparation for in vitro fertilization (IVF), freshly collected or frozen saline sperm can be washed and resuspended in 4 x 105 spermatozoa in PORCPRO IVF medium. Sperm concentration can be analyzed by computer assisted semen analysis (SPERMVISION, Minitube, Verona, WI). Intravenous sperm injection can be finalized in a volume of 10 μl with a final concentration of about 40 mobile sperm per oocyte, depending on the sperm. All fertilized oocytes are incubated at 38.7 ° C for 6 hours in a 5.0% CO2 atmosphere. At 6 hours after sperm injection, the putative zygote can be washed in NCSU-23 and transferred to the same 0.5 mL of medium. Such systems can produce approximately 20-30% blastocysts for most fowls, with a fertile semen injection rate of 10-30%.

The linearized nucleic acid construct can be injected into one precursor. The injected oocyte can then be transferred to the recipient female (e.g., into the fallopian tube of the recipient female) and generated in the recipient female to produce the transgenic animal. In particular, in vitro fertilized embryos can be centrifuged at 15,000 x g for 5 minutes to sediment lipids and visualize the nucleus. The embryos can be injected using an Eppendorf FEMTOJET injector and cultured until blastocysts are formed. Embryo cutting and blastocyst formation rate and quality can be recorded.

The embryo can be surgically transferred into the uterus of an asynchronous recipient. Typically, 100 to 200 (e.g., 150 to 200) embryos can be placed into the uterine tube-ampulla-isthmus junction of the fallopian tube using a 5.5-inch TOMCAT® catheter. After surgery, a real-time ultrasound pregnancy test may be performed.

In a somatic cell nuclear transfer, a gene-transferable host cell (for example, a transgenic pig cell or a small cell) containing the above-described nucleic acid construct, such as an embryo sac, a fetal fibroblast, an adult ear fibroblast or a granulosa cell, And introduced into the parent cell to construct a combined cell. The oocytes can be partially cleaved around the polar body and then be extruded out of the cytoplasm in the incision area to remove the nucleus. Typically, gene-grafted cells are injected into the oocyte where the nucleus has been removed from the second meiosis using an injection pipette with a sharp beveled tip. In some practices, oocytes suspended in the second meiosis are referred to as oocytes. After producing pigs or small embryos (eg, by fusing and activating oocytes), about 20 to 24 hours after activation, the embryos are transferred to the fallopian tube of the recipient female. See, e.g., Cibelli et al., Science 280: 1256-1258, 1998, and U.S. Pat. 6,548,741. In the case of pigs, the females can be confirmed pregnant about 20 to 21 days after the embryo has been transferred.

Standard breeding techniques can be used to generate animals that are homozygous for exogenous nucleic acids from early heterozygote pounder animals. However, homozygosity may not be required. The transgenic pigs described herein can be propagated with other interested pigs.

In some embodiments, the nucleic acid of interest and the selectable marker may be provided on an individual transposon and may be provided to the embryo or cell in an unequal amount, wherein the amount of transposon containing the selectable marker is the amount of the nucleic acid of interest (5 to 10-fold more) than the amount of transposon. Transgenic cells or animals expressing the nucleic acid of interest can be isolated based on the presence and expression of a selectable marker. Since transposons can be integrated into the genome in an accurate and irrelevant manner (independent transposition events), nucleic acids of interest and selectable markers are not genetically linked and are easily separated by genetic sequencing through standard breeding . Thus, transgenic animals can be produced that are not limited to maintaining selectable markers in the next generation, which is a concern with respect to public safety.

Once the transgenic animal is produced, the expression of the exogenous nucleic acid can be assessed using standard techniques. Initial screening can be accomplished by Southern blot analysis, which determines whether integration of the construct has occurred. For a detailed description of Southern analysis, see Sambrook et al., Molecular Cloning, A Laboratory Manual, second edition, Cold Spring Harbor Press, Plainview; NY., 1989]. Polymerase chain reaction (PCR) techniques can also be used in initial screening. PCR refers to a process or technique by which a target nucleic acid is amplified. Generally, sequence information from the end of the region of interest or beyond is used to design oligonucleotide primers that match or are similar in sequence to the opposite strand of the template to be amplified. PCR can be used to amplify specific sequences from DNA and RNA, including sequences from total genomic DNA or total cellular RNA. Primers are typically 14 to 40 nucleotides in length, but may range in length from 10 nucleotides to hundreds of nucleotides. For example, PCR can be performed as described in PCR Primer: A Laboratory Manual, ed. Dieffenbach and Dveksler, Cold Spring Harbor Laboratory Press, 1995. The nucleic acid may also be amplified by ligase chain reaction, standard displacement amplification, self-sustaining sequence replication, or nucleic acid sequence-based amplification. See, for example, Lewis, Genetic Engineering News 12: 1, 1992; Guatelli et al., Proc. Natl. Acad. Sci. USA, 87: 1874,1990; And Weiss, Science 254: 1292, 1991). At the blastocyst stage, embryos are individually processed for analysis by PCR, Southern hybridization and splinkerette PCR (see, e.g., Dupuy Cet al. Proc Natl Acad Sci USA, 99: 4495, 2002) .

Expression of nucleic acid sequences encoding polypeptides in tissue samples of transgenic pigs can be determined by, for example, noxious blot analysis of tissues obtained from an animal, in situ hybridization analysis, Western analysis, immunoassay such as enzyme- Can be evaluated using techniques including reverse-transcription PCR (RT-PCR).

Interfering RNA

A variety of interfering RNAs (RNAi) are known. Double-stranded RNA (dsRNA) induces sequence-specific degradation of homologous gene transcripts. The RNA-induced silencing complex (RISC) degrades the dsRNA into small interfering RNAs (siRNA) of small 21-23 nucleotides. RISC contains double strand RNAse (dsRNase, e.g., Dicer) and ssRNase (e.g., Argonaut 2 or Ago2). RISC uses antisense strand as a guide for finding cleavage targets. Both siRNA and microRNA (miRNA) are known. Methods for destroying genes in genetically modified animals include inducing RNA interference against the target gene and / or nucleic acid so that expression of the target gene and / or nucleic acid is reduced.

For example, an exogenous nucleic acid sequence can induce RNA interference against a nucleic acid encoding the polypeptide. For example, double-stranded small interfering RNA (siRNA) or small hairpin RNA (shRNA) homologous to the target DNA can be used to reduce the expression of such DNA. Constructs for siRNA are described, for example, in Fire et al., Nature 391: 806, 1998; Romano and Masino, Mol. Microbiol. 6: 3343,1992; Cogoni et al., EMBO J. 15: 3153, 1996; Cogoni and Masino, Nature, 399: 166, 1999; Misquitta and Paterson Proc. Natl. Acad. Sci. USA, < / RTI > 96: 1451,1999; And Kennerdell and Carthew, Cell, 95: 1017, 1998. Constructs for shRNAs can be generated as described by McIntyre and Fanning (2006) BMC Biotechnology 6: 1. Generally, an shRNA is transcribed as a single-stranded RNA molecule containing a complementary region, which can be annealed to form a short hairpin.

The probability of finding a single discrete siRNA or miRNA for a specific gene is high. For example, the predictability of the specific sequence of an siRNA is about 50%, but many interfering RNAs can be produced with considerable confidence that at least one of them can be effective.

Embodiments include genes, such as in vitro cells expressing RNAi against an optional gene for the developmental stage, in vivo cells, and genetically modified animals such as livestock animals. For example, RNAi can be selected from the group consisting of siRNA, shRNA, dsRNA, RISC, and miRNA.

Guidance system

The induction system can be used to regulate gene expression. A variety of inducible systems capable of controlling the expression of genes in a spatio-temporal manner are known. Several systems have been demonstrated to be functional in vivo in transgenic animals. The term inducible system includes traditional promoters and inducible gene expression elements. An example of an inducible system is the tetracycline (tet) -on promoter system, which can be used to regulate the transcription of nucleic acids. In such a system, the mutated Tet repressor (TetR) is fused to the activation domain of the herpes simplex virus VP16 trans-activator protein to produce tetracycline-regulated transcription activator (tTA), which is tet or doxycycline (dox) Lt; / RTI > In the absence of antibiotics, transcription is minimized while transcription is induced in the presence of tet or dox. Alternative inducible systems include exdysone or rapamycin systems. It is an insect hatching hormone whose production is controlled by the products of the heterodimer of the exydon receptor and the ultraspiracle gene (USP). Expression is induced by treatment with exendin, or exendin analog such as myuristone A, for example. A reagent that is administered to an animal to induce an inducible system is referred to as an inducer.

A tetracycline-inducible system and a Cre / loxP recombinase system (constitutive or inducible) are more commonly used inducible systems. The tetracycline-inducible system involves a tetracycline-regulated trans-acting transcription factor (tTA) / reverse tTA (rtTA). Methods for using such a system in vivo include generating two strains of genetically modified animals. One animal line expresses an activator (tTA, rtTA, or Cre recombinase) under the control of a selected promoter. Another set of transgenic animals express the receptor, wherein the expression of the gene of interest (or the gene to be modified) is under the control of the target sequence for the tTA / rtTA trans-acting transcription factor (or is present on the side of the loxP sequence box). Crossing two mouse strains provides control of gene expression.

The tetracycline-dependent regulatory system (the tet system) is a tetracycline-dependent regulatory system that contains two components: the tetracycline-regulated transactivation transcription factor (tTA or rtTA) and the tTA / dependent on the rtTA-dependent promoter. In the absence of tetracycline or a derivative thereof (e.g., doxycycline), tTA binds to the tetO sequence and enables transcriptional activation of the tTA-dependent promoter. However, in the presence of doxycycline, tTA can not interact with its target and transcription does not occur. The Tet system using tTA is referred to as tet-OFF because tetracycline or doxycycline enables down-regulation of transcription. Administration of tetracycline or a derivative thereof allows the transient control of the expression of the metastatic gene in vivo. rtTA is a variant of tTA that is not functional in the absence of doxycycline, but requires the presence of a ligand for transactivation. This is the tet system and is therefore referred to as tet-ON. tet system has been used in vivo for inducible expression of several reporter genes, cancer genes, or some transplant genes encoding proteins, e.g., in signal transduction cascades.

The Cre / lox system uses Cre recombinase, which catalyzes site-specific recombination by crossing between two distinct Cre sequences, the loxP site. The DNA sequence introduced between the two loxP sequences (termed floxed DNA) is cleaved by Cre-mediated recombination. Controlling Cre expression in transgenic animals using spatial control (using a tissue-specific or cell-specific promoter) or temporal control (using an inducible system) is the control of DNA cleavage between two loxP sites . One use is for conditional gene inactivation (conditional knockout). Another approach is protein overexpression, wherein a phloxed stop codon is inserted between the promoter sequence and the DNA of interest. The genetically modified animal does not express the transgene until Cre is expressed, which cleaves the phloxed stop codon. Such systems have been applied for tissue-specific tumorigenesis and for the control of antigen receptor expression in B lymphocytes. Inducible Cre recombinases have also been developed. The inducible Cre recombinase is activated only by administration of an exogenous ligand. The inducible Cre recombinase is a fusion protein containing the original Cre recombinase and the specific ligand-binding domain. The functional activity of the Cre recombinase depends on the external ligands capable of binding to this specific domain in the fusion protein.

Embodiments include in vitro cells, in vivo cells, and genetically modified animals such as domestic animals, including genes under the control of an inducible system. The genetic modification of an animal can be a genome or a mosaic. For example, the inducible system may be selected from the group consisting of Tet-On, Tet-Off, Cre-lox, and Hif1 alpha. An embodiment is a gene described herein .

Dominance voice

Thus, the gene may be destroyed by the generation / expression of a dominant negative mutant of the protein which has an inhibitory effect on the normal function of the gene product, as well as elimination or RNAi inhibition. The expression of the dominant negative (DN) gene can alter the phenotype and (a) the titration effect of passive competing with endogenous gene products for co-factors or endogenous genes of the endogenous gene, ), (b) a poison pill (or monkey wrench) effect in which the dominant negative gene product actively interferes with the process required for normal gene function, (c) the DN activates the negative regulator of gene function As shown in FIG.

Founder animal, Animal line, Trait and breeding

Founder animals (F0 generation) can be produced by cloning and by the methods described herein. The founder may be homozygous for genetic modification, in which case the zygote or primary cell undergoes homozygous transformation. Similarly, a pounder that is a heteroduplex can also be produced. The founder can be genetically modified, meaning that cells in the genome undergo transformation. The pounder may be mosaic to the strain, as may occur when the vector is typically introduced into one of the cells in the embryo at a blastocyst stage. The offspring of the mosaic animal can be tested to identify genetically modified offspring. When animal pools are produced that can be fertile or reproducible by ancillary breeding techniques, animal systems are constructed and heterozygous or homozygous offspring consistently express deformation.

In livestock, it is known that multiple alleles can be linked to a variety of traits such as production traits, type traits, work traits and other functional traits. Those skilled in the art are familiar with monitoring and quantifying such traits, for example as described in Visscher et al., Livestock Production Science, 40: 123-137, 1994, U.S. Pat. No. 7,709,206, U.S. Pat. 2001/0016315, U.S. Pat. 2011/0023140, and U.S. Pat. 2005/0153317]. Animal lines may include traits selected from traits in the group consisting of production traits, type traits, working traits, reproductive traits, maternal traits, and disease tolerance traits. Additional traits include expression of the recombinant gene product.

Recombinant enzyme

Embodiments of the invention include administering a targeted nocrelease system with a recombinant enzyme (e.g., RecA protein, Rad51) or other DNA-binding protein associated with DNA recombination. The recombinant enzyme forms a filament with a nucleic acid fragment and, in fact, searches the cellular DNA to find a DNA sequence that is substantially homologous to the sequence. For example, a recombinant enzyme can be combined with a nucleic acid sequence serving as a template for HDR. The recombinant enzyme is then combined with the HDR template to form filaments and is located within the cell. The recombinant enzyme and / or HDR template in combination with the recombinant enzyme may be placed in the cell or embryo as a protein, mRNA, or with a vector encoding a recombinant enzyme. The disclosure of US 2011/0059160 (U.S. Patent Application Serial No. 12 / 869,232) is hereby incorporated by reference for all purposes and, where contradictory, is subject to the present disclosure. The term recombinant enzyme refers to a recombinant enzyme that enzymatically catalyzes the conjugation of relatively short DNA fragments between two relatively longer DNA strands in a cell. Recombinant enzymes include Cre recombinase, Hin recombinase, RecA, RAD51, Cre, and FLP. Cre recombinase is a type I topoisomerase from P1 bacteriophage that catalyzes site-specific recombination between DNA and loxP sites. Hin recombinase is a 21 kD protein consisting of 198 amino acids found in Salmonella bacteria. Hin belongs to the serine recombinase family of DNA invertase, which relies on the serine of the active site to initiate DNA cleavage and recombination. RAD51 is a human gene. Proteins encoded by these genes are members of the RAD51 protein family that help repair DNA double-strand breaks. The RAD51 family member is homologous to the bacterium RecA and yeast Rad51. Cre recombinase is an enzyme used in experiments to eliminate specific sequences located on the side by loxP sites. FLP refers to the Flippase recombinase (FLP or Flp) derived from the 2μ plasmid of Saccharomyces cerevisiae , a baker's yeast.

Here, " RecA " or " RecA protein " refers to a family of RecA-like recombinant proteins that have essentially all or nearly the same functions, particularly the following: (i) The ability to properly position oligonucleotides or polynucleotides on a homologous target; (ii) the ability to topologically prepare a duplex nucleic acid for DNA synthesis; And (iii) the ability of a RecA / oligonucleotide or RecA / polynucleotide complex to efficiently locate and bind complementary sequences thereto. The most characteristic RecA protein is derived from E. coli ; In addition to the original allelic form of the protein, a RecA-like protein such as RecA803 has been identified. In addition, a number of organisms have RecA-like strand-transfer proteins, including yeast, Drosophila , mammals including humans, and plants. Such proteins include, for example, Rec1, Rec2, Rad51, Rad51B, Rad51C, Rad51D, Rad51E, XRCC2 and DMC1. One embodiment of the recombinant protein is the RecA protein of E. coli . Alternatively, the RecA protein may be a mutant RecA-803 protein of E. coli , a RecA protein from another bacterial source, or a homologous recombinant protein from another organism.

Compositions and kits

The present invention also relates to a composition comprising, for example, a nucleic acid molecule encoding a nucleic acid site-specific endonuclease, such as CRISPR, Cas9, ZNF, TALEN, RecA-gal4 fusions, polypeptides, nucleic acids, proteins or polypeptides thereof, A kit and a composition containing the engineered cell line. An effective HDR can also be provided for gene transfer of the indicated allele. Such items can be used, for example, as research tools or therapeutically.

Example

Unless otherwise stated, the method is as follows.

Tissue culture and transfection.

The pigs were maintained at 37% in 5% CO 2 in DEME supplemented with 10% fetal bovine serum, 100 IU / ml penicillin and streptomycin, and 2 mM L-glutamine. For transfection, all TALEN and HDR templates were transfected using the NEON transfection system (Life Technologies). In short, the low passage number of Osasabaw, Landrace, which reached 100% confluence, was divided into 1: 2 and harvested the next day at 70% to 80% confluence. Each transfectant was composed of 500,000 to 600,000 cells resuspended in " R " buffer mixed with TALEN mRNA and oligos, using a 100 [mu] l tip providing 100 [mu] l working volume by the following parameters: : Input voltage; 1800V; Pulse width; 20ms; And the number of pulses; 1. Typically, 1-2 μg of TALEN mRNA and 1-4 μM HDR template specific for the gene of interest (single stranded oligonucleotide) were included in each transfectant. The deviations from this amount are shown in the figures and legends. After transfection, cells were plated in wells of a 6-well dish for 3 days and cultured at 30 ° C. After 3 days, cell populations were plated for colony assays and / or propagated at 37 [deg.] C for at least 10 days for the stability of the compartments.

Surveyor mutation detection and RFLP analysis

PCR was performed on the side of the intended site using PLATINUM Taq DNA polymerase HiFi (Life Technologies) with 1 μl of cell lysate according to the manufacturer's recommendation. Using the SURVEYOR Mutation Detection Kit (Transgenomic) according to the manufacturer's recommendations, 10 μl of PCR product as described above was used to analyze the mutation frequency in the population. RFLP analysis was performed on 10 [mu] l of the above PCR reaction using the indicated restriction enzymes. Surveyor and RFLP reactions were analyzed on 10% TBE polyacrylamide gels and visualized by ethidium bromide staining. Band density measurements were performed using IMAGEJ, and the mutation ratios of the surveillance reactions were calculated as described in Guschin et al., 2010 (1). The percent homology target recovery (HDR) was calculated by dividing the sum of the RFLP fragment intensities by the sum of the intensities of the parent band + RFLP fragments. The RFLP analysis of the colonies was similarly treated except that the PCR products were amplified by 1X MYTAQ RED MIX (Bioline) and analyzed on a 2.5% agarose gel.

Dilution Cloning:

On the third day after transfection, 50 to 250 cells were seeded on a 10 cm dish and cultured until the diameter of individual colonies reached about 5 mm. At this point, 6 ml of TRYPLE (Life Technologies) diluted 1: 5 (volume / volume) in PBS was added, the colonies were aspirated, transferred to wells of a 24-well dish and incubated under the same conditions. Colonies that reached confluence were harvested and separated for cryopreservation and genotype analysis.

sample preparation:

Groups of transfected cells on days 3 and 10 were collected from the wells of 6-well dishes and resuspended in 50 [mu] l of 1X PCR compatible lysis buffer: 10 [mu] g / ml Proteinase K was fresh 10 mM Tris-Cl pH 8.0, 2 mM EDTA, 0.45% TRYTON X-100 (volume / volume), 0.45% TWEEN-20 (volume / volume) The lysate was treated in a thermal cycler using the following program: 55 ° C for 60 minutes, 95 ° C for 15 minutes. Colony samples from diluted cloning were treated as above using 20 to 30 [mu] l of lysis buffer.

[Table D]

Example 1: Multiplex gene editing of porcine RAG2 and IL2R?

Six conditions of TALEN mRNA and HDR template indicated in pig RAG2 and IL2Ry were co-transfected into porcine fibroblasts. A fixed amount of RAG2 mRNA and template was used for each transfection, while the amount of IL2Rg TALEN mRNA and HDR template was varied for each condition as indicated. Doses of TALEN mRNA and HDR template had both on and off target effects. Increased TALEN mRNA for IL2Rγ while giving rise to an increase in both HDR and NHEJ to IL2Rγ, NHEJ level for RAG2 did not change. Increased IL2R? HDR template reduced HDR in the RAG2 locus, suggesting nonspecific inhibition of homologous target recovery by elevated concentrations of oligonucleotides. Colonies with double-allele HDR at RAG2 and IL2Ry were obtained at 4% and 2% from the two conditions (Figures 4c and 4d), which was 2% and above the expected frequency. The expected frequency is calculated by multiplying each HDR allele by the 3rd-order HDR level, which treats each HDR allele as an independent event. 4a-4d, multiplexed gene editing of porcine RAG2 and IL2Ry . Figure 4a Surveyor and RFLP assay for measuring the efficiency of non-homologous terminal junctions (NHEJ) and homology-dependent restorative HDR in a population of cells on day 3 after transfection. Figure 4b RFLP analysis of homology-dependent recovery in the 11th day cell population after transfection. Figure 4c Percentage of colonies positive in HDR at IL2Ry , RAG2 , or both. Cells were plated from the group labeled " C " in FIG. 4A. The distribution of the colony genotype is shown at the bottom. Figure 4d Colony analysis from TALEN mRNA in amounts of 2 and 1 [mu] g for IL2R [ gamma] and RAG2 and cells transfected with 1 [mu] M HDR template for each. The distribution of the colony genotype is shown at the bottom.

Example 2: Multiplex gene editing of porcine RAG2 and IL2R?

Four conditions of TALEN mRNA and HDR template indicated in pig APC and p53 were co-transfected into porcine fibroblasts. The amount of APC mRNA was sequentially decreased from left to right (Fig. 5b); The remaining amount was kept constant as indicated. The HDR percent decreased linearly with decreasing APC mRNA. There was little effect on p53 HDR according to the modified dose of APC TALEN. Colony genotyping analysis was higher than the predicted union of clones with HDR allele in both APC and p53 compared to the value of day 11 ; In the case of Figures 5c and 5d, 18% and 20% vs. 13.7% and 7.1% , respectively . Reference is made to multiplex gene editing of porcine APC and p53 with reference to Figures 5a to 5d. Figure 5a Surveyor and RFLP assay to measure the efficiency of non-homologous terminal junctions (NHEJ) and homology-dependent restorative HDRs in a population of cells on day 3 after transfection. Figure 5b RFLP analysis of homology-dependent repair in a population of cells on day 11 after transfection. Figures 5c and 5d. Percentage of positive colonies from the population of cells indicated for HDR (indicated as "C" and "D" in FIG. 5A) in APC , p53 or both. Colonies with three or more HDR alleles were listed at the bottom.

Example 3: Multiplex with at least 3 genes

In Example 1, it was not known whether 2+ HDR oligos could be effective without non-specific inhibition of HDR, since non-specific reduction in HDR was observed in high concentrations of HDR oligos. Two concentrations of 1 uM and 2 uM were tested for each target site. While TALEN activity was not significantly altered between the two conditions, HDR was significantly slowed at 2 uM concentration for each template. Clones derived from 1 uM conditions had various genotypes, some of which had complements in each gene and had fewer than 7 alleles (Figs. 7a and 7b). When treated as an independent event, the expected frequency of genotypes marked "a" was 0.001% when seven alleles were compiled. The binomial distribution predicts the likelihood of identifying 2+ colonies of this genotype at a sample size of 72 and is less than 0.000026% as performed herein. This high success rate was unpredictable and unexpected. These results were repeated using two addition combinations of TALEN / HDR templates (Figs. 8A and 8B, and 9A and 9B). From the results of the first test, colonies with HDR compartments were obtained with no more than 7 alleles and no more than 4 genes (Table A). Several genotypes were recovered at a much greater frequency than expected. Fifty of the 50 karyotypes tested from cells in the third test were normal (data not shown), although the problem with simultaneous double-strand breaks in some loci leads to unintended chromosomal rearrangements.

6a and 6b: Effect of oligonucleotide HDR template concentration on five gene multiplex HDR efficiencies. The indicated amounts of TALEN mRNA indicated in pig RAG2, IL2Rg, p53, APC and LDLR co-transfected into porcine fibroblasts with each homologous HDR template of either 2 uM (Figure 6a) or 1 uM (Figure 6b) . NHEJ and HDR percent were measured by the Surveyor and RFLP assays. 7a and 7b: Colony genotypes from five gene multiplex HDRs. Colony genotypes were evaluated by RFLP analysis. In Figure 7a, each line represents a genotype of a single colony in each particular locus. Three genotypes were identified; A second allele having a predicted RFLP genotype of heterozygous HDR or homozygous HDR and those with RFLP positive fragments and a visible size shift indicating an insert or indel allele. The percentage of colonies with compartments at a particular locus was shown under each column. Figure 7b provides a record of colony numbers edited from 0 to 5 loci. 8a-8b: Colony genotype of the second 5 gene multiplex test. Figure 8a: Each line represents the genotype of one colony at each specific locus. Three genotypes were identified; A second allele having a predicted RFLP genotype of heterozygous HDR or homozygous HDR, and those with RFLP positive fragments and a visible size shift indicating an inserted or deleted allele. The percentage of colonies with compartments at a particular locus was shown under each column. Figure 8b: Record of the number of colony edited from 0 to 5 loci. 9a and 9b: Colony genotype of the third five gene multiplex tests. Figure 9a: Each line represents the genotype of one colony at each particular locus. Three genotypes were identified; A second allele having a predicted RFLP genotype of heterozygous HDR or homozygous HDR, and those with RFLP positive fragments and a visible size shift indicating an inserted or deleted allele. The percentage of colonies with compartments at a particular locus was shown under each column. Figure 9b Recording of the number of colony edits from 0 to 5 loci.

Examples 4A to 4D

Example 4A: Generation of RAG2 / IL2Rg null (RG-KO) porcine fibroblasts by multiplex gene editing. Male pig embryonic fibroblasts were transfected using previously defined methods (Tan, W., et al., Efficient nonmeiotic allele introgression in livestock using custom endonucleases . PNAS, 110 (41): 16526-16531, 2013.) And transfected with TALEN and oligonucleotide templates to disrupt RAG2 and IL2Rg . The RG-KO candidates were identified by, for example, RFLP, as confirmed by sequencing. At least about 5 validated RG-KO colonies were pooled as resources for cloning and chimera generation.

Example 4B: Production of chimeric embryos using RG-KO host blastocysts.

Host RG-KO embryos and female EGFP-labeled donor cells were produced using the chromatin transfer technique and then cultured to in vitro blastocyst stage by in vitro culture. RG-KO cells from Example 1 can be used. The 7th day intercell mass clump from EGFP blastocysts was injected into synchronized sows on day 6 RG-KO embryos prior to embryo transfer. Using this approach, Nagashima and colleagues observed chimeras in over 50% of the born piglets (Nagashima H. et al., Sex differentiation and germ cell production in chimeric pigs produced by inner cell mass injection into Blastocyst. Biol Reprod, 70 (3): 702-707, 2004). The male phenotype was dominant in the injection chimera for both mouse and pig. Thus, the XY RG-KO host injected with female donor cells exclusively delivered the male host genetic trait. Pregnancy checks were performed when appropriate, e.g., on day 25, day 50, and day 100. The pregnant sows were monitored four times daily approximately 100 days after pregnancy, and the C-section of the piglets was induced to about 114 days.

Example 4C: Non-chimeric offspring confirmed defects in T, B and NK cells.

Non-chimeric offspring were tested to determine if they were defective for T, B, and NK cells. The following process is one technique for this. The C-section induction was performed for each of the sows that had produced the presumptive chimeras and the litters that gave birth to the pregnant sows and wild-born piglets. Umbilical blood was isolated from each piglet immediately after C-section induction. Umbilical cord blood leukocytes were evaluated by fluorescence-activated cell sorting (FACS) for T, B, and NK cell populations and donor-induced EGFP expression. Chimerism was also evaluated by PCR from cord blood, ear and tail biopsies. This initial analysis was completed within 6 hours of birth, and non-chimeric piglets can be artificially euthanized closely as an indication of infection. Some of the non-chimeric animals, or some of the animals lacking immune cells, were euthanized for autopsy.

Example 4D: Identification of chimeric pigs and identification of origin of T, B and NK cells.

Chimeric pigs were tested to determine the origin of T, B and NK cells. The following process is one technique for this. Chimeric piglets were identified using the above method. Circulating lymphocytes and serum immunoglobulins were evaluated weekly and compared between chimeric, non-chimeric, and wild-type pigs over 2 months. Groups of sorted T, B and NK cells were evaluated for EGFP expression and microsatellite analysis was performed to determine donor origin. Maintenance of samples and semen collection from chimeric pigs was supported by the RCI until Phase II funding became available.

Sample procedure for Examples A to D:

Cord blood and peripheral blood FACS.

Evaluation of blood lymphocyte and EGFP chimeric phenomena was performed as described above in (2), applying on pig specimens. Umbilical cord blood was collected from each young pig immediately after C-section delivery. A portion of the remnant blood was treated and cryopreserved for potential allograft treatment while the remaining cord blood was used for FACS analysis of lymphocytes. Peripheral blood samples were collected by standard methods at 2, 4, 6, and 8 weeks of age. RBCs were removed and approximately 1-2E + 5 cells were dispensed into the tubes. The aliquots were labeled with anti-swine antibodies for the identification of T cells (CD4 and CD8), B cells (CD45RA ad CD3), NK cells (CD16 and CD3) and myeloma cells (CD3). Antigen expression was quantified on a LS RII flow cell counter (BD Biosciences). Fluorescence assays were carefully selected to allow multiplex evaluation of donor-derived EGFP cells with surface antigens. Spleen-derived single cell suspensions were analyzed by the same method.

inspection

All major organs and tissues were examined extensively for appropriate anatomical development and were assessed for all major organs and tissues including the pancreas, liver, heart, kidney, lung, stomach, immune system (peripheral and mucosal lymph nodes and spleen) Samples were collected for DNA isolation. Single cell suspensions were prepared from the spleen for FACS analysis. Tissues were prepared for histological examination and further assessed for the presence of chimerism, any changes that may be associated with chimeric status, and the presence of any underlying disease.

Evaluation of chimera phenomenon

Quantitative PCR was performed on rem, ears, and tail biopsies using primers specific for the EGFP transgene gene and compared to the standard curve of known rates of EGFP versus wild type cells. The samples were also evaluated for the RG-KO allele via previously described RFLP assays. Engraftment of EGFP + cells was visually assessed on whole animals and organs during autopsy. Tissue from major organs was cut for EGFP immunohistochemistry and contrasted with DAPI (4 ', 6-diamidino-2-phenylindole) to determine the ratio of donor versus host cells.

Analysis of microsomes.

Animals were screened for informative microsomes of host and donor genetic characteristics from those routinely used in the laboratory. Tissues and blood (sorted lymphocyte or myeloma lineage, EGFP positive and negative) were evaluated. The relative amounts of donor versus host cells were evaluated by multiplexed amplicon sequencing on a MISEQ instrument (Illumina).

animal

Non-chimeric pigs without T, B and NK cells in cord blood and peripheral blood were prepared. The chimeric pigs were substantially similar in level to wild type. In addition, T, B, and NK cell positive chimeras had virtually normal immune function and remained healthy when raised under standard conditions.

Example 5: CRISPR / Cas9 design and production.

Gene specific gRNA sequences were cloned into the Church lab gRNA vector (Addgene ID: 41824) according to their methods. Cas9 nuclease was provided by co-transfection of hCas9 plasmid (Addgene ID: 41815) or by mRNA synthesized from RCIScript-hCas9. RCIScript-hCas9 was constructed by subcloning the XbaI-AgeI fragment from the hCas9 plasmid (containing the hCas9 cDNA) with RCIScript plasmid. The synthesis of mRNA was performed as described above except that the linearization was performed using KpnI.

Example 6: Multiplex gene editing using targeted endonuclease and HDR.

FIG. 13A is a schematic of each gene in a multiplex experiment (shown as cDNA-exon indicated by cross-hatching), showing sites targeted by TALENS. Sequences encoding the DNA binding domain of each gene are shown below. Pig fibroblasts were transfected with 1 ug of each TALEN mRNA and 0.1 nMol of each HDR oligo (FIG. 13b) designed for insertion of the novel HindIII RFLP site for early termination codon and genotype analysis, To co-transfect. A total of 384 colonies were isolated for genotyping. GATA4 and Nkx2-5 RFLP assays were performed (Figure 13c) and MESP1 was evaluated by sequencing (not shown). Two colonies (2/384, 0.52%) were homozygous HDR knockout for all three genes. Triple knockout was labeled with an asterisk (Figure 13c). Additional genotypes could be observed in FIG. 13c, for example, colonies 49 without HDR complements; Colonies 52 and 63 with heterozygous complements for NKX2-5; Colony 59 with heterozygous complements for both NKX2-5 and GATA4, and the like.

Example 7: Multiplex gene-editing using a combination of TALEN and RGEN.

See FIG. Porcine fibroblasts were cotransfected with 02 nMol of HDR oligos for TALENS (1 ug EIF4G 14.1 mRNA) + Cas9 / CRISPR components (2 ug Cas9 mRNA + 2 ug p65 G1s guide RNA) and each gene. Transfected cells were evaluated by RFLP assay showing HDR at both sites. Cells from these populations were plated for colony isolation and isolates with compartments from both genes were identified.

Example 8: Human-pig chimera blastocyst.

An important first step in generating human organs / cells in pigs using blastocyst supplementation is to determine whether human stem cells can be integrated into the inner cell mass as opposed to the nutritional ectoderm and bladder cavity. To determine if human stem cells could be integrated into the inner cell mass, the analysis system was developed using parthenogenetic blastocysts. Parthenotes were generated by the electrical activation of porcine oocytes to form diploid cells from a combination of DNA from the maternal nucleus and the polar body. Subsequently, single diploid cells are cleaved and become well-formed blastocysts suitable for injection of human stem cells on day 6 after activation. Six days after the electrical activation, 10 hUCBSCs were injected into individual pig-born reproductive blastocysts. The distribution of hUCBSC was then examined at day 7 and 8, and the number of human stem cells at each time point was determined using antibodies recognizing human nuclear antigen (HNA) to visualize individual hUCBSCs. It was found that the vast majority of hUCBSCs were incorporated into the inner cell mass (Figs. 15A to 15G, and 15F). HUCBSC was also injected into blastocysts and continued to proliferate for 2 days (Figure 15g)

Example 9: Human-pig chimeric fetus.

Another important step in the production of human organs / cells through blastocyst complementation is to demonstrate that porcine blastocysts implanted with human stem cells can produce porcine fetuses containing human cells. To overcome this problem, hUCBSC was injected into a female reproductive blastocyst and the chimeric blastocyst was transferred to a hormonally synchronized sow. Fetuses were harvested at the 28th gestational age (Fig. 16a). Histological analysis of tissue sections revealed HNA-positive cells in the internal organs of the chimeric fetus (Fig. B). These results demonstrate that hUCBSC can contribute to the development of pig embryos.

Human-pig chimeric fetus derived from complemented PITX3 knockout blastocysts. Swine-black dopamine neurons from pig-pig chimeras were also generated and characterized; Human-porcine chimeric human-black dopamine neurons were also generated and characterized. NURR1, LMX1A, and PITX3 knockout blastocysts were generated using TAELN technology in fibroblasts and cloning. The knockout blastocysts were determined to be able to make a supplement based on the black dopamine neurons using a pig pool labeled as a source of stem cells. This approach has previously been used in exogenous pig-pancreatic pancreas (Matsunari et al, 2013). When the fetus reached a head hip length of about 17 mm, fetal pigs were sacrificed on day 34-35 embryo. At this stage of development, VM and other brain structures were compared to fetal rat size at day E15 and human fetuses were used for cell transplantation in the first trimester. Identification of porcine-pig exogenous dopamine neurons in the fetal VM from NURR1, LMX1A, or PITX3 blastocysts was a milestone in the development of human-pig chimeras.

TALEN-knockout of LMX1A, PITX3 , and NURR1 in porcine fibroblasts . TALEN was developed to be cleaved at exons 1, 2, and 3, respectively, for LMXA1, PITX3, and NURR1, another gene that plays a major role in the development of dopamine neurons (see Figure 17a, black triangles). TAELN was co-transfected with a novel termination codon, a HindIII site, and a homology-dependent repair template designed to introduce frame-shifts after the new termination codon for the destruction of the targeted allele. A population of transfected cells was analyzed for HindIII-dependent cleavage produced by PCR-restricted fragment polymorphism analysis (Fig. 17B). The percentage of chromosomes with the new HindIII-knockout allele (represented by the cleavage product, open triangle) is shown on the gel. Individual colonies were cryopreserved for complementation studies, which were derived from this population and identified by double-allele knockout by RFLP and sequencing.

Example 10 PITX3 Knockout Pig Ovary phenotype was constructed by supplementing blastocysts and human stem cells .

To determine if human stem cells could complement PITX3 deficiency in pigs, hUCBSC was injected into PITX3 knockout pig blastocysts and blastocysts were transferred to hormonally synchronized young sows. On the 62nd day of pregnancy, chimeric embryos were harvested and the condition of the eyelids was examined (Figs. 18a, 18c, and 18e). Some of the chimera embryos had similar eyelids to those of the wild-fetus fetus and others showed occluded eyelids. These results suggest that PITX3 knockout in pig blastocysts is an appropriate model for investigating the effects of human stem cells on ectoderm lineages.

Example 11: ETV2 Knockout pig embryo

Etv2 is the master regulatory gene in blood vessels and hematopoietic lines and is an ideal candidate for genetic editing studies. The Etv2 locus was mutated to generate porcine embryos deficient in blood vessels and hematopoiesis for several reasons. First, Etv2 has been thoroughly demonstrated to be the master regulatory gene for angiogenesis and hematopoiesis in mice (Ferdous 2009, Rasmussen 2011, Koyano-Nakagawa 2012, Rasmussen 2012, Chan 2013, Rasmussen 2013, Behrens 2014, Shi 2014). Using a gene-based tracing strategy, it has been shown that Etv2-expressing cells produce vascular / endothelial and hematopoietic lines (Rasmussen 2011, Koyano-Nakagawa 2012, Rasmussen 2012). Second, a comprehensive gene deletion strategy has been demonstrated to demonstrate that Etv2 mutant mouse embryos can not survive because of lack of blood vessels and hematopoietic lines (Ferdous 2009, Koyano-Nakagawa 2012, Rasmussen 2012, Rasmussen 2013). Using transcript analysis, it was determined that Tie2 was not significantly controlled in the absence of Etv2 (Ferdous 2009, Koyano-Nakagawa 2012). In addition, using gene transfer techniques and molecular biology techniques (transcriptional analysis, EMSA, ChIP, and mutagenesis), Spi1 , Tie2 and Lmo2 were found to be direct downstream targets of Etv2 (Ferdous 2009, Koyano- Nakagawa 2012, Shi 2014 ). Third, the forced expression of Etv2 in the differentiating ES / EB system markedly increased endothelial and hematopoietic populations, proving that Etv2 is a single factor that can regulate the molecular cascade leading to both strains (Koyano-Nakagawa 2012).

Example 12: ETV2 Knockout pig embryos lacked blood vessels and hematopoietic lines.

Previous studies have shown that Etv2 is important for angiogenesis and hematopoiesis in mice, since embryos deficient in Etv2 are fatal at about E9.5 without blood vessels and blood (Ferdous 2009, Rasmussen 2011, Koyano-Nakagawa 2012). Without intending to be bound by any theory, ETV2 is an important regulator of mammalian blood vessels and blood, thus assuming that ETV2 knockout in pigs replicates mice. To investigate the role of ETV2 in pigs, the entire ETV2 coding sequence was removed using two TALEN pairs located on the side of the gene of porcine fibroblasts (Figs. 19A and 19B). This process was 15% efficient for complete gene removal; 79/528 of the genotyped clones were homozygous for deletion of the ETV2 gene. ETV2 homozygous knockout fibroblast clone was used for Somatic Cell Nuclear Transfer (SCNT) to generate ETV2 null embryos transferred to the surrogate sow. The cloning efficiency was 29%, which is higher than the average success rate of 20%.

The embryos were harvested and analyzed at E18.0 (Figures 20a-20h). At E18.0, wild-type (Wt) embryos formed blood vessels with well-developed vascular plexus in the urethra (Fig. 20a) and had evidence of blood development (Fig. 20c). In contrast, ETV2 KO embryos showed definite developmental defects. Both embryos were in the 24-depleted phase (Figure 20b) and had a deficient blood and vasculature (Figures 20c-20h), retarding growth in ETV2 KO compared to wild-type embryos. The ETV2 KO embryo lacked the main vein, lobar aorta, and endocardium that evidently appeared in wild-type embryos (Figures 20e-20h). These results reflect a similar phenotype and suggest that the function of ETV2 is conserved between mouse and pig. In addition, this data strongly supports the hypothesis that multiple mutations can be induced in the porcine genome to support the growth of humanized chimeric organs in one or more cell types.

Example 13: Using human iPSC ETV2 Knockout pig bladder supplementation.

Further studies were conducted to determine if hiPSC could complement ETV2 deficiency in pigs. hiPSC were injected into ETV2 knockout pig blastocysts and these blastocysts were transferred to a hormonally synchronized young sow. The chimeric embryos were harvested on the 18th day of pregnancy and the status of hiPSC was examined immunohistochemically (Figs. 21a to 21c). Human cells were identified by genomic alignment hybridization by staining for the use of probes against Alu repeat sequences and human nuclear antigen (HNA). ETV2 knockout in porcine blastocysts observes the presence of human CD31 and human cells expressing human vWF (vascular / endothelial cell markers), which supports the concept of an excellent model for investigating whether human stem cells contribute to blood vessels and hematopoietic lineages Respectively.

Example 14: Nkx2-5 and HandII as important regulators of heart development.

Cardiac outgrowth is a complex highly coordinated event involving the differentiation, proliferation, migration and differentiation of cardiac precursor cells that are electrically coupled and ultimately form a functional oligomer. This step of cardiac development is governed by a transcriptional network that has been shown to be important for cardiac formation and viability using gene disruption technology (Lyons 1995, Srivastava 1997, Tanaka 1999, Bruneau 2001, Yamagishi 2001, Garry 2006, Ferdous 2009, Caprioli 2011) (Table 1). Nkx2-5 is a vertebrate homolog of Tinman (Csx), a fruit fly homeodomain protein. Tymene mutations do not result in heart formation in flies (Bodmer 1993). Nkx2-5 is one of the earliest transcription factors expressed in the cardiovascular system. Destruction of targeted Nkx2-5 results in unstable cardiac morphogenesis, severe growth retardation and embryonic mortality at approximately E9.5 (Lyons 1995, Tanaka 1999). HandII (dHand) is a bHLH transcription factor and plays an important role in cardiac morphogenesis. The HandII mutant embryo is fatal in the early embryonic development and has severe right ventricular dysplasia and aortic arch defects (Srivastava 1997). In addition, mice deficient in both Nkx2-5 and HandII show ventricular dysfunction and have only a single atrial chamber (Figs. 22a-22d) (Yamagishi 2001). These gene disruption studies in mouse models illustrate the effect of using genetic editing strategies in pig models .

Example 15: NKX2-5 and HANDII Multiplex knockout of genes.

The combination of TALEN stimulated HDR was used to generate NKX2-5 / HANDII mutant porcine fibroblasts. Each gene was targeted within or immediately prior to its conserved transcription factor / DNA binding domain (Fig. 23A). This strategy was preferred over targeting genes near the transcription initiation site to reduce the chance of producing functional peptides by initiation in downstream AUGs. In the case of NKX2-5 , a homologous template was provided to generate a new in-frame termination codon, a restriction site for RFLP screening, and an additional 5 base inserts following the termination codon to prevent functional read-pass proteins Respectively. A double mutant was identified (Fig. 23B). The ability to stably produce double-null porcine fibroblast cell lines from a single shot is a unique and complementary transgenic technique.

Example 16: Disturbed heart development in triple knockout pig embryos.

Preliminary studies have identified a number of important transcription factors (ie, MESP1, GATA4, NKX2-5, HANDII, TBX5, etc.) that lead to disturbed heart development and provide an important new model for the study and potential treatment of pig congenital heart disease Lt; / RTI > Here, it has been demonstrated that the conceptual proof of successful targeting and generation of homozygotes for the deletion of the NKX2-5 / HANDII / TBX5 gene. Triplicate knockout fibroblast clones were transferred to surrogate sows using nuclear cloning (SCNT) to generate NKX2-5 / HANDII / TBX5 null porcine embryos. The embryos were harvested and analyzed in E18, equivalent to E11 in mice. At E18, the triple knockout pig embryo had a vascular system, skeletal muscle, and blood vessels, but essentially lacked the heart (minimal GATA4 immunocytochemically positive cardiac cells) when compared to wild-type control pig embryos (Figures 24a-24c). These data support the rationale and validity of using the NKX2-5 / HANDII double knockout pig model to limit the intervention of other systems (ie, the nervous system lineage in the TBX5 KO), including congenital heart disease models (ie, hypoxic right- Defects) in the process. This approach results in the manipulation of two ventricular chambers that are humanized in the pig model.

Example 17: Myf5, Myod and Mrf4 as important regulators of muscle differentiation.

The discovery of the Myod family, including Myod, Myf5, Mrf4, and Myog, provided a basic platform for understanding the regulatory mechanisms of skeletal muscle differentiation (Figs. 25a and 25b).

A number of strategies have been used to investigate the regulation network of the Myod family during muscle differentiation, such as transcript analysis, promoter analysis, and ChIP-seq. Myogenic family members are master origin modulators when transactivating a wide range of gene families, including muscle specific genes, transcription factors, cell cycle genes, etc., to promote myogenic cell fate. Previous gene disruption studies have shown that mice lacking Myf5 / Myod / MRF4 do not have skeletal muscle and that they die prematurely after birth due to dyspnea (due to diaphragmatic absence). This gene disruption study in mice explains the effect of using genetic editing strategies in pigs.

Use of TALEN and homology-dependent recovery (HDR) to knock out MYOD, MYF5, and MRF4 . To investigate the role of MYF5 / MYOD / MRF4 (also known as MYF6) in pigs, each coding sequence was disrupted using TALEN-stimulated HDR (Fig. 26a-c).

MYF5 / MYOD / MRF4 knockout pig embryos lack the skeletal muscle lineage. Embryos were harvested and analyzed at E18.0 (Figures 27a and 27b). The results in mice and pigs reflect a similar phenotype and support the notion that the function of MYF5 / MYOD / MRF4 is conserved between mouse and pig because the mutant embryo lacks skeletal muscle. In addition, this data strongly supports the hypothesis that multiple mutations are induced in the porcine genome to support the growth of humanized chimeric organs in one or more cell types.

Example 18: MYF5 / MYOD / MRF4 Knockout phenotype and complementation of GFP wild type pig navel.

Porcine MYF5 / MYOD / MRF4 knockout blastocysts were generated using SCNT and injected with GFP-labeled porcine oocytes (oocytes were used in this experiment because no proven pig ES cells were available). The resulting chimera was transplanted into pseudopregnant sows and examined at E20. Liver and laryngeal sacs were GFP positive, thus proving the possibility of supplementation. It was also estimated that about 10% of pig MYF5 / MYOD / MRF4 knot blastocysts were GFP-labeled (Figs. 28a-c). These data support swine supplementation in these pig mutant hosts. These data support the creation of triple knockouts in pig model without skeletal muscle, thus creating a place for ultimately complemented tissue formation. It is used throughout this study to generate humanized skeletal muscle in pigs.

Example 19: PDX1 Knockout produced a fetal pig without a pancreas.

Pdx1 - / - mice die shortly after birth because they do not have a pancreas and no pancreatic buds within mature organs (Offield et al ., 1996). The structure of the mouse Pdx1 - / - phenotype by blastocyst supplementation has been demonstrated by the injection of wild type mice or rat iPCS into Pdx1 - / - mouse blastocysts, producing mice with a normal functioning pancreas derived from donor cells (Kobayashi et al ., 2010). Supplementation of Pdx1-deficient blastocysts has also recently been described in pigs, where wild-type staphylococcal cells labeled with a porcine blastocyst expressing the Pdx1: hES1 grafting gene predominantly with functional pancreas are injected and then produced in a transplanted pancreas-free pig (Matsunaria et al., 2013). Cloned Pdx1 knockout pigs are unaffected by the unpredictable nature of the locational effects or expression levels observed when using the transgene gene and provide a more consistent platform for the production of pancreatectomized pigs. TALEN technology has been used extensively to use the TALEN pair that targets the major homeobox domain of the PDX1 gene to knock out the PDX1 gene in pig fibroblasts (Fig. 29a) in a double-blind enemies, it concluded to build an HDR Codons, frame shifts, and novel restriction enzyme sites. The homozygous PDXl knockout was obtained at a rate of 41% (76/184 clones) (Figure 29b). These PDX1 - / - fibroblasts and chromatin delivery cloning techniques were used to generate PDX1 - / - blastocysts and demonstrated pancreatic elimination in PDX1 - / - porcine embryos harvested at E30 (FIGS. 29c and 29d). Early β-cells expressing Pdx1 and insulin are present in the porcine pancreas of wild-type embryos harvested at E32 (Figure 29e).

Example 20: HHEX Knockout caused liver loss in fetal pigs

Generation of HHEX KO clones. Without intending to be bound by any theory, it was assumed that HHEX regulates liver development (Fig. 70). In earlier studies, the efficiency of these gene-editing methods was tested by generating HHEX KO clones. Constructs were developed to cleave the exon 2 of the HHEX gene (see the black triangle in Figure 30a) within the N-terminus of the homeome-domain-like region that is critical for DNA binding. Fibroblasts were transfected with a vector construct and a homology-dependent repair template designed to introduce a novel termination codon, a HindIII site, and a frame-shift mutation after the new termination codon for the destruction of the targeted allele. More than 50% of the transfected populations were positive for the HindIII KO allele by PCR-restriction fragment polymorphism analysis (Fig. 30b), and several individual clones from this population were heterozygous or homozygous for the KO allele ( 30C). Overall, 22 clones with sequence-proven KO allele were cryopreserved. The same vector constructs were used to generate both HHEX and Ubc KO blastocysts.

HHEX KO was lethal in embryos in pigs. To determine the effect of HHEX KO in pigs, HHEX - / - fibroblasts were cloned into SCNT and delivered to synchronized recipients. Embryos were harvested at 30-32 days of gestation and evaluated for liver development. All embryos were genotyped and confirmed knockout of HHEX. All specimens showed a delayed outbreak due to a clear absence of liver (Fig. 31b). For the further editing of these knockouts and the compilation of other targeted genes, such as ETV2, to generate human liver with human vasculature, for the purpose of growing fibroblasts as a source of HHEX knockout cells, Lt; / RTI >

Example 21: Summary of preliminary studies on porcine gene knockout and incorporation of human stem cells in fetal pigs.

Preliminary studies have demonstrated the ability of pig-targeted gene knockouts to destroy the development of the eye, heart, lung, liver, skeletal muscle, pancreas, vascular structures, hematopoietic cells, and dopaminergic neurons. In addition, it has been demonstrated that human stem cells injected into porcine morula / blastocysts are integrated within the inner cell mass and contribute to the development of fetal pigs. Significantly, the contribution of human stem cells to fetal pigs was also observed in the context of supplementing the blastocyst. These results show that there is a possibility to manipulate human organs and cells in pigs.

Example 22: MR imaging of fetal pig organs at 16.4T.

Imaging of organs produced in pigs through blastocyst supplementation was promoted using high field MRI. The UMN center's 16.4T magnet for magnetic resonance studies is the most powerful magnet in the world today used for imaging. 33 shows fetal pigs of the 30th gestational age (20 mm head-buttock length), wherein all internal organs are shown in greater detail. The pulse sequences used in these figures have been optimized to visualize the liver. Other pulse sequences have been developed to optimize contrast for other organs in order to quantify parameters such as organ volume in addition to the 3D form to provide important information about the anatomical features of the complementary organ. This provides a rapid quantitative approach to determining the success of complementation following knockout of a target gene to produce a particular organ.

Example 23: Dopaminergic neuron manipulation for restoring motor function

Parkinson's disease is a movement disorder caused by the gradual loss of dopaminergic neurons in the black zone of the brain. Recent treatments include drugs such as L-DOPA, a precursor of dopamine synthesis. L-DOPA therapy is effective over a period of time, but it is undesirable because it causes drug-induced motor impairment. Clinical trials with transplanted human fetal dopamine cells for the treatment of Parkinson's disease demonstrate an improvement in motor deficit (Lindvall et al., 1989; Freed et al., 2001; Olanow et al., 2003). Also, a follow-up study of transplanted patients over a long period of up to 18 years post-transplant surgery reports that they have discontinued medication to treat Parkinson's disease (Kefalopoulou et al., 2014). A major hurdle in the adoption of cell therapy for the overall treatment of Parkinson's disease is the limited access to human fetal brain tissue that is the source of donor dopamine neurons. The recent iPSC approach is incapable of completely producing true black dopamine neurons. Genes important for the development of dopamine neurons in the substantia nigra can be identified and targeted for knockout for genuine neuron production through blastocyst supplementation.

Blastocysts are produced from each type of gene knockout mouse. GFP-labeled mouse iPSC cells are injected into blastocysts and transferred to surrogate mothers. The offspring are analyzed for histological evidence of GFP-positive cells in the brain. In pig studies, pig blastocysts are generated from each type of gene knockout. GFP-labeled porcine NK cells are injected into blastocysts and transferred to surrogate sows / young sows. The fetus is analyzed on the 60th day of pregnancy for histological evidence of GFP-positive cells in the brain. Human stem cells are injected into blastocysts to evaluate human-pig supplementation.

Without wishing to be bound by any theory, we hypothesized that PITX3 functions in the development of dopaminergic neurons / eye lens (FIG. 34). The PITX3 gene was successfully removed using TALEN (Figs. 17 and 34). Figure 35 shows the procedure used to introduce donor hiPSC or human umbilical cord blood stem cells into a PITX3 KO pig-lost embryo. A chimeric embryo was generated as shown in Fig. PITX3 knockout of the pig blastocyst was supplemented with human stem cells to repair the developmental defects of the eyes (Figs. 18 and 37). Pork PITX3 knockout also resulted in the loss of dopamine neurons in fetal black color (Figs. 38A and 38B). Supplementation with human source neurons resulted in incorporation of human source neurons into chimeric embryos and rescued the loss of dopamine neurons due to knockout of PITX3 (Figures 39a-39d). In addition, hiPSC supplementation induced the survival of black chromatin dopamine neurons in chimeric embryos to levels similar to wild-type pigs, while PITX3 knockout caused loss of dopaminergic neurons (FIGS. 40 and 41).

Without wishing to be bound by any theory, it was hypothesized that the LMX1A and PITX3 genes are important for the development of dopamine neurons (FIG. 42). To investigate whether the complement could rescue the phenotype induced by LMX1A / PITX3 knockout, wild type precursor GFP was introduced into the LMX1A ^{- / -} / PITX3 ^{- / -} blastocyst (FIG. 43). PITX3 / LMX1A knockout fetal pig-pig supplementation restored fetal development (Figs. 44A-44F). The lens was removed from the PITX3 knockout animal (Figs. 45A and 45B). Pig-pig supplementation in the PITX3 / LMX1A knockout animals restored lens development (Figs. 46a-c). Donor-derived cells (GFP-positive cells) were identified in chimeric fetal pig brain (Figures 47a-47d). DA neurons (dopamine neurons) were identified in the primordial midbrain of chimeric pigs suggesting that pig-pig supplementation resulted in the development of dawn neurons in the primordial midbrain (Figs. 48a-c).

Table E provides a list of genotypes of the edited carrier (host), and a list of donor genotypes used to complement the animal (structure).

[Table E]

Example 24: Fabrication of proliferating glial progenitor cells for spinal cord recovery

Neurological disorders such as, for example, multiple sclerosis, leukodystrophy, and traumatic spinal cord injury result in loss of myelin formation. These diseases may be effective in cell-based therapies that prevent additional loss of a few seconds or restore a lost myelin. High-purity rarely proliferating glial cell precursor cells (OPC) differentiated in vitro from human embryonic stem cells plant neurons after spinal cord transplantation (Nistor et al., 2005). This has been emphasized in the effect of potential mechanisms for observed functional recovery (Keirstead et al., 2005; Sharp et al., 2010). Therefore, a potential treatment strategy is to manufacture rare proliferative glia progenitor cells (OPCs). Recent iPSC-based approaches result in poor yields and incomplete reprogramming of OPCs. Genes involved in the development of OPC can be identified and targeted for knockout for mass production of genuine human OPC in the porcine brain.

Mixing knockout of OLIG1 and OLIG2 in mice Knockout Investigate to see if blastocysts can produce rat OPC after rat-rat supplementation. 1) OLIG1 and OLIG2 knockout mice are generated and information about the OPC deficiency is obtained; 2) Mouse sparse glia progenitor cells (OPCs) express OLIG1 / OLIG2 knockout blastocysts (or NKX2.1 , NKX2.2 and / SOX10 selection), 3) it is implanted in a mouse with congenital malformations, and verifies the formation of herpes by confirming the functionality of OPC.

Without wishing to be bound by any theory, it was hypothesized that OLIG1 / OLIG2 is important for the development of sparse dendritic cells (Fig. 65). In order to investigate the function of OLIG1 / OLIG2, it was generated OLIG1 / OLIG2 knockout fibroblasts (Fig. 66a to 66c). GFP expression was induced by OLIG1 / OLIG2 knockout blastocysts to produce chimeric pigs. GFP expression was observed in whole body fluorescence images of porcine fetuses supplemented with wild type cells (Figs. 67A and 67B). GFP-expressing cells were also incorporated into the central nervous system of chimeric pigs (Figures 68a and 68b, 69a and 69b). In particular, GFP-expressing cells were present in both chimeric pig brain (Figures 68a and 68b) and spinal cord (Figures 69a and 69b).

Table F provides a list of genotypes of the edited carrier (host), and a list of donor genotypes used to complement the animal (structure).

[Table F]

Example 25: Young blood manipulation to rejuvenate an old brain

Recent studies demonstrate that parabiotic coupling of young and old mice can rejuvenate brain function in older animals. However, the clinical application of this approach to treat patients with aging / degenerative brain requires that each patient receive transfusion from a young donor. Due to the limited availability of young blood it may be difficult to apply this approach to the majority of patients. By editing key genes involved in hematopoiesis, a self-supply of young blood is created. Knockout blastocysts can be used for complementary studies to generate young blood from mice and pigs. Blood from young mice is given to old Alzheimer's mice to rejuvenate brain function. At the same time, the resulting young mouse and old Alzheimer's mouse are combined with a concomitant surgery to demonstrate the rejuvenation of brain function through direct sharing of blood circulation with "proof of concept". In addition, cognitive function and motor function were rescued in aging-related neurodegenerative disease mouse models including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) Evaluate the efficacy of young human blood. Success will lead to unrestricted self-feeding of young blood for aging and / or rejuvenation of the degenerative brain.

Blastocysts with knockout of RAG2, IL2rg, C-KIT, and ETV2 alone or in combination can be used to induce hematopoiesis in rats through complementation with GFP-labeled mouse iPSC. Immune cells can be identified through a panel of antibodies designed to differentiate between mouse and human cells. T cell panels are used to isolate T cell populations using CD3, stain helper T cells using CD4, stain cytotoxic T cells using CD8a, and CD25 as active markers for each of these T cell subtypes. In a separate panel, FoxP3 can be used to identify regulatory T cells, and CD25 is used to identify activated regulatory T cells. CD45 and CD11b are stained to analyze microglial cells. Also in this panel, CD200 is a microglial cell stop marker and CD163 is a marker of an alternate activated M2-like microglia. Young mice exhibiting strong complementation are used as younger cohesive partners for circulatory association. Young blood / plasma is supplied to both old and Alzheimer's mice using both the habituation and plasma injection approaches. Young mice that have been engineered to produce human blood are bound to aging or Alzheimer's mice through a cohesive surgery. At the same time, plasma is collected from young mice and injected intravenously into aging or Alzheimer's mice. From 3 months to 6 months after surgery / plasma injection, a series of behavioral functional tests, including open field testing, elevated cruciate test, novel object recognition test, and Morris water maze test, Conjugated pair) mice. Age matched mice not treated and not treated were used as controls.

The pig study evaluates RAG2, IL2rg, C-KIT, and ETV2 knockout alone or in combination for the production of porcine hematopoietic cells using labeled piglets. See Figures 71-73. As in mouse studies, to identify the cellular phenotype of the pigs (CD3, CD21 and CD79a for CD4: B cells to identify CD45, CD3, delta-chain TCR, CD8, For CD16, CD172a, CD2, and CD8; and FoxP3 for regulatory T cells (Treg)). The results from the pig-pig chimera provide information on which knockout is suitable for producing human hematopoiesis in pigs. Until the study of pig-pig chimeras is completed, we identify human stem cell candidates from Technical Aim III to begin research into manipulating human blood in pigs. Antibody panels (e.g., CD45, CD3, CD4, CD8, and CD19) that specifically recognize human blood cells are used for cell phenotype analysis, including hierarchical analysis and multicolor flow cytometry, in which species- .

The genotype of the host cell (carrier) used is as follows: RAG2 ^{- / -} / IL2rg ^{- / -} / C-KIT ^{- / -} / ETV2 ^{- / -} RAG2 ^{- / -} / IL2rg ^{- / - / -; RAG2 - / - /} IL2rg - / - / ETV2 - / -; IL2rg - / - / C-KIT - / - / ETV2 - / -; RAG2 - / - / IL2rg - / -; RAG2 - / - / ^{C-KIT - / -; RAG2} - / - / ETV2 - / -; IL2rg - / - / C-KIT - / - /; IL2rg - / - / ETV2 - / -; C-KIT - / - / ETV2 - / ^- RAG2 ^{- / -} IL2rg ^{- / -} C-KIT ^{- / -} ETV2 ^{- / -} C-KIT ^{- / -} .

Without wishing to be bound by any theory, it was hypothesized that RAG2 / IL2Rg is important for T cell, B cell, and NK cell development and thymogenesis (FIGS. 49 and 50). We also hypothesized that the C-KIT gene is important for T-cell, B-cell, and NK cell development and thymus development. In order to investigate the effect of supplementation of IL2Rg / RAG2 knockout animals, chimeric animals were generated by introducing wild type precursor GFP into IL2Rg / RAG2 knockout blastocyst (FIG. 51). In addition IL2Rg / RAG2 / C-KIT animals were generated (Figures 77-79). IL2Rg / RAG2 / C-KIT piglets supplemented with wild type cells (Receiver # 6035) were harvested and further studied. The phenotypic analysis showed that the supplemented animal could have both wild-type and mutant genomes (Figure 80). Supplementation of IL2Rg / RAG2 / C-KIT knockout rescued gene disruption and resulted in the development of thymus (Figures 52a-52b). GFP ⁺ immune cells were observed in cells collected from umbilical cord blood, thymus, spleen, peripheral blood mononuclear cells (PBMC) and mesenteric lymph nodes (MLN) (Figure 53). Immune cells were generated from the thymus of chimeric animals (Figs. 54a to 54f). In blood and spleen, chimeric pig embryos contained similar amounts of T cells as wild-type pig embryos while T cells were significantly reduced in IL2Rg / RAG2 / C-KIT knockout pig embryos (FIGS. 55 and 56). A similar phenotype was observed in association with B cells and NK cells (Figures 57-60). In short, chimeric pig embryos have similar immune cell profiles to wild-type pig embryos, while immune cells in knockout pig embryos are significantly reduced.

Table G provides a list of the genotypes of the edited carriers (hosts), and a list of donor genotypes used to complement the animal (structure).

[Table G]

Example 26: Hematopoietic cell manipulation for skin recovery

The genotype of the carrier used (host) includes: RUNX1 ^{- / -} / C-KIT ^{- / -} / FLK1 ^{- / -} ; RUNX1 ^{- / -} / FLK1 ^{- / -} ; RUNX1 ^{- / -} / C-KIT ^{- / -} ; C-KIT ^{- / -} / FLK1 ^{- /} ; RUNX1 ^{- / -} ; C-KIT ^{- / -} ; FLK1 ^{- / -} .

Blastocysts are produced from each type of gene knockout mouse. GFP-labeled mouse iPSC cells are injected into blastocysts and transferred to surrogate mothers. The offspring are analyzed for histological evidence of GFP-positive cells in blood, bone marrow, thymus, lymph nodes, and skin.

Histopathologic demonstration of cells in blood, bone marrow, bone marrow, thymus, lymph nodes, and skin of mice expressing GFP and expressing mesenchymal and hematopoietic markers CD45, CD3 and PDGFR1 alpha represents a complementary success.

FACS charts and micrographs showing the histological evidence of cells in the blood, bone marrow, bone marrow, thymus, lymph nodes, and skin of GFP, CD45, CD3, and PDGFR1 alpha-labeled mice indicate the success of the supplement.

Blastocysts are produced from each type of gene knockout pig. GFP-labeled porcine NK cells are injected into blastocysts and transferred to surrogate sows / young sows. Analyze the fetus at 60 days of gestation for histological evidence of GFP-positive cells in blood, bone marrow, thymus, lymph nodes, and skin.

Histopathological demonstration of cells in the blood, bone marrow, thymus, lymph nodes, and skin of porcine embryos that are labeled with GFP and express the mesoderm and hematopoietic markers CD45, CD3 and PDGFR1 alpha.

Table H provides a list of the genotypes of the edited carriers (hosts), and a list of donor genotypes used to complement the animal (structure).

[Table H]

Example 27: Vascular manipulation for revascularization

Vascular disease is very common in peripheral arterial disease, with more than 10 million Americans developing it, with more than 150,000 limb amputations per year in the United States (Hirsch 2013). In addition, over 300,000 patients undergo coronary artery bypass grafting (surgical revascularization). These diseases increased overall as the incidence of diabetes, obesity, and cardiovascular disease increased. Importantly, these complications lead to significant morbidity and mortality. Recent medical treatments for vascular disease include limb amputation, vascular bypass (using the patient's diseased vascular structure), or vascular grafts - all of these therapeutic solutions have significant limitations. Etv2 was previously found as a major regulator of the development of blood vessels and hematopoietic lineages, and Etv2 null embryos were fatal and lacked the hematopoietic endothelial system (Ferdous 2009, Rasmussen 2011, Koyano-Nakagawa 2012, Rasmussen 2012, Rasmussen 2013, Behrens 2014, Shi 2014). Using gene editing technology, ETV2 mutant porcine embryos also showed lack of hematopoietic endothelial system. Humanized vascular structures are produced in the ETV2 mutant pig model. This not only provides an unrestricted source of humanized vascular grafts, but also provides a platform for multiplexing different gene editing strategies and manipulating various organs with humanized vascular structures. As is known that cell surface antigens (galactose-alpha (1,3) -galactose) present in porcine endothelial cells are the major cause of hyperacute rejection and intravascular coagulation in heterologous organ transplantation, tremendous.

ETV2 mutant porcine embryos are produced by SCNT and are thoroughly analyzed. GFP-labeled piglets are injected into the ETV2 mutation- deficient embryos . This GFP-labeled inhibitor is also generated using SCNT. The injected embryos are transferred to sows, embryos are collected at E18, E24, and newborns are collected 7 days after birth (P7). Investigate the contribution of GFP-positive cells to embryos. Inject ETV2 mutant lethal embryos into human embryonic stem cells (analyze four separate lines). The injected embryo is transferred to sows and embryos are collected at E18 and E24. Porcine or human stem cells supplemented ETV2 null pig embryos are generated and examined for cardiovascular function using MRI and echocardiogram ultrasound, respectively. Pig-pig chimeras are analyzed at E18, E24, and P7, and human-pig chimeras are analyzed at E18 and E24.

Host genotypes include the following: ETV2 ^{- / -} .

Table I provides a list of genotypes of the edited carriers (hosts), and a list of donor genotypes used to complement the animal.

[Table I]

Example 28: Operation of blood heart for restoration of heart function

Congenital cardiovascular anomalies are the most common congenital anomalies and cause late or terminal heart failure in children and adults. Congenital heart disease occurs in approximately 1% of all neonates and has significant morbidity and mortality rates (Garry 2006, Hoffman 1995, Kang 2000, Kramarow 2012, Rasmussen 2011). In congenital heart disease-induced heart failure, the only treatment that has a therapeutic effect is allograft transplantation. Lack of organs for transplantation Understands that less than 2% receive such life saving treatments. Those who receive heart transplants require lifelong immunosuppression, which also has adverse side effects and limits survival. Therefore, there is a need to develop alternative sources of human cardiac tissue. A humanized eccentric heart is created that contributes as an unrestricted source of organ for transplantation and provides a platform for paradigm shifts in the treatment of congenital heart disease and terminal heart failure. Previously published studies demonstrate an important role for Nkx2-5 and Hand2 in the specification of ventricular myocardium (Yamagishi 2001). Therefore, the NKX2-5 / HANDII double knockout pig embryo can be manipulated to defeat the ventricular myocardium using gene editing techniques. Human stem cells, SCNT and blastocyst supplementation can be used to produce humanized eccentric hearts. In addition to contributing as a new source of human ventricular myocardium for the treatment of cardiovascular disease, humanized pigs contribute to large animal models for studying response to pharmacologic agents or regeneration of the human system, and congenital hypoplasia of the right and left heart Thereby improving the treatment for cardiovascular diseases including heart failure diseases.

The NKX2-5 / HandII mutation loss factor is generated using SCNT and fully characterized in E18 and E24. NKX2-5 / HandII Mutant Loss Embryos are injected with GFP-labeled pig pool . This GFP-labeled inhibitor is also generated using SCNT. The injected embryos are transferred to sows, embryos are collected at E18, E24, and newborns are collected 7 days after birth (P7). Investigate the contribution of GFP-positive cells to embryos. Human stem cells are injected into the NKX2-5 / HandII mutation- deficient embryos (four separate lines are analyzed and screened). The injected embryo is transferred to sows and embryos are collected at E18 and E24. In Annex I-9.4, pig or human stem cell-supplemented NKX2-5 / HandII double-knockout pig embryos are generated and examined for cardiovascular function via MRI and trans -thoracic echocardiography. The pig-pig chimera is analyzed at E18, E24 and P7, and the human-pig chimera is analyzed at E18 and E24.

Genotypes of host and donor cells used include: NKX2-5 ^{- / -} / HANDII ^{- / -} / TBX5 ^{- / -} ; NKX2-5 ^{- / -} / HANDII ^{- / -} ; HANDII ^{- / -} / TBX5 ^{- / -} ; NKX2-5 ^{- / -} / TBX5 ^{- / -} ; HANDII ^{- / -} ; TBX5 ^{- / -} ; NKX2-5 ^{- / -} .

Table J provides a list of genotypes of the edited carriers (hosts), and a list of donor genotypes used to complement the animal (structure).

[Table J]

Example 29: Skeletal muscle manipulation to restore limb function

Muscular disorders such as muscular dystrophies and aging are common and fatal. Skeletal muscles have tremendous regenerative capacity, but this potential is eventually weakened by disease and aging. There are currently no treatments available for end-stage myopathy, and 50% of the elderly suffering from the disease die. It also loses considerable training time due to musculoskeletal injuries in the US Army, even in the lightning. The incidence of these injuries accounts for 56% of the total diagnosis. The longer recovery period usually requires long-term physical therapy (Smith and Cashman, 2002). Xenotransplantation of extracellular matrix has been shown to be useful for muscle regeneration following traumatic injury (Sicari et al., 2014). The long-term goal and clinical significance of this proposal is the production of humanized skeletal muscle using MYF5 / MYOD / MRF4 knockout pigs (also known as Myf6). These humanized pigs contribute to large animal models for studying the response to pharmacological agents and / or the regeneration of human skeletal muscle. Skeletal muscle manipulated in this way has potential as a future source of muscle transplantation. Genetically engineered mouse models were pre-generated to determine the necessary network for muscle differentiation and regeneration.

MYF5 / MYOD / MRF4 triple mutant pig embryos are generated by SCNT and are thoroughly analyzed. A GFP-labeled porcine oocyte is injected into the MYF5 / MYOD / MRF4 triple mutation loss vessel. This GFP-labeled inhibitor is also generated using SCNT. The injected embryos are transferred to sows, embryos are collected at E24, E50, and newborns are collected 7 days after birth (P7). Investigate the contribution of GFP-positive cells to embryos. In Annex I-10.3, human stem cells can be injected into MYF5 / MYOD / MRF4 triple mutant mice (four separate lines can be analyzed and screened as outlined in Technical Area III). The injected embryos are transferred to sows and embryos are collected at E24 and E50. In Annex I-10.4, pig or human stem cell-supplemented MYF5 / MYOD / MRF4 null porcine embryos are generated and examined for skeletal muscle function via MRI, shrinkage test and abdominal examination. Pig-pig chimeras are analyzed at E24, E50, and P7, and human-pig chimeras are analyzed at E24 and E50.

Genotypes of host and donor cells used include: MYF5 ^{- / -} / MYOD ^{- / -} / MRF4 ^{- / -} ; MYF5 ^{- / -} / MYOD ^{- / -} ; MYF5 ^{- / -} / MRF4 ^{- / -} ; MYOD ^{- / -} / MRF4 ^{- / -} ; MYF5 ^{- / -} ; MYOD ^{- / -} ; MRF4 ^{- / -} ; PAX3 ^{- / -} .

Without wishing to be bound by any theory, we hypothesized that PAX3 regulates muscle differentiation (Figure 61). Chimeric mice were generated to investigate whether supplementation rescues the phenotype caused by PAX3 knockout (FIGS. 62A, 62B, and 74A). In Pax3 mutant mice complemented with GFP-expressing wild-type iPSC, GFP-positive cells were selectively distributed to limb skeletal muscle (Fig. 62B). The supplemented mice also developed muscle tissue / organ structure of the hind legs (Figures 74b and 74c). Pax3 knockout pigs were also generated (Figures 75a-75b). Mutant pigs exhibited phenotypes similar to mutant mice (Figures 75c to 75f). PAX3 mutant pigs lost limb skeletal muscle.

Table K provides a list of genotypes of the edited carrier (host), and a list of donor genotypes used to complement the animal (structure).

[Table K]

Example 30: Liver manipulation to restore liver function

Alcohol, obesity, diabetes mellitus, metabolic syndrome, and viral infections are major contributors to chronic liver disease. The incidence of nonalcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma is just before the global epidemic. For example, the incidence of NAFLD in the United States is estimated at 20-30% of the general population, reaching 75-100% of those with obesity (BMI> 30) and morbidly obesity (BMI> 40) (Farrell and Larter, 2006]). Although there are many treatment options available for these diseases, liver transplantation remains the most successful option in many cases. Although surgery has increased 3.7-fold between 1988 and 2009 (Wertheim et al., 2011), the increased spacing between donor availability and demand for transplantation remains a difficult problem.

Generation of HHEX and Ubc knockout blastocysts - Among the genes known to be important for early liver development are the homeobox gene HHEX and the polyubiquitin gene Ubc . (i) Knock out any of these genes in the mouse zygote using TALEN and CRISPR gene editing techniques; (ii) sequencing the genome of the KO zygote to determine the absence of the full length of the HHEX and Ubc genes; And (iii) in vitro produced HHEX- KO and Ubc- KO zygotes to the blastocyst stage, Extensive characterization.

Generation of human-mouse liver chimeras by blastocyst supplementation- hLDPCs derived from hepatocytes isolated from original healthy human liver biopsies can be used to generate human-mouse chimeras. In a preliminary study, hLDPC was differentiated into blastocysts and was found to be able to efficiently engraft the mouse liver. The blastocyst supplementation is performed by injecting hLDPC into HHEX- KO and Ubc- KO mouse blastocysts, which are transplanted into 57BL / 6 female mice. Study the engraftment of LDPC after injection into mouse embryos. Analyze the liver of cubs born to female recipients of blastocysts. Notably, HHEX and Ubc mice are each deadly embryos, and these mouse embryos survive beyond E14.5 only if hepatocyte and hepatic epithelial progenitor cell proliferation are complemented by transplanted hLPDC.

Generation of human-to-pig liver chimeras - To produce chimeric liver in pigs, like chimeras in mice, and to assess the humanized liver function produced in pigs, check the following:

Liver function in both in vivo and ex vivo ;

· Human cell chimeric sex of hepatocytes isolated from the liver produced;

· Contribution of transplanted human LDPC to hepatic vascular structure formation; And

· Enzyme function of isolated hepatocytes and comparison with major human hepatocytes.

Genotypes of host and donor cells used include: HHEX ^{- / -} / Ubc ^{- / -} ; HHEX ^{- / -} ; Ubc ^{- / -} .

Table L provides a list of genotypes of the edited carriers (hosts), and a list of donor genotypes used to complement the animal (structure).

[Table L]

Example 31: Pancreatic manipulation for the treatment and transplantation of diabetes

Treatment of pancreatic diseases and disorders, including diabetes, is currently fairly limited due to the lack of available human pancreas for whole tissue or islet transplantation. The blastocyst supplementation of the pancreatic defect phenotype proved to be an autologous cell of exogenous rat iPSC and Pdx1: Hesl pig of Pdx1 ^{- / -} mice (Kobayashi et al ., 2010, Matsunaria et al ., 2013). In both cases, the pancreas formed in the supplemented animal was entirely derived from the offspring of the donor cell. Producing cloned Pdx1 ^{- / -} pigs, which are used to generate whole human pancreases derived from offspring of human stem cells in pig-human chimeras, allowing the production of human pancreatic organs and islets for transplantation And is a technology platform for producing patient-tailored pancreas for autologous transplantation.

Pdx1 ^{- / -} pancreatic complement the place available to the pig is the wild type, GFP + ve pig cleavage obtain the Pdx1 ^{- / -} injected into the pig blastocyst and pregnancy of the litter compensate for the presence of GFP-expressing cells in the chimeric embryos initial medium and It is first proved by analyzing early after birth. Investigate human stem cell supplementation of Pdx1 gene knockout (and double knockout of Pdx1 and ETV2 genes) in pigs. Human stem cells that have been optimally supplemented can be injected into cloned Pdx1 ^{- / -} or Pdx1 ^{- / -} Etv2 ^{- / -} porcine blastocysts. In vitro and in vivo studies, including testing chimeric embryos in mid-pregnancy, early neonatal and post-natal postpartum pigs, and the ability of pig-generated human islets to restore blood glucose homeostasis in diabetic rodent and non-human primate models Provides human pancreatic tissue and islands for my testing.

Genotypes of host and donor cells used include: Pdx1 ^{- / -} / Etv2 ^{- / -} ; Pdx1 ^{- / -} ; Etv2 ^{- / -} .

Without wishing to be bound by any theory, we hypothesized that PAX1 regulates pancreatic development (Figure 63). To investigate the effect of the PDX1 gene were generated PDX1 gene knockout pigs. In the PDXl knockout pig, pancreatic development did not occur (Figures 29a-29e).

Table M provides a list of genotypes of the edited carriers (hosts), and a list of donor genotypes used to complement the animal (structure).

[Table M]

Example 32: Lung manipulation to restore lung function

Lung disease causes 400,000 deaths annually in the United States and organ transplantation is the only "primary" treatment for many end-stage lung diseases such as chronic obstructive pulmonary disease (COPD), emphysema, idiopathic pulmonary fibrosis, primary pulmonary hypertension and cystic fibrosis. Treatment ". However, only 2,000 lung transplants are performed annually. Recent reports that 14% of US troops returning from Iraq and Afghanistan have inhaled lung injury are particularly important to military personnel. The long-term effects of these impairments, including chronic bronchitis and pulmonary vascular remodeling, certainly increase the incidence of irreversible lung disease requiring organ transplants for these veterans. The major obstacles to lung transplantation include the lack of available donor lungs, the chronic rejection usually associated with non-HLA-matched lungs, the need for lifelong immunosuppression, and high mortality rates. New sources of implantable lung tissue that are not rejected are therefore essential. Ultimately, in a blastocyst supplementation study to generate human lungs, genes involved in lung development are tested to see which genes can be targeted for knockout.

Test knockout of activated transcription factors and cell lines of lung development (epithelial Nkx2.1, Sox2, Id2, mesenchymal Tbx4) at different steps to ensure that the corresponding blastocysts have differential capacity for supplementation. Generate Nkx2.1 ^{- / -} by crossing the available Nkx2.1 ^+/- from MMRRC. TALENS gene editing is used to generate other KO fibroblasts. KO mouse embryos are injected with wild-type mouse GFP ⁺ ES cells. Repeat the successful supplementation using mouse iPS cells. Test knockout of activated transcription factors and cell lines of lung development (epithelial Nkx2.1, Sox2, Id2, mesenchymal Tbx4) at different steps to determine if the porcine fetus produced is lung-defective. KO pig fibroblasts generated using TALENS gene editing successfully regenerate blastocyst-supplemented knockout. KO pigs are cloned using a virgin reproductive pig blastocyst to assess the generation of a pulmonary-deficient phenotype. For these KOs, pulmonary defects are identified and GFP-expressing piglets are injected into the KO blastocyst. Supplementation of pulmonary phenotype and donor cell engraftment are confirmed in chimeric fetal pigs at 30 and 60 days of gestation to confirm the complementary ability of KO. GFP-expressing human iPS cells, pure iPS cells, UCBSC or MAPC are injected into KO porcine blastocysts to verify that human pluripotent stem cells can complement pulmonary-deficient porcine blastocysts. At 30 days and 60 days of pregnancy, the lungs are evaluated for mosaic type and complement. Using the best-engrafted human embryonic stem cell line identified, the most promising knockout bladder supplementation identified in Annex I-13.3 is performed. Pulmonary morphogenesis was assessed using immunohistochemistry and flow cytometry and human cells were identified. To evaluate pulmonary maturation, further studies of successful combinations in late pregnancy are scheduled for evaluation of pulmonary function (pulmonary function test), surfactant and mucus production.

The genotypes of host and donor cells used include Nkx2.1 ^{- / -} / Sox2 ^{- / -} / Id2 ^{- / -} / Tbx4 ^{- / -} Nkx2.1 ^{- / -} / Sox2 ^{- / -} / Id2 ^{- / -} ; Nkx2.1 ^{- / -} / Sox2 ^{- / -} / Tbx4 ^{- / -} ; Nkx2.1 ^{- / -} / Id2 ^{- / -} / Tbx4 ^{- / -} ; Sox2 ^{- / -} / Id2 ^{- / -} / Tbx4 ^{- / -} ; Nkx2.1 ^{- / -} / Sox2 ^{- / -} ; Nkx2.1 ^{- / -} / Id2 ^{- / -} ; Nkx2.1 ^{- / -} / Tbx4 ^{- / -} ; Sox2 ^{- / -} / Id2 ^{- / -} ; Sox2 ^{- / -} / Tbx4 ^{- / -} ; Id2 ^{- / -} / Tbx4 ^{- / -} ; Nkx2.1 ^{- / -} ; Sox2 ^{- / -} ; Id2 ^{- / -} ; Tbx4 ^{- / -} .

It was hypothesized that NKX2.1 regulates lung development without intent to be bound by any theory (Fig. 64). To investigate the effect of the NKX2.1 gene on lung development, NKX2.1 knockout pigs were generated. Knockout of porcine fibroblasts against transcription factor Nkx2.1 , an important gene for lung development (TALEN gene editing). 30 day old porcine embryos showed slowed lung growth at the early pseudoglandular stage (Figs. 32A-32F). Therefore, complementation with human stem cells at the blastocyst stage can be a source of producing human lungs for organ transplantation or lung disease studies. NKX2.1 knockout pigs can be used to address the lack of donor lungs for organ transplantation and the lack of a suitable in vivo model of human lung disease.

Table N provides a list of genotypes of the edited carrier (host), and a list of donor genotypes used to complement the animal (structure).

[Table N]

Additional disclosure

The patents, patent applications, publications and articles mentioned herein are incorporated herein by reference; In the event of conflict, the present specification shall control. Implementations have various features; These features may be mixed and matched as functional implementations are needed. The headings and subheadings are provided for convenience, but are not essential and do not limit the scope of the contents described.

                               SEQUENCE LISTING <110> REGENTS OF THE UNIVERSITY OF MINNESOTA       RECOMBINETICS, INC.   <120> COMPOSITIONS AND METHODS FOR CHIMERIC EMBRYO-ASSISTED ORGAN       PRODUCTION <130> 370006.00011 (WO) <140> PCT / US2016 / 059206 <141> 2016-10-27 <150> 62 / 246,926 <151> 2015-10-27 <150> 62 / 246,927 <151> 2015-10-27 <150> 62 / 246,929 <151> 2015-10-27 <150> 62 / 246,947 <151> 2015-10-27 <150> 62 / 247,092 <151> 2015-10-27 <150> 62 / 247,096 <151> 2015-10-27 <150> 62 / 247,115 <151> 2015-10-27 <150> 62 / 247,117 <151> 2015-10-27 <150> 62 / 247,118 <151> 2015-10-27 <150> 62 / 247,122 <151> 2015-10-27 <160> 68 <170> PatentIn version 3.5 <210> 1 <211> 90 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 1 ctcttttcgc aggcacaggt ctacgagctg gagcgacgct tctaagcttg cagcagcggt 60 acctgtcggc tcccgagcgt gaccagttgg 90 <210> 2 <211> 90 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 2 aaccctgtgt cgtttcccac ccagtagata tgtttgatga ctaagcttct cggaaggcag 60 agagtgtgtc aactgcgggg ccatgtccac 90 <210> 3 <211> 60 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 3 tgcggttgct cccccgcctc gtccccgtaa gcttgactcc tggtgcagcg ccccggccag 60 <210> 4 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 4 cccaaarrtt cartrttt 18 <210> 5 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 5 ccaartrcaa ttcatrtact 20 <210> 6 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 6 accttcctcc tctccrct 18 <210> 7 <211> 17 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 7 ctaarctrct tttraat 17 <210> 8 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 8 rraaraarta tcarccat 18 <210> 9 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 9 racccaraat ttctrt 16 <210> 10 <211> 17 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 10 rrcacccrtr tccrcrc 17 <210> 11 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 11 catrtactct ractt 15 <210> 12 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 12 rctctactct acccc 15 <210> 13 <211> 17 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 13 rcacatraar tcrccca 17 <210> 14 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 14 ccrtcctttr ccaacctt 18 <210> 15 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 15 trrrrrccca crrttrct 18 <210> 16 <211> 17 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 16 ctcctacaar trrattt 17 <210> 17 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 17 crracccrtc cttrcact 18 <210> 18 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 18 rractracca ctatt 15 <210> 19 <211> 17 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 19 araraattrtr rtccarc 17 <210> 20 <211> 17 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 20 crcarrcaca rrtctac 17 <210> 21 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 21 accrctrctr cttra 15 <210> 22 <211> 17 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 22 rcrrttrctc ccccrcc 17 <210> 23 <211> 17 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 23 rrccrrrrcr ctrcacc 17 <210> 24 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 24 atrtttratr acttc 15 <210> 25 <211> 17 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 25 rrccccrcar ttracac 17 <210> 26 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 26 cgtcaccaac ggtctcctct cgg 23 <210> 27 <211> 90 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 27 ttccactcta ccccccccaa aggttcagtg ttttgtgtaa gcttcaatgt tgagtacatg 60 aattgcactt gggacagcag ctctgagctc 90 <210> 28 <211> 90 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 28 ctctaaggat tcctgccacc ttcctcctct ccgctaccca gactaagctt tgcacattca 60 aaagcagctt agggtctgaa aaacatcagt 90 <210> 29 <211> 90 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 29 ccagatcgcc aaagtcacgg aagaagtatc agccattcat ccctcccagt gaagcttaca 60 gaaattctgg gtcgaccacg gagttgcact 90 <210> 30 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 30 tgcccgaggt ggtgaggcgc t 21 <210> 31 <211> 90 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 31 gtgctgcgtg ccctttactg ctctactcta ccccctacca gcctaagctt gtgctgggcg 60 acttcatgtg caagttcctc aactacatcc 90 <210> 32 <211> 90 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 32 cccagacttc actccgtcct ttgccgactt cggccgacca gcccttagca accgtgggcc 60 cccaaggggt gggccaggtg gggagctgcc 90 <210> 33 <211> 90 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 33 ccgagacggg aaatgcacct cctacaagtg gatttgtgat ggatccgaac accgagtgca 60 aggacgggtc cgctgagtcc ctggagacgt 90 <210> 34 <211> 90 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 34 aaagtggcct ggcccaaccc ctggactgac cactcgagta ttgaagcacg taagtatgct 60 ggaccacatt ctctatggct gtagacattc 90 <210> 35 <211> 90 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 35 ctcttttcgc aggcacaggt ctacgagctg gagcgacgct tctaagcttg cagcagcggt 60 acctgtcggc tcccgagcgt gaccagttgg 90 <210> 36 <211> 60 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 36 tgcggttgct cccccgcctc gtccccgtaa gcttgactcc tggtgcagcg ccccggccag 60 <210> 37 <211> 90 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 37 aaccctgtgt cgtttcccac ccagtagata tgtttgatga ctaagcttct cggaaggcag 60 agagtgtgtc aactgcgggg ccatgtccac 90 <210> 38 <211> 90 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 38 gctcccactc ccctgggggc ctctgggctc accaacggtc tcctcccggg ggacgaagac 60 ttctcctcca ttgcggacat ggacttctca 90 <210> 39 <211> 69 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 39 agctcgccac ccccgccggg cacccgtgtc cgcgccatgg ccatctaagc ttaaagaagt 60 cagatta 69 <210> 40 <211> 60 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 40 gccgctgtct actgtgggcc tgcaaggcgt gcaaacgcaa gaccactaac gccgaccgcc 60 <210> 41 <211> 60 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 41 gccactgcct catgtgggcc tgcaaagcgt gcaagaggaa atccaccacc atggatcggc 60 <210> 42 <211> 59 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 42 cccctgccag gaccaaatgc ccccggaagc tgggagcgac agcagtggag aggaacatg 59 <210> 43 <211> 84 <212> DNA <213> Sus scrofa <220> <221> CDS <222> (1) (84) <400> 43 aag gag cag cag cag cag cag cag cag cag cag cag cag cag cag cag cag cag cag gag Lys Glu Glu Gln Gln Gln Gln Leu Arg Arg Lys Ile Asn Ser Arg Glu 1 5 10 15 cgg aag cgc atg cag gac ctg aac ctg gcc atg gac 84 Arg Lys Arg Met Gln Asp Leu Asn Leu Ala Met Asp             20 25 <210> 44 <211> 28 <212> PRT <213> Sus scrofa <400> 44 Lys Glu Glu Gln Gln Gln Gln Leu Arg Arg Lys Ile Asn Ser Arg Glu 1 5 10 15 Arg Lys Arg Met Gln Asp Leu Asn Leu Ala Met Asp             20 25 <210> 45 <211> 91 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <220> <221> CDS <222> (1) <220> <221> CDS &Lt; 222 > (52) <400> 45 aag gag cag cag cag cag cag cag cag cag cag cag cag cag cag cag cag cag cag gag Lys Glu Glu Gln Gln Gln Gln Leu Arg Arg Lys Ile Asn Ser Arg Glu 1 5 10 15 taa gct tcg gaa gcg cat gca gga cct gaa cct ggc cat gga c 91     Ala Ser Glu Ala His Ala Gly Pro Glu Pro Gly His Gly                 20 25 <210> 46 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       peptide <400> 46 Lys Glu Glu Gln Gln Gln Gln Leu Arg Arg Lys Ile Asn Ser Arg Glu 1 5 10 15 <210> 47 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       peptide <400> 47 Ala Ser Glu Ala His Ala Gly Pro Glu Pro Gly His Gly 1 5 10 <210> 48 <211> 84 <212> DNA <213> Sus scrofa <220> <221> CDS <222> (1) (84) <400> 48 tcg tcg tcc acg tcg tca gcg gct gcg tcg tcc acc aag aag gac aag 48 Ser Ser Ser Ser Ser Ser Ser Ala Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Thr 1 5 10 15 aaa cag atg act gaa ccc gag ctg cag cag cta cgc 84 Lys Gln Met Thr Glu Pro Glu Leu Gln Gln Leu Arg             20 25 <210> 49 <211> 28 <212> PRT <213> Sus scrofa <400> 49 Ser Ser Ser Ser Ser Ser Ser Ala Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Thr 1 5 10 15 Lys Gln Met Thr Glu Pro Glu Leu Gln Gln Leu Arg             20 25 <210> 50 <211> 91 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <220> <221> CDS <222> (1) <220> <221> CDS &Lt; 222 > (52) <220> <221> CDS <222> (58). (66) <220> <221> CDS &Lt; 222 > (70) <400> 50 tcg tcg tcc acg tcg tca gcg gct gcg tcg tcc acc aag aag gac aag 48 Ser Ser Ser Ser Ser Ser Ser Ala Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Thr 1 5 10 15 taa gct taa aca gat gac tga acc cga gct gca gca gct acg c 91     Ala Thr Asp Asp Thr Arg                     20 25 <210> 51 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       peptide <400> 51 Ser Ser Ser Ser Ser Ser Ser Ala Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Thr 1 5 10 15 <210> 52 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       peptide <400> 52 Thr Arg Ala Ala Ala Ala Thr 1 5 <210> 53 <211> 48 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 53 ttccactgca ggctcggcta cccgtgaagt ggatggcacc cgagagca 48 <210> 54 <211> 48 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 54 tgctctcggg tgccatccac ttcacgggta gccgagcctg cagtggaa 48 <210> 55 <211> 27 <212> PRT <213> Mus sp. <400> 55 Ile Lys Asn Asp Ser Asn Tyr Val Val Lys Gly Asn Ala Arg Leu Pro 1 5 10 15 Val Lys Trp Met Ala Pro Glu Ser Ile Phe Asn             20 25 <210> 56 <211> 27 <212> PRT <213> Sus scrofa <400> 56 Ile Arg Asn Asp Ser Asn Tyr Val Val Lys Gly Asn Ala Arg Leu Pro 1 5 10 15 Val Lys Trp Met Ala Pro Glu Ser Ile Phe Ser             20 25 <210> 57 <211> 48 <212> DNA <213> Sus scrofa <400> 57 aggctcggct acccgtgaag tggatggcac ccgagagcat tttcaact 48 <210> 58 <211> 48 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <400> 58 aggctcggct acccatgaag tggatggccc cggaatctat tttcaact 48 <210> 59 <211> 87 <212> DNA <213> Sus scrofa <220> <221> CDS <222> (1). (87) <400> 59 gag cag caa cag cag cgg cag cag aag Glu Gln Gln Gln Gln Leu Arg Arg Lys Ile Asn Ser Arg Glu Arg Lys 1 5 10 15 cgc atg cag gac ctg aac ctg gcc atg gac gcg ctg cgc 87 Arg Met Gln Asp Leu Asn Leu Ala Met Asp Ala Leu Arg             20 25 <210> 60 <211> 29 <212> PRT <213> Sus scrofa <400> 60 Glu Gln Gln Gln Gln Leu Arg Arg Lys Ile Asn Ser Arg Glu Arg Lys 1 5 10 15 Arg Met Gln Asp Leu Asn Leu Ala Met Asp Ala Leu Arg             20 25 <210> 61 <211> 94 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <220> <221> CDS <222> (1) <220> <221> CDS <222> (46). (93) <400> 61 gag cag cag cag cag cag cag cag cag cag cag cag cag cag cag cag cag cag cag gag Glu Gln Gln Gln Gln Leu Arg Arg Lys Ile Asn Ser Arg Glu Ala 1 5 10 15 tcg gaa gcg cat gca gga cct gaa cct ggc cat gga cgc gct gcg c 94 Ser Glu Ala His Ala Gly Pro Glu Pro Gly His Gly Arg Ala Ala                 20 25 30 <210> 62 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       peptide <400> 62 Glu Gln Gln Gln Gln Leu Arg Arg Lys Ile Asn Ser Arg Glu 1 5 10 <210> 63 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       peptide <400> 63 Ala Ser Glu Ala His Ala Gly Pro Glu Pro Gly His Gly Arg Ala Ala 1 5 10 15 <210> 64 <211> 86 <212> DNA <213> Sus scrofa <400> 64 acgtcgtcag cggctgcgtc gtccaccaag aaggacaaga aacagatgac tgaacccgag 60 ctgcagcagc tacgcctcaa gatcaa 86 <210> 65 <211> 29 <212> PRT <213> Sus scrofa <400> 65 Thr Ser Ser Ala Ala Ser Ser Thr Lys Lys Asp Lys Lys Gln Met 1 5 10 15 Thr Glu Pro Glu Leu Gln Gln Leu Arg Leu Lys Ile Lys             20 25 <210> 66 <211> 93 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       자이클립 <220> <221> CDS <222> (1) (39) <220> <221> CDS &Lt; 222 > (43) <220> <221> CDS &Lt; 222 > (49) .. (57) <220> <221> CDS &Lt; 222 > (61) <400> 66 acg tcg tca gcg gct gcg tcg tcc acc aag aag gac aag taa gct taa 48 Thr Ser Ser Ala Ala Ser Ser Thr Lys Lys Asp Lys Ala 1 5 10 aca gat gac tga acc cga gct gca gca gct acg cct caa gat caa 93 Thr Asp Thr Arg Ala Ala Ala Thr Pro Gln Asp Gln 15 20 25 <210> 67 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       peptide <400> 67 Thr Ser Ser Ala Ala Ser Ser Thr Lys Lys Asp Lys 1 5 10 <210> 68 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic       peptide <400> 68 Thr Arg Ala Ala Ala Thr Pro Gln Asp Gln 1 5 10

Claims (83)

A chimeric embryo comprising a non-human embryo having at least one human cell, wherein both alleles of one or more endogenous genes of a non-human embryo responsible for the occurrence of one or more endogenous organs or tissues are destroyed, Wherein at least one gene of a human cell responsible for the development of a human organ or tissue complements the function of at least one destroyed endogenous gene such that the animal resulting from said chimeric embryo comprises at least one human organ or tissue,
Wherein said endogenous gene comprises NURR1, LMX1A and / or PITX3 and said human organ or tissue comprises dopamine neurons;
Wherein the endogenous gene comprises OLIG and / or OLIG2 and the human organs or tissues comprise a rare dendritic glial cell;
Wherein said endogenous gene comprises RAG2, IL2rg, C-KIT and / or ETV2 and said human organ or tissue comprises young blood;
Wherein said endogenous gene comprises RUNX1, C-KIT and / or FLK1 and said human organ or tissue comprises hematopoietic cells;
Wherein said endogenous gene comprises ETV2 and said human organ or tissue comprises human vascular cells;
Wherein said endogenous gene comprises MYF5, MYOD, MRF4 and / or PAX3 and said human organ or tissue comprises skeletal muscle cells;
Wherein said endogenous gene comprises NKX2-5, HANDII and / or TBX5 and said human organ or tissue comprises myocardial cells;
Wherein said endogenous gene comprises Pdx and / or ETV2 and said human organ or tissue comprises pancreatic cells;
Wherein said endogenous gene comprises HHEX and / or Ubc and said human organ or tissue comprises human liver cells; or
Wherein the endogenous gene comprises Nkx2.1, Sox2, Id2 and / or Tbx4, and wherein the human organ or tissue comprises lung cells. A chimeric embryo comprising a non-human embryo having at least one human cell, wherein both alleles of one or more endogenous genes of a non-human embryo responsible for the occurrence of one or more endogenous organs or tissues are destroyed, Wherein at least one gene of a human cell responsible for the development of a human organ or tissue complements the function of at least one destroyed endogenous gene such that the animal resulting from said chimeric embryo comprises at least one human organ or tissue,
Wherein said endogenous gene comprises NURR1, LMX1A and / or PITX3 and said human organ or tissue comprises dopamine neurons;
Wherein the endogenous gene comprises OLIG and / or OLIG2 and the human organs or tissues comprise a rare dendritic glial cell;
Wherein said endogenous gene comprises RAG2, IL2rg, C-KIT and / or ETV2 and said human organ or tissue comprises young blood;
Wherein said endogenous gene comprises RUNX1, C-KIT and / or FLK1 and said human organ or tissue comprises hematopoietic cells;
Wherein said endogenous gene comprises PAX3 and said human organ or tissue comprises skeletal muscle cells;
Wherein said endogenous gene comprises Pdx and / or ETV2 and said human organ or tissue comprises pancreatic cells;
Wherein said endogenous gene comprises HHEX and / or Ubc and said human organ or tissue comprises human liver cells; or
Wherein said endogenous gene comprises Nkx2.1, Sox2, Id2 and / or Tbx4 and said human organ or tissue comprises lung cells. A chimeric embryo comprising a non-human embryo having at least one human cell, wherein both alleles of one or more endogenous genes of a non-human embryo responsible for the development of one or more endogenous organs or tissues have been destroyed, Wherein at least one gene of a human cell responsible for the development of a human organ or tissue complements the function of at least one destroyed endogenous gene such that the animal resulting from said chimeric embryo comprises at least one human organ or tissue,
Wherein said endogenous gene is RAG2 and IL2rg and / or ETV2 and said human organ or tissue comprises young blood;
Wherein said endogenous gene is MYF5, MYOD and MRF4 and / or PAX3 and said human organ or tissue comprises skeletal muscle cells; or
Wherein said endogenous gene is NKX2-5, HANDII and / or TBX5 and said human organ or tissue comprises myocardial cells. A chimeric embryo comprising a non-human embryo having at least one human cell, wherein both alleles of one or more endogenous genes of a non-human embryo responsible for the development of one or more endogenous organs or tissues have been destroyed, Wherein at least one gene of a human cell responsible for the development of a human organ or tissue complements the function of at least one destroyed endogenous gene such that the animal resulting from said chimeric embryo comprises at least one human organ or tissue,
Wherein said endogenous gene is RAG2 and IL2rg and / or ETV2 and said human organ or tissue comprises young blood;
Wherein said endogenous gene is PAX3 and said human organ or tissue comprises skeletal muscle cells; or
Wherein said endogenous gene is NKX2-5, HANDII and / or TBX5 and said human organ or tissue comprises myocardial cells. 2. The chimeric embryo of claim 1, wherein said endogenous gene comprises NURR1, LMX1A, and / or PITX3 and said human organ or tissue comprises dopamine neurons. 2. The chimeric embryo according to claim 1, wherein said endogenous gene comprises OLIG and / or OLIG2 and said human organs or tissues comprise rare dendritic glue cells. 2. The chimeric embryo according to claim 1, wherein said endogenous gene comprises RAG2, IL2rg, C-KIT and / or ETV2 and said human organ or tissue comprises young blood. The chimeric embryo according to claim 1, wherein the endogenous gene comprises RUNX1, C-KIT and / or FLK1, and the human organs or tissues comprise hematopoietic cells. 2. The chimeric embryo according to claim 1, wherein the endogenous gene comprises ETV2 and the human organs or tissues comprise human blood vessel cells. 2. The chimeric embryo of claim 1, wherein said endogenous gene comprises MYF5, MYOD, MRF4 and / or PAX3 and said human organ or tissue comprises skeletal muscle cells. 2. The chimeric embryo according to claim 1, wherein said endogenous gene comprises NKX2-5, HANDII and / or TBX5 and said human organ or tissue comprises myocardial cells. 2. The chimeric embryo according to claim 1, wherein said endogenous gene comprises Pdx and / or ETV2 and said human organ or tissue comprises pancreatic cells. 2. The chimeric embryo according to claim 1, wherein the endogenous gene comprises HHEX or Ubc and the human organs or tissues comprise human liver cells. The chimeric embryo according to claim 1, wherein the endogenous gene comprises Nkx2.1, Sox2, Id2 and / or Tbx4, and the human organs or tissues comprise lung cells. 15. A chimeric embryo according to any one of claims 1 to 14, wherein the non-human embryo is a non-human vertebrate embryo. 16. The chimeric embryo of claim 15, wherein the vertebrate non-human embryo is an artiodactyl embryo or a non-human primate embryo. 16. The chimeric embryo of claim 15 wherein said non-human vertebrate embryo is selected from the group consisting of cows, horses, pigs, sheep, chickens, birds, rabbits, goats, dogs, cats, laboratory animals, crustaceans, . 17. The chimeric embryo of claim 16, wherein the vertebrate non-human embryo is a cow, a pig, a sheep, a goat, a chicken, or a rabbit embryo. 19. The method according to any one of claims 1 to 18, wherein one or more endogenous genes of a non-human embryo responsible for the development of one or more endogenous organs or tissues are selected from the group consisting of Transcription Activator-Like Effector Nucleases (CRISPR), CRISPR-related protein 9 (Cas9), Zinc Finger Nucleases (ZFNs), site-directed mutagenesis, A chimeric embryo that has been destroyed by a molecule encoding a specific endonuclease, a synthetic artificial chromosome, a RecA-gal4 fusion, an RNAi, a CRISPRi, or a combination thereof. 20. The chimeric embryo of claim 19, wherein said one or more endogenous genes are disrupted by Cas9. 21. The method of any one of claims 1 to 20, wherein the human cells are derived from at least one donor cell, and wherein the at least one donor cell is selected from the group consisting of embryonic stem cells, tissue-specific stem cells, Wherein the chimeric embryo is a pluripotent stem cell or an induced pluripotent stem cell. 22. The method of any one of claims 1 to 21, wherein said destruction comprises both genetic editing, knockout, insertion of one or more DNA moieties, deletion of one or more bases, or insertion and deletion of one or more DNA moieties Chimeric embryos that are one. 22. The chimeric embryo according to any one of claims 1 to 21, wherein said destruction comprises substitution of one or more DNA residues. 24. The chimeric embryo of claim 23, wherein said destruction comprises substitution of one or more DNA residues. 24. An animal generated from a chimeric embryo according to any one of claims 1 to 24. 25. A human tissue or organ harvested from an animal resulting from a chimeric embryo according to any one of claims 1 to 25. A method of producing a chimeric embryo comprising the steps of:
(a) destroying both alleles of one or more endogenous genes responsible for the occurrence of one or more organs or tissues in at least one non-human cell or non-human embryo;
(b) when step (a) is performed in a non-human cell, cloning the cell to produce an embryo; And
(c) introducing at least one human cell into the embryo of step (a) or step (b), wherein said human cell carries one or more genes responsible for the development of one or more organs or tissues to produce a chimeric embryo ;
Wherein said endogenous gene comprises NURR1, LMX1A and / or PITX3 and said human organ or tissue comprises dopamine neurons;
Wherein the endogenous gene comprises OLIG and / or OLIG2 and the human organs or tissues comprise a rare dendritic glial cell;
Wherein said endogenous gene comprises RAG2, IL2rg, C-KIT and / or ETV2 and said human organ or tissue comprises young blood;
Wherein said endogenous gene comprises RUNX1, C-KIT and / or FLK1 and said human organ or tissue comprises hematopoietic cells;
Wherein said endogenous gene comprises ETV2 and said human organ or tissue comprises human vascular cells;
Wherein said endogenous gene comprises MYF5, MYOD, MRF4 and / or PAX3 and said human organ or tissue comprises skeletal muscle cells;
Wherein said endogenous gene comprises NKX2-5, HANDII and / or TBX5 and said human organ or tissue comprises myocardial cells;
Wherein said endogenous gene comprises Pdx and / or ETV2 and said human organ or tissue comprises pancreatic cells;
Wherein said endogenous gene comprises HHEX and / or Ubc and said human organ or tissue comprises human liver cells; or
Wherein said endogenous gene comprises Nkx2.1, Sox2, Id2 and / or Tbx4 and said human organ or tissue comprises lung cells. A method of producing a chimeric embryo comprising the steps of:
(a) destroying both alleles of one or more endogenous genes responsible for the occurrence of one or more organs or tissues in at least one non-human cell or non-human embryo;
(b) when step (a) is performed in a non-human cell, cloning the cell to produce an embryo; And
(c) introducing at least one human cell into the embryo of step (a) or step (b), wherein said human cell carries one or more genes responsible for the development of one or more organs or tissues to produce a chimeric embryo ;
Wherein said endogenous gene comprises NURR1, LMX1A and / or PITX3 and said human organ or tissue comprises dopamine neurons;
Wherein the endogenous gene comprises OLIG and / or OLIG2 and the human organs or tissues comprise a rare dendritic glial cell;
Wherein said endogenous gene comprises RAG2, IL2rg, C-KIT and / or ETV2 and said human organ or tissue comprises young blood;
Wherein said endogenous gene comprises RUNX1, C-KIT and / or FLK1 and said human organ or tissue comprises hematopoietic cells;
Wherein said endogenous gene comprises PAX3 and said human organ or tissue comprises skeletal muscle cells;
Wherein said endogenous gene comprises Pdx and / or ETV2 and said human organ or tissue comprises pancreatic cells;
Wherein said endogenous gene comprises HHEX and / or Ubc and said human organ or tissue comprises human liver cells; or
Wherein said endogenous gene comprises Nkx2.1, Sox2, Id2 and / or Tbx4 and said human organ or tissue comprises lung cells. A method of producing a chimeric embryo comprising the steps of:
(a) destroying both alleles of one or more endogenous genes responsible for the occurrence of one or more organs or tissues in at least one non-human cell or non-human embryo;
(b) when step (a) is performed in a non-human cell, cloning the cell to produce an embryo; And
(c) introducing at least one human cell into the embryo of step (a) or step (b), wherein said human cell carries one or more genes responsible for the development of one or more organs or tissues to produce a chimeric embryo ;
Wherein said endogenous gene is RAG2 and IL2rg and / or ETV2 and said human organ or tissue comprises young blood;
Wherein said endogenous gene is MYF5, MYOD and MRF4 and / or PAX3 and said human organ or tissue comprises skeletal muscle cells; or
Wherein said endogenous gene is NKX2-5, HANDII and TBX5 and said human organ or tissue comprises myocardial cells. A method of producing a chimeric embryo comprising the steps of:
(a) destroying both alleles of one or more endogenous genes responsible for the occurrence of one or more organs or tissues in at least one non-human cell or non-human embryo;
(b) when step (a) is performed in a non-human cell, cloning the cell to produce an embryo; And
(c) introducing at least one human cell into the embryo of step (a) or step (b), wherein said human cell carries one or more genes responsible for the development of one or more organs or tissues to produce a chimeric embryo ;
Wherein said endogenous gene is RAG2 and IL2rg and / or ETV2 and said human organ or tissue comprises young blood;
Wherein said endogenous gene is PAX3 and said human organ or tissue comprises skeletal muscle cells; or
Wherein said endogenous gene is NKX2-5, HANDII and TBX5 and said human organ or tissue comprises myocardial cells. 33. The method according to any one of claims 30 to 32, wherein the endogenous gene comprises NURR1, LMX1A, and / or PITX3 and the human organ or tissue comprises dopamine neurons. 28. The method of claim 27, wherein the endogenous gene comprises OLIG and / or OLIG2 and wherein the human organs or tissues comprise rare dendritic glial cells. 28. The method of claim 27, wherein said endogenous gene comprises RAG2, IL2rg, C-KIT and / or ETV2 and said human organ or tissue comprises young blood. 28. The method of claim 27, wherein said endogenous gene comprises RUNX1, C-KIT and / or FLK1 and said human organ or tissue comprises hematopoietic cells. 28. The method of claim 27, wherein said endogenous gene comprises ETV2 and said human organ or tissue comprises human vascular cells. 28. The method of claim 27, wherein the endogenous gene comprises MYF5, MYOD, MRF4, and / or PAX3, wherein the human organ or tissue comprises skeletal muscle cells. 28. The method of claim 27, wherein said endogenous gene comprises NKX2-5, HANDII, and / or TBX5 and said human organ or tissue comprises myocardial cells. 28. The method of claim 27, wherein said endogenous gene comprises Pdx and / or ETV2 and said human organ or tissue comprises pancreatic cells. 28. The chimeric embryo of claim 27, wherein said endogenous gene comprises HHEX and / or Ubc and said human organ or tissue comprises human liver cells. 28. The chimeric embryo according to claim 27, wherein the endogenous gene comprises Nkx2.1, Sox2, Id2 and / or Tbx4 and the human organs or tissues comprise lung cells. 41. The method of any one of claims 27 to 40, wherein the non-human embryo is a non-human vertebrate embryo. 42. The method of claim 41, wherein the vertebrate non-human embryo is a right embryo or a non-human primate embryo. 42. The method of claim 41, wherein the non-human vertebrate embryo is selected from the group consisting of cows, horses, pigs, sheep, chickens, birds, rabbits, goats, dogs, cats, laboratory animals, and fish. 44. The method of any one of claims 27 to 43, wherein said at least one human donor cell is selected from the group consisting of embryonic stem cells, tissue-specific stem cells, mesenchymal stem cells, pluripotent stem cells, or induced pluripotent stem cells Way. 45. The method according to any one of claims 27 to 44, further comprising the step of transplanting the chimeric embryo into the uterus of an animal, wherein the chimeric embryo occurs with a chimeric animal comprising human cells . 46. The method of claim 45, further comprising harvesting said human cells from said chimeric animal. 47. The method of claim 46, further comprising transplanting said human cells into a human patient in need thereof. 48. The method of claim 47, wherein said at least one human cell is donated by a human patient. 48. The method of any one of claims 27-48, wherein at least one endogenous gene of said non-human embryo responsible for the occurrence of one or more endogenous organs or tissues is transcriptionally activated by a transcriptional activator-like effector nuclease (TALENS) (CRISPR), a CRISPR-related protein 9 (Cas9), a zinc finger nuclease (ZFNS), a molecule encoding a site-specific endonuclease, a synthetic artificial chromosome, a RecA- gal4 fusion, RNAi, CRISPRi, or a combination thereof. 50. The method of claim 49, wherein the method is Cas9. 50. The method according to any one of claims 49 to 50, further comprising the step of introducing a homology directed repair (HDR) template having a template sequence homologous to one of said endogenous genes , Wherein said template sequence replaces at least a portion of said endogenous gene sequence to destroy an endogenous gene. 52. The method of claim 51, further comprising introducing a plurality of homologous target recovery (HDR) templates, each having a template sequence that is homologous to one of said endogenous genes, wherein each said template sequence Is to replace at least a portion of one of said endogenous gene sequences to destroy the endogenous gene. 54. The method of claim 51 or 52, wherein said disruption comprises the substitution of one or more DNA residues of said endogenous gene. 54. The method of claim 51 or 52, wherein said disruption consists of substitution of one or more DNA residues of said endogenous gene. A chimeric embryo or chimeric animal produced using the method of any one of claims 27 to 54. A method of producing a human or humanized organ or tissue in a non-human host animal, comprising the steps of:
(a) destroying both alleles of one or more endogenous genes responsible for the development of organs or tissues in at least one cell of a non-human embryo;
(b) when step (a) is performed in a cell of an animal host, cloning the cell to produce an embryo; And
(c) introducing at least one human cell into the embryo of step (a) or step (b) to produce a chimeric host embryo, said human cell comprising one or more genes responsible for the generation of the corresponding human organ or tissue Lt; / RTI &gt;
Herein, the animal resulting from the chimeric host embryo is a human or humanized organ or organism in a non-human host animal, including a human or humanized organ or tissue,
Wherein said endogenous gene comprises NURR1, LMX1A and / or PITX3 and said human organ or tissue comprises dopamine neurons;
Wherein the endogenous gene comprises OLIG and / or OLIG2 and the human organs or tissues comprise a rare dendritic glial cell;
Wherein said endogenous gene comprises RAG2, IL2rg, C-KIT and / or ETV2 and said human organ or tissue comprises young blood;
Wherein said endogenous gene comprises RUNX1, C-KIT and / or FLK1 and said human organ or tissue comprises hematopoietic cells;
Wherein said endogenous gene comprises ETV2 and said human organ or tissue comprises human vascular cells;
Wherein said endogenous gene comprises MYF5, MYOD, MRF4 and / or PAX3 and said human organ or tissue comprises skeletal muscle cells;
Wherein said endogenous gene comprises NKX2-5, HANDII and / or TBX5 and said human organ or tissue comprises myocardial cells;
Wherein said endogenous gene comprises Pdx and / or ETV2 and said human organ or tissue comprises pancreatic cells;
Wherein said endogenous gene comprises HHEX and / or Ubc and said human organ or tissue comprises human liver cells; or
Wherein said endogenous gene comprises Nkx2.1, Sox2, Id2 and / or Tbx4 and said human organ or tissue comprises lung cells. A method of producing a human or humanized organ or tissue in a non-human host animal, comprising the steps of:
(a) destroying both alleles of one or more endogenous genes responsible for the development of organs or tissues in at least one cell of a non-human embryo;
(b) when step (a) is performed in a cell of an animal host, cloning the cell to produce an embryo; And
(c) introducing at least one human cell into the embryo of step (a) or step (b) to produce a chimeric host embryo, said human cell comprising one or more genes responsible for the generation of the corresponding human organ or tissue Lt; / RTI &gt;
Herein, the animal resulting from the chimeric host embryo is a human or humanized organ or organism in a non-human host animal, including a human or humanized organ or tissue,
Wherein said endogenous gene comprises NURR1, LMX1A and / or PITX3 and said human organ or tissue comprises dopamine neurons;
Wherein the endogenous gene comprises OLIG and / or OLIG2 and the human organs or tissues comprise a rare dendritic glial cell;
Wherein said endogenous gene comprises RAG2, IL2rg, C-KIT and / or ETV2 and said human organ or tissue comprises young blood;
Wherein said endogenous gene comprises RUNX1, C-KIT and / or FLK1 and said human organ or tissue comprises hematopoietic cells;
Wherein said endogenous gene comprises PAX3 and said human organ or tissue comprises skeletal muscle cells;
Wherein said endogenous gene comprises Pdx and / or ETV2 and said human organ or tissue comprises pancreatic cells;
Wherein said endogenous gene comprises HHEX and / or Ubc and said human organ or tissue comprises human liver cells; or
Wherein said endogenous gene comprises Nkx2.1, Sox2, Id2 and / or Tbx4 and said human organ or tissue comprises lung cells. A method of producing a human or humanized organ or tissue in a non-human host animal, comprising the steps of:
(a) destroying both alleles of one or more endogenous genes responsible for the development of organs or tissues in at least one cell of a non-human embryo;
(b) when step (a) is performed in a cell of an animal host, cloning the cell to produce an embryo; And
(c) introducing at least one human cell into the embryo of step (a) or step (b) to produce a chimeric host embryo, said human cell comprising one or more genes responsible for the generation of the corresponding human organ or tissue &Lt; / RTI &gt;
Wherein said endogenous gene is RAG2 and IL2rg or ETV2 and said human organ or tissue comprises young blood;
Wherein said endogenous gene is MYF5, MYOD and MRF4 or PAX3 and said human organ or tissue comprises skeletal muscle cells; or
Wherein said endogenous gene comprises NKX2-5, HANDII and / or TBX5 and said human organ or tissue comprises myocardial cells. A method of producing a human or humanized organ or tissue in a non-human host animal, comprising the steps of:
(a) destroying both alleles of one or more endogenous genes responsible for the occurrence of one or more organs or tissues in at least one non-human cell or non-human embryo;
(b) when step (a) is performed in a non-human cell, cloning the cell to produce an embryo; And
(c) introducing at least one human cell into the embryo of step (a) or step (b), wherein said human cell carries one or more genes responsible for the development of one or more organs or tissues to produce a chimeric embryo ;
Wherein said endogenous gene is RAG2 and IL2rg and / or ETV2 and said human organ or tissue comprises young blood;
Wherein said endogenous gene is PAX3 and said human organ or tissue comprises skeletal muscle cells; or
Wherein said endogenous gene is NKX2-5, HANDII and TBX5 and said human organ or tissue comprises myocardial cells. 57. The method of claim 56, wherein the endogenous gene comprises NURR1, LMX1A, and / or PITX3 and wherein the human organ or tissue comprises dopamine neurons. 57. The method of claim 56, wherein the endogenous gene comprises OLIG and / or OLIG2 and wherein the human organs or tissues comprise rare lobular glial cells. 57. The method of claim 56, wherein said endogenous gene comprises RAG2, IL2rg, C-KIT and / or ETV2 and said human organ or tissue comprises young blood. 57. The method of claim 56, wherein said endogenous gene comprises RUNX1, C-KIT and / or FLK1 and said human organ or tissue comprises hematopoietic cells. 57. The method of claim 56, wherein said endogenous gene comprises ETV2 and said human organ or tissue comprises human vascular cells. 57. The method of claim 56, wherein said endogenous gene comprises MYF5, MYOD, MRF4 and / or PAX3 and said human organ or tissue comprises skeletal muscle cells. 57. The method of claim 56, wherein said endogenous gene comprises NKX2-5, HANDII, and / or TBX5, and said human organ or tissue comprises myocardial cells. 57. The method of claim 56, wherein said endogenous gene comprises Pdx and / or ETV2 and said human organ or tissue comprises pancreatic cells. 57. The method of claim 56, wherein said endogenous gene comprises HHEX and / or Ubc and said human organ or tissue comprises human liver cells. 57. The method of claim 56, wherein the endogenous gene comprises Nkx2.1, Sox2, Id2, and / or Tbx4 and wherein the human organ or tissue comprises lung cells. 71. The method of any one of claims 56 to 69, wherein the non-human embryo is a non-human vertebrate embryo. 70. The method of claim 70, wherein the vertebrate non-human embryo is a right embryo or a non-human primate embryo. 71. The method of claim 70, wherein the non-human vertebrate embryo is selected from the group consisting of cows, horses, pigs, sheep, chickens, birds, rabbits, goats, dogs, cats, laboratory animals, and fish. 72. The method according to any one of claims 56 to 72, wherein said at least one human cell is an embryonic stem cell, tissue-specific stem cell, mesenchymal stem cell, pluripotent stem cell or induced pluripotent stem cell . 73. The method of any one of claims 56 to 73, further comprising harvesting human cells from a chimeric animal. 75. The method of claim 74, further comprising transplanting said human cells into a human patient in need thereof. 77. The method of claim 75, wherein said at least one human cell is donated by a human patient. 76. The method according to any one of claims 56 to 76, further comprising the step of introducing a homologous target recovery (HDR) template having a template sequence homologous to one of said endogenous genes, Wherein at least a portion of the endogenous gene sequence is replaced to destroy the endogenous gene. 78. The method of claim 77, further comprising introducing a plurality of homologous target recovery (HDR) templates, each having a template sequence that is homologous to one of said endogenous genes, Is to replace at least a portion of one of said endogenous gene sequences to destroy the endogenous gene. 78. The method of claim 77 or 78 wherein the disruption comprises a substitution of one or more DNA residues of the endogenous gene. 78. The method of claim 77 or 78 wherein said disruption consists of substitution of one or more DNA residues of said endogenous gene. 80. The method according to any one of claims 56 to 80, wherein at least one endogenous gene of said non-human embryo responsible for the occurrence of one or more endogenous organs or tissues is selected from the group consisting of transcriptional activator-like effector nuclease (TALENS) (CRISPR), a CRISPR-related protein 9 (Cas9), a zinc finger nuclease (ZFNS), a molecule encoding a site-specific endonuclease, a synthetic artificial chromosome, a RecA- gal4 fusion, RNAi, CRISPRi, or a combination thereof. 83. The method of claim 81, wherein at least one endogenous gene of the non-human embryo responsible for the occurrence of one or more endogenous organs or tissues is destroyed by Cas9. 82. A chimeric animal produced using the method of any one of claims 56 to 82.

Images